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Abstract
Understanding how genetic variation propagate to differences in phenotypes in individuals
is an ongoing challenge in genetics. Genome-wide association studies have allowed for
the identification of many trait-associated genomic loci. However, they are limited in their
inability to explain the altered cellular mechanism. Genetic variation can drive disease by
altering a range of mechanisms, including signalling networks, transcription factor (TF)
binding, and protein folding. Understanding the impact of variants on such processes has
key implications in therapeutics, drug development, protein engineering and more. This
thesis aims to utilise computational predictors to shed light on how cellular mechanisms
are altered in the context of genetic variation and better understand how they drive both
molecular and organism-level phenotypes. Many binding events in the cell are mediated by
short stretches of sequence motifs. The ability to discover these underlying rules of binding
could greatly aid our understanding of variant impact. Kinase-substrate phosphorylation
is one of the most prominent post-translational modifications (PTMs) which is mediated
by such motifs. We first describe a computational method which utilises interaction and
phosphorylation data to predict sequence preferences of kinases. Our method was applied to
57% of human kinases capturing known well-characterised and novel kinase specificities.
We experimentally validate four understudied kinases to show that predicted models closely
resemble true specificities. We further demonstrate that this method can be applied to different
organisms and can be used for other phospho-recognition domains. The described approach
allows for an extended repertoire of sequence specificities to be generated, particularly in
organisms for which little data is available. TF-DNA binding is another mechanism driven
by sequence motifs, which is key for the tight regulation of gene expression and can be
greatly altered by genetic variation. We have comprehensively benchmarked current methods
used to predict non-coding variant effects on TF-DNA binding by employing over 20,000
compiled allele-specific binding variants across 43 TFs. We show that machine learning-
based approaches significantly outperform more rudimentary methods such as the position
weight matrix. We further note that models for many TFs with distinct binding specificities
were unable to accurately assess the impact of variants. For these TFs, we explore alternative
mechanisms underlying TF-binding, such as methylation, co-operative binding, and DNA
xshape that drive poor performance. Our results demonstrate the complexity of predicting
non-coding variant effects and the importance of incorporating alternative mechanisms into
models. Finally, we describe a comprehensive effort to compile and benchmark common
sequence and structure-based predictors of mutational consequences and predict the effect of
coding and non-coding variants in the reference genomes of H. sapiens, S. cerevisiae, and
E. coli. Predicted mechanisms include the impact on protein stability, interaction interfaces,
PTMs and TF-binding. These variant effects are provided through mutfunc, a fast and
intuitive web tool by which users can interactively explore pre-computed mechanistic variant
impact predictions. We validate computed predictions by analysing known pathogenic
disease variants and provide mechanistic hypotheses for causal variants of unknown function.
We further employ our predictions to devise gene burden scores in S. cerevisiae strains that
are used to perform gene-phenotype association tests and uncover several known and novel
associations.
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Chapter 1
Introduction
The cell is an intricate system of interconnected components governing the phenotype through
a combination of genetic and environmental factors. Changes to the genetic composition of
an individual that are either inherited or arise during development are one of the major driving
forces of phenotypic variability both at the organismal and molecular level. Even the simplest
changes in the genome can alter protein levels or function, ultimately interfering with critical
biological processes that then manifest as changes in molecular and organismal phenotypes.
The advent of next-generation sequencing (NGS) and omics profiling technologies, has
resulted in a substantial increase in the availability of genomes and corresponding phenotypic
readouts [1, 2]. This has unravelled the era of modern genetics and has significantly propelled
the bridging of the genotype-phenotype gap. The increased availability of such data has
also led to the development of computational and statistical methods that are critical to
implicating thousands of genetic loci to changes in phenotype [3]. Understanding the
articulate relationship between genotype and phenotype is an ongoing challenge in genetics
and one that is the basis of this thesis.
1.1 Genetic variation
Genetic variation refers to changes in the underlying DNA and range from single nucleotide
variation (SNV) to larger chromosomal rearrangements, such as copy number variation
(CNVs). SNVs involve a single substitution from one nucleotide to another, insertions or
deletions occur when a stretch of sequence with one or more bases are either inserted or
removed from the genome and CNVs occur when regions of the genome are repeated or
deleted. SNVs are, by far, the most common form of genetic variation with over 14 million
identified in the human genome alone [4]. As such, SNVs will be the primary focus of this
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thesis and any reference to genetic variation henceforth can be assumed to be SNVs unless
otherwise stated.
SNVs exist throughout the genome in both noncoding and coding regions and are re-
sponsible for a wide range of phenotypic consequences [5]. Those which are observed in
coding regions can be categorized into nonsynonymous (or missense), synonymous, nonsense
and nonstop. Nonsynonymous SNVs are those that result in an amino acid substitution,
whereas synonymous SNVs, due to the redundancy of the genetic code, results in a change
on the DNA level but not to the encoded amino acid. Although studies have shown that
synonymous SNVs can alter messenger RNA (mRNA), splicing [6], mRNA stability [7]
and protein folding [8] because no changes are made to the amino acid sequence they are
generally often benign relative to their nonsynonymous counterparts [9]. The remaining
categories include nonsense SNVs, which introduce a premature stop codon in the protein
sequence and nonstop SNVs that results in the loss of a stop codon, both of which have
detrimental effects on protein function [10].
Within a population, SNVs typically exhibit two alleles, where one is more frequently
observed than the other. These are referred to as the major and minor alleles, respectively,
and the frequency at which they occur in the population is referred to as the allele frequency.
For instance, if an SNV with the minor allele, T, occurs in 10% of the population, it has
a minor allele frequency (MAF) of 0.10. If the minor allele of an SNV is prevalent in the
population, typically at a MAF of greater than 1%, it is often referred to as a single nucleotide
polymorphism (SNP).
Genetic variation is acquired by an individual through one of two ways. Germline
variants are inherited from maternal and paternal genomes during homologous recombination,
whereas somatic variants arise throughout the lifespan of the individual. In diploid organisms
such as human, the acquired SNV can be classified as heterozygous or homozygous, depending
on whether the allele is observed on one or both copies of the genome, respectively.
1.2 Genotype-phenotype association
Over the past decade, there has been significant progress towards bridging the genotype-
phenotype gap. This has been propelled by the development of sophisticated statistical
methods aimed at associating genetic variation to complex phenotypic traits, both on the
organismic and molecular level. Such methods have helped identify many causal variants in
both human and model organisms, and the increasing availability of genotype and phenotype
data is further enabling additional discoveries. Here, I briefly discuss the approaches taken
by association-based methods, the advances made and challenges faced.
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1.2.1 Genome-wide association studies
A key challenge of genetics is to identify the role risk factors play in Mendelian diseases
that can be linked to a single gene, such as cystic fibrosis and muscular dystrophy, as well as
common complex disorders that are instead governed by a more complex genetic architecture,
such as heart disease and obesity. Linkage studies, a process involving the tracking of genetic
variation through family lineages, have been pivotal at pinpointing causal genetic variants in
Mendelian diseases such as cystic fibrosis [11] and tuberous sclerosis [12]. Such phenotypes
are often highly penetrant, meaning the presence of the causal allele often implies a high
likelihood of exhibiting the phenotype. However, these approaches often do not extrapolate
well to phenotypes of a more complex genetic nature.
With the advent of sequencing and genotyping technologies, large-scale approaches
employing statistical means to establish a map between genomic loci and phenotype have
become increasingly abundant and key to identifying risk factors in human disease. Genome-
wide association studies (GWAS) is the most common approach, which interrogates, on a
genome-wide scale, millions of SNPs for associations to a trait of interest. Unlike linkage
analysis, GWASs are able to dissect complex phenotypes due to the abundance of data
involved and have been largely successful at identifying causal variants for a multitude of
both Mendelian and complex diseases, those of which include sickle cell anaemia [13],
type 2 diabetes [14], inflammatory bowel disease [15], multiple sclerosis [16, 17] and
obesity [18, 19]. In addition to disease phenotypes, GWASs have also associated genetic
variation with other physical traits, such as height [20], hair colour [21], and even facial
morphology [22]. Another field to which GWAS is increasingly contributing to is that of
pharmacogenomics where many genetic variants have been associated with drug efficacy,
metabolism, and toxicity [23–25]. These results, in turn, can be used to modulate drug
dosage to patients, giving rise to the era of personalised medicine. GWAS has also been
applied to several plant species [26, 27] and bacterial species [28], shedding light on the
genetic architecture of other organisms.
The design of a GWASs relies on the concept of linkage disequilibrium (LD), which is
defined as the non-random co-occurrence of alleles of two SNPs in close proximity to one
another and is caused by forces such as natural selection and random drift [29, 30]. Because
genomic loci in close proximity are more likely to co-segregate during recombination, they are
therefore more likely to co-occur. Regions in the genome with a group of co-occurring alleles
are referred to as haplotype blocks, which can be leveraged to identify a set of representative
or "tag" SNPs within each haplotype thereby avoiding redundancy and minimising the number
of genotyped SNPs. The international haplotype map project (HapMap) has facilitated this
process by cataloguing SNP allele frequencies and their associations with nearby SNPs in a
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diverse set of individuals. The third and latest release from the HapMap project contains 1.5
million SNPs, genotyped across 1,397 individuals across 11 human populations [31]. The
haplotype map streamlines the process of identifying tag SNPs and is key in designing an
effective GWAS study.
GWASs are carried out by carefully defining two sets of individuals, those that harbour
a particular trait (case) and those that do not or that harbour an alternative trait (control).
Each group is then genotyped for tag SNPs, typically through SNP microarrays, and allelic
frequencies of SNPs from each group are compared using contingency table methods,
commonly the chi-squared test. Because of the high number of statistical tests carried
out, rigorous multiple testing correction is often required with a stringent p-value selection
criterion for identification of causal variants.
In contrast to more traditional approaches for surveying risk factors, such as linkage
analysis, GWASs are able to comprehensively survey the genome in a hypothesis-free and
unbiased manner, employing elegant statistical methods to uncover variant associations.
GWASs are not limited to families and can instead leverage information in a large number
of individuals from a diversity of outbred populations. In addition, GWASs are capable of
identifying causal variants in low-penetrance phenotypes [32]. The endless possibilities of
GWASs, combined with its robustness makes it a valuable tool for dissecting the complex
underlying genetic architecture driving qualitative and quantitative traits.
1.2.2 Quantitative trait loci mapping
Quantitative trait loci (QTL) mapping is another association-based approach used for asso-
ciating genetic variation with changes in phenotype. QTL studies are similar in nature to
GWAS studies in that they both aim to identify genomic loci that correlate with changes
in the phenotype. However, QTLs differ in that they typically underlie quantitative traits,
which can range from morphological features such as height and weight to molecular-level
phenotypes such as protein levels and gene expression. QTLs can be applied to outbred pop-
ulations, such as human populations or experimental crosses carried out in model organisms,
where variation in recombinant offspring is inherited from either the maternal or paternal
genome. They have contributed significantly to further the interpretation of GWAS-derived
variants [33] and the genetics of several model organisms including S. cerevisiae [34] and D.
melanogaster [35] in which crosses can be easily achieved.
Expression QTLs (eQTLs) is one of the most commonly studied types of QTLs in which
an allele is able to explain differences in gene expression. The genotype of an individual is
first obtained through SNP genotyping or whole genome sequencing followed by a measure
of the individuals mRNA levels, typically through RNA sequencing (RNA-Seq). For each
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SNP, individuals are grouped based on the allele they carry and mRNA expression levels for
each group are tested against each other using statistical methods, such as linear regression, to
assess the significance of difference amongst the groups and the magnitude of the difference
(effect size).
Brem et al. [34] carried out one of the first comprehensive eQTL studies in S. cerevisiae,
in which microarrays were used to identify over 1,500 differentially expressed genes amongst
recombinant offspring, over a third of which were associated with variation at one or more
genomic loci. This set a precedent for and propelled the field of gene regulation. Today, QTL
studies are carried out on a much larger scale. For instance, the GTEx consortia measured
genotype and expression for 7,051 samples across 44 different human tissues carrying out
millions of association tests and identifying tens of thousands of significant eQTLs [36].
New derivatives of QTL studies are constantly being developed, such as those that survey
protein levels (pQTL) [37], histone modifications (hQTLs) [38] and methylation (mQTL)
[39]. Such studies provide the ability to dissect the complex genetic architecture underlying
the human genome and will allow us to better understand complex diseases and help develop
targeted therapies.
1.2.3 Limitations of association-based methods
Despite the successes of both GWAS and QTL-based studies, they are not without limitations.
For instance, rare variants require a significantly large sample size for appropriate statistical
power, which may not always be feasible [40]. The phenotype being assessed must also
display a substantial degree of variation within the population to be considered. Furthermore,
due to the extremely large number of statistical tests being carried out combined with
multiple testing, the increasing false positive rates further hinder the discovery of causal
variants [40]. More importantly, a fundamental drawback of association-based approaches
is their inability to pinpoint the underlying biological mechanisms driving the phenotypic
change. Through assessing quantitative molecular phenotypes, QTL-based studies focusing
on molecular phenotype offer a step closer to identifying the altered mechanism but are
nevertheless unable to provide the exact altered mechanisms driving this change. For example,
a GWAS-identified casual variant may also be identified as an eQTL, suggesting that alters a
transcriptional regulatory mechanism. However, the exact mechanism by which this occurs
remains unknown and could be due to a number of altered mechanisms such as changes in
epigenetic marks or altered binding of regulatory factors. Thus, a complete understanding of
how genetic variation is propagated to change in a phenotype requires the interpretation of
molecular consequences of mutations.
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1.3 Molecular phenotypes impacted by single nucleotide
variants
GWAS and QTL-based studies have significantly accelerated our understanding of how
genetic variation ties into phenotypic diversity. Yet, a complete understanding of the role of
variation in phenotype requires going beyond what is contributed by such approaches. The
lack of biological information provided by GWASs limits our ability to understand disease
origins and develop treatments accordingly.
A causal variant can affect protein function in a number of ways. For example, it can alter
gene expression through modifying key regulatory regions in the genome, affect the protein
stability, disrupt interactions between proteins, and affect other key physiologically properties
of proteins. Here, I describe a number of commonly-studied biological mechanisms by which
genetic variation can alter protein function. I further discuss advances in the computational
methodologies used to model these mechanisms and describe how they are employed to
assess the impact of genetic variation.
1.3.1 Transcription factor binding
Transcription is a key process in the central dogma, governing the creation of mRNA from
DNA the and thereby regulating the rate at which a gene is expressed. Regulatory sequences
encode a series of instructions that direct transcription. A key challenge in genetics is to
understand how the instructions encoded within sequence give rise to complex patterns
of transcription and how this is affected by sequence context (e.g. tissue or cell type).
Understanding this will allow us to understand the role of transcription in differentially
expressed patterns of genes.
The intricate process of transcription revolves around DNA-binding proteins known
as transcription factors (TFs), along with other factors that control chromatin structure.
Together, they have a central role in controlling the initiation of transcription through the
recruitment of the transcriptional machinery to core promoters of a gene. TFs carry this
out by recognising short stretches of regulatory sequences, typically between 6-18 bp, that
exist in close proximity to the promoter (cis-regulatory elements), or distal sequences,
such as enhancers (trans-regulatory elements), that are brought into close proximity of the
promoter with the aid of chromatin looping. This leads to the assembly of complexes that are
responsible for carrying out transcription initiation.
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High-throughput approaches for assaying transcription factor binding
Characterization of TF binding sites (TFBSs) was initially carried out using techniques such
as electrophoretic mobility shift assay (EMSA), where shifts in molecular weights through a
polyacrylamide or agarose gel are used to determine the occupancy of the TF [41]. Although
effective, and applicable both in vivo and in vitro, such low-throughput approaches do not
scale. High-throughput approaches based on microarrays, chromatin immunoprecipitation
(ChIP) and NGS [42] were soon after developed to facilitate large-scale identification of
TF-occupied regions in vivo [42].
Developed in the early 1990s, systematic evolution of ligands by exponential enrichment
(SELEX) was the first high throughput approach to assay protein-DNA interactions in vitro
[43]. The process begins with the generation of a large fixed-width double-stranded oligonu-
cleotide library, which is then incubated with the immobilised TF. Unbound oligonucleotides
are then purged, typically using affinity chromatography [44], and bound oligonucleotides
are eluted, subjected to PCR, and reincubated with the TF for subsequent rounds of binding
and selection to ultimately identify the consensus binding sequence [45]. This process is
repeated a number of times, where each round is referred to as a cycle. One of the inherent
limitations of SELEX is that it promotes over-selection of high-affinity binders. Medium
and low-affinity binders are critical to understanding the full extent of binding specificity
and shed light on the position-specific variability [46]. This poses an issue since, in the
classical SELEX methodology, such sequences are eventually purged out. Modern SELEX
derivatives, known as SELEX-seq, have mitigated this effect by incorporating massively
parallel sequencing of bound DNA after each round of selection [47, 48] (Figure 1.1a). This,
in turn, reduces the number of cycles required and allows for identification of sequences with
varying degree of binding affinity.
With the advances of methods for production and fluorescent detection, modern DNA
microarrays were born in the late 1990s. Protein binding microarrays (PBM) is an approach to
detect in vitro TF-bound DNA sequences [49]. Contrary to SELEX, the DNA array containing
a library of immobilised double-stranded oligonucleotides are exposed to a purified and
expressed TF of interest, which is modified to carry an epitope tag. After multiple rounds of
washing away unbound material, the array is exposed to a fluorophore-conjugated antibody
specific to the epitope (e.g. glutathione S-transferase), resulting in the fluorescing of bound
sequences [50] (Figure 1.1b). To eliminate any biases related to the probed double-stranded
oligonucleotides, a parallel control experiment is often carried out in which DNA is directly
stained using a second fluorescence signal, such as the fluorescent dye Sybrgreen I, which is
specific to double-strand DNA [51]. Fluorescent signals from both the control and treatment
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experiments are used to obtain a normalised score indicating TF protein-binding. PBMs have
since been applied to systematically successfully identify TFBSs [52, 51] (Figure 1.1b).
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Fig. 1.1 Diagrams of common high-throughput approaches for assaying TFBSs, including
(a) SELEX (b) PBMs and (c) ChIP-seq.
Methods that utilise ChIP were later developed that were capable of assaying TF-binding
both in vitro and in vivo. ChIP followed by microarray hybridization (ChIP-chip) is one such
approach that utilises DNA microarrays. Here, the TF is first cross-linked to the genomic
DNA using formaldehyde fixation. Cells are then subject to lysis and DNA is sheared
by sonication or enzymatic digestion into fragments of 150-500 bp [53]. A TF-specific
antibody is then used to precipitate the TF-DNA complexes and heat can be used to reverse
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the generated formaldehyde-generated cross-links. The remaining DNA is purified and
labelled with a fluorescent probe that is then exposed to a DNA microarray containing a
library of potentially complementary single-stranded DNA. To increase the signal-to-noise
ratio, dynamic range and leverage advances in sequencing technology, the ChIP sequencing
(ChIP-seq) protocol was developed. Instead of purified DNA being labelled and exposed to a
microarray, it is instead subject to high throughput DNA-sequencing [54] (Figure 1.1c). It is
noteworthy to mention that the performance of ChIP-based methods largely hinges on the
availability and quality of the TF-antibody, crosslinking efficiency and the native abundance
of the TF [54].
Computational methods for modelling transcription factor specificity
The mode by which TFs recognise their binding sites in vivo is a non-trivial and ongoing
challenge in the field of gene regulation. The DNA-binding domain (DBD) of many TFs
exhibit a high degree of sequence specificity towards their binding sites, which is driven
primarily by a unique chemical signature displayed by the base pairs of a binding site [55].
This sequence specificity is thought to be driven primarily by favourable hydrogen bonds,
Van der Waals (VdW) contacts and electrostatic interactions between residue side chains
in the DBD and the bases in the binding site [56]. The abundance of TFBS profiling data
made available through methods like ChIP-seq and SELEX have propelled the systematic
discovery of sequence specificity through computational approaches aimed at extracting
underlying de novo sequence motifs for binding [57].
Computational approaches have utilised known binding sites of a TF to model the
properties of its sequence specificity, thereby allowing for potential binding sites in the
genome to be predicted in silico. Consensus sequences were the first approach to modelling
TF specificity. Given a set of fixed-width aligned sequences, the consensus sequence simply
reflected the most common base at each position (Figure 1.2a-b). To account for position-
specific variability, position weight matrices (PWMs) were introduced in 1982 by Gary
Stormo [58] as an alternative approach to consensus sequences, and have been one of the first
approaches to quantitatively model TF-binding [59]. For a given set of fixed-width binding
sites for a TF, a PWM is a matrix reflecting the log likelihood of observing each given base
(A, T, C and G) at a position.
PWMs are constructed by tallying up the position-specific counts for each base, termed
position frequency matrix (PFM). The probability of observing a base at a position is
computed and a PWM is constructed by computing the log ratio of observed to expected
probability (Figure 1.2c-d). The PWM can then be used to provide a quantitative score
reflecting the likelihood of binding (Figure 1.2e).
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The TF sequence specificity is often graphically represented as a sequence logos, which
reflect the position-specific conservation of bases. The conservation at a given position is
computed as the Shannon entropy, reflecting the information content (IC). Each position in a
sequence logo is depicted as a stack of letters, where the height of each letter is relative to its
relative frequency of the IC (Figure 1.2f).
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Fig. 1.2 Modelling TF-binding using PWMs. (a) Given a set of binding sites for a TF, (b) the
consensus sequence provides a qualitative approach of describing the TF specificity. (c-d)
PFMs and PWMs instead model specificity quantitatively, which can then (e) be used to
score potential binding sites. (f) The specificity of a TF can be visualised using the sequence
logo. Figure adapted from [60].
Today, PWMs remain the de facto standard for predicting TFBSs, offering a flexible,
and intuitive approach to modelling TF sequence specificity. However, they do possess
several drawbacks. First, a PWM assumes positional independence, meaning that each
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position independently contributes independently to the final score. Many studies have,
however, shown that co-dependent positions do exist and play a significant role in binding
affinity [61–63]. Second, and more importantly, not all regions predicted as TFBSs sites will
correspond to functional regulatory sites, particularly in short length motifs where matches
are more likely to occur by random chance. This results in a high false positive rate. Other
limitations of PWMs include that they do not account for other mechanisms of binding such
as the sequence context around the immediate motif, which has been shown to facilitate
binding [64, 65].
Adapted versions of PWMs have been developed in an attempt to reduce the effects
of some of these drawbacks. For example, the dinucleotide weight matrix was developed
to account for co-dependency between positions [66]. Predictions from PWMs have also
been limited to regions more likely to be functional, such as those with regions of high
sequence conservation, or phylogenetic footprints, in attempt to increase identification of
functional binding sites. More recently, sophisticated approaches employing hidden Markov
models (HMMs), and machine learning including support vector machines (SVMs) [67],
deep learning [68, 69], and random forests [70] have been used to model TF specificity and
predict TFBSs. Such approaches have been trained on both regulatory and random genomic
sequences to learn far more complex patterns underlying the TFBSs, beyond what is capable
by PWMs.
Computational predictors of TFBSs have significantly advanced over the past several
decades. However, much work is yet to be done for improved sensitivity and accuracy.
Sequence specificity alone is not sufficient to capture all variability observed in TF-binding.
Specifically, many other factors have been shown to dictate binding for many TFs such as
geometric complementarity between DNA and the DBD [71], epigenetics [72], chromatin
accessibility [73] and cofactor availability [74]. For instance, a recent study that incorporated
three-dimensional features of DNA shape was able to bring a substantial improvement to
the performance of PWMs [71]. Incorporating a larger number of such mechanisms into
TF-binding models will be key to accurate modelling of TF binding in the future.
Genetic variation in TFBSs
Given the structured patterns encoded within TFBSs, genetic variation can alter sequence-
specific binding sites and either abolish or create a novel binding site. Known disease
variants have been found to be enriched in both cis and trans-regulatory regions [75, 76] and
specifically in TFBSs [77]. Understanding how variation alters binding is therefore crucial to
understand the exact mechanisms underlying aberrant gene regulation.
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Early approaches used mutagenesis combined with EMSA to assay the impact of sequence
variation. The first of such studies appeared in the early 1990s which investigated the role
disease variants in the gain or loss of TF binding, for a limited number of TFs with well-
characterized DNA binding specificities at the time. One of the first was that by Martin et
al., who attributed the increased expression of the HBG gene in hereditary persistence of
fetal haemoglobin to a variant in its core promoter that altered binding specificity to create a
novel binding site for GATA1 TF [94] (Table 1.1). Another example is that of Crossley et al.
where a haemophilia-associated variant directly upstream of the F9 gene transcription start
site (TSS) disrupts the binding site for androgen receptor (AR) (Table 1.1). A larger list of
examples is listed in (Table 1.1).
Today, the extensive availability of TF-binding specificity models has allowed for in silico
prediction of variants impacting TFBSs. A typical way of approaching this is to the assess the
difference between the PWM score of two alleles, where a larger difference indicates a larger
impact on TF-specific binding [77]. Other methods such as gkmSVM [103], DeepSEA [69]
and DeepBind [68] have devised similar approaches using machine learning-based predictors,
instead of PWMs. Such approaches are limited in their interpretability since they employ
black box approaches, the direct impact of a variant cannot be graphically represented. They
do, however, harness the ability to model far more complex binding mechanisms.
A relatively novel experimental approach to characterising the impact of genetic variation
on TF binding is the analysis of allele-specific binding (ASB) in ChIP-seq data [104, 105].
Given ChIP-seq data measuring the occupancy for a particular TF in a sample (tissue or cell-
line), along with the corresponding genotype for the sample, one can identify heterozygous
variants and count the number of ChIP-seq reads that map to the reference and alternate
alleles. Loci exhibiting significant imbalances in mapped read counts are then classified
as ASB events, in which one allele exhibits a significantly lower number of mapped reads
compared to the other; in particular, significance here can be tested using a binomial test
[104, 106]. Identified ASB events are not necessarily causal and the observed effect can
instead be caused by another variant in LD, epistatic effects, whereby multiple variants
contribute to the effect [107] or epigenetic effects influencing binding [108]. Nevertheless,
ASB mapping provides an elegant alternative to prioritizing causal variants and assessing the
impact of variants on TF binding.
TF binding is a complex mechanism that is collectively driven by a number of factors
including sequence specificity. Altered TF binding has the ability to alter gene expression and
future improvement to binding predictors will allow us to more accurately pinpoint causal
variants.
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1.3.2 Post-translational modifications
Post-translational modifications (PTMs) are reversible or irreversible chemical modifications
made to a protein and are involved in a multitude of biological functions such as cellular
signalling [109], protein folding and degradation [110] and metabolism [111] to name
a few. PTMs act as molecular switches by introducing conformational changes to the
protein’s structure, promoting or disrupting protein interactions or altering protein localization
[112, 113] ultimately extending the functional repertoire of the proteome. Over 200 different
types of PTMs have been characterized [114] and amongst the most commonly occurring
include phosphorylation, acetylation and ubiquitination (Table 1.2). Modified sites have
been well-characterised and collated into resources such as UniProt [115], dbPTM [116]
and PhosphoSitePlus [117]. Commonly, PTMs are reversible and involve two enzymes a
writer, responsible for attaching the modification and an eraser responsible for removing the
modification. PTMs are often attached to side chains of certain amino acids that act as strong
(S, T, Y, R, K, H, D, E, M, C) or weak (N, Q) nucleophiles. For instance, acetylation involves
the addition of an acetyl group to lysine residues (Table 1.2).
Modification Number of
proteins
Number of
sites
Commonly modified
residues
Phosphorylation 19,655 231,160 S, T, Y
Ubiquitination 9,022 63,729 K, C
Acetylation 7,555 22,762 K, A, M
Methylation 5,607 14,807 R, K, C
Sumoylation 2,155 6,987 K
O-linked Glycosylation 764 4,738 T, S, K
N-linked Glycosylation 1,134 2,976 N, K, D
Disulfide bond 167 1,136 C
S-nitrosylation 448 749 C
Hydroxylation 38 274 P, K, N
Palmitoylation 93 179 C
Pyrrolidone carboxylic acid 82 83 Q
Gamma-carboxyglutamic acid 10 82 E
S-Nitrosylation 70 82 C
Table 1.2 Identified PTM sites in human collected from public databases dbPTM [118] and
PhosphoSitePlus [117]. For each PTM, the number of proteins with at least one site and the
total number of sites are shown. Only the top 15 PTM types, as defined by the number sites
are shown.
Given the functional relevance of PTMs, it is evident that variants affecting PTM sites
can alter the modification through disrupting the modifiable site and affecting downstream
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function. Indeed there have been many reported cases where mutations of PTM sites
were directly associated with disease phenotypes. For instance, in the androgen receptor
(AR), loss of acetylation has been associated with spinal and bulbar muscular atrophy, a
neurodegenerative disorder affecting muscle movement. In the wild-type AR, mutations of
residues K630, K632 and K633 to alanine disrupt acetylation sites and have been shown
to significantly impede nuclear translocation. Furthermore, K632A and K633A mutants
aggregate and co-localise with other proteins (HSP70/HSP90) resulting in loss of proteasome
function [119]. Another example is that of the prion protein (PRNP), where the substitution
T183A was implicated in spongiform encephalopathy through the loss of N-glycosylation
[120]. More systematic studies have shown that PTM sites are under strong negative selection
and are significantly enriched in disease mutations [121]. The study of PTMs in the context
of genetic variation can, therefore, offer insight into altered mechanisms and help identify
causal mutations.
Kinase-substrate phosphorylation
Phosphorylation is the most prominent PTM and involves the transfer of a phosphate group
(PO3−4 ) to different amino acids, including serine, threonine or tyrosine residues of proteins.
In humans, this process is catalysed by over 500 protein kinases [122], which regulate a
spectrum of function. This process is crucial for the regulation of a diverse range of cellular
process, including growth, metabolism, cell cycle progression, differentiation, and apoptosis
[122].
The mode by which protein kinases recognize specific target residues depends on numer-
ous factors such as co-expression, residue surface accessibility, and other PTMs [123]. More
importantly, kinases have been shown to have preferences for certain amino-acids flanking
the central phospho-acceptor residue [123]. These preferences define the kinase-substrate
specificity often referred to as the kinase-substrate ‘motif’, which were initially defined by
searching for consensus patterns among a set of known target phosphosites. For example, the
cyclin-dependent kinase (CDK2) is known to preferentially target the motif [ST]PX[RK] (a
proline at position +1, any amino-acid at position +2 and an arginine or lysine at position +3)
[123].
Kinase-substrate motifs were initially employed to predict potential targets for kinases
[124]. However, to allow for the modelling of kinase-substrate specificity and quantitative
prediction of potential targets, PWMs have been employed. Similar to TFs, using a set
of target phosphosites sequences a PFM is constructed, where the observed amino acid
frequencies are tallied up for each position. This matrix can then be used to generate the
PWM by calculating the log ratio of observed versus expected relative frequencies. Generated
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PWMs can be used to provide a quantitative score for a peptide describing the likelihood
of kinase-specific phosphorylation. Sophisticated methods that employ machine learning
approaches such as neural networks [125], SVMs [126] and random forests [127] have since
been developed that similarly, model kinase sequence specificity and successfully predict
putative target phosphosites with a higher degree of accuracy [125].
The role of genetic variation on kinase-substrate phosphorylation
Disease variants occurring in kinase-substrate sequence motifs have been shown to rewire
phosphorylation networks and potentially drive disease [148, 146]. Variants falling within
specificity determinants could alter kinase-substrate phosphorylation either by diminishing
an existing site (loss-of-binding) or introducing a novel binding site (gain-of-binding) (Fig-
ure 1.3a). By altering phosphorylation, these variants individually or collectively interfere
with underlying signalling networks that may contribute to disease properties.
Several studies have described disease mutations altering key residues in kinase-substrate
phosphorylation motifs. For instance, mutations in protein-tyrosine phosphatase 1B (PTPN1)
have frequently been associated with type 2 diabetes. Specifically, the rare P387L substitution
disrupts phosphorylation of the phosphosite S386, resulting in altered phosphatase activity
[131] (Figure 1.3b). Another example is that of KCNH2, a member of the potassium voltage-
gated channel family. Here, the substitution K897T introduces a novel phospho-acceptor
residue for the Akt protein kinase, resulting in altered protein regulation that contributes to
cardiac arrhythmias (Figure 1.3b). A larger set of examples are summarised in Table 1.3. In
addition to these examples, recent analyses of cancer driver mutations in regions flanking the
phospho-acceptor have implicated phosphorylation as an altered mechanism in disease [148].
Predicting the impact of variants on kinase-substrate phosphorylation
There have been a number of studies systemically exploring the impact of phosphorylation-
associated variation and numerous resources have been developed to categorize likely causal
variants in phosphorylation. The PTMVar dataset provided within the PhosphoSitePlus
database collates disease mutations curated in the UniProt resource [149] that occur in the
vicinity of experimentally identified phosphosites, identifying over 19,000 variants falling
within seven residues of a phosphosite [117]. The PTM-SNP database more generally
identifies ~180,000 variants occurring in proximity to any PTM-modified residues including
phosphorylation [150].
While such documented variants are more likely to play a role in altering signalling
networks, additional information on whether they impact underlying mechanisms driving
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phosphorylation is not provided. As such, several resources were developed that take into
account the modelling of kinase-binding preferences. For example, Ryu et al. modelled
kinase-binding preferences using SVMs and used them to assess the impact of over 33,000
nonsynonymous mutations obtained from Swiss-Prot [151, 149]. Impact predictions were
then provided through the PhosphoVariant database [151]. Similarly, Ren et al. used the
kinase-specific phosphorylation site predictor GPS 2.0 [152] to assess the impact of over
64,000 nonsynonymous variants from the dbSNP resource [4] and provide results into the
PhosSNP database [153].
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Fig. 1.3 Genetic variation in kinase-substrate phosphosites. (a) Substitutions of residues
critical to the sequence specificity of a can either result disrupt existing phosphosites or create
new ones. (b-c) Two examples of disease variants altering specificity determinants. (b) The
loss of a proline at position +1 disrupts a key motif for the CDK1 kinase, resulting in the loss
of phosphorylation at S386 [131]. (c) The substitution of a lysine to threonine introduces a
novel phosphorylation site for the AKT1 kinase [137].
The described databases contain pre-computed predictions on a static set of variants. To
facilitate flexibility in predicting any mutations, user-friendly tools were then developed,
the first of which was the machine learning approach MIMP [146]. Briefly, MIMP employs
PWMs to model binding specificities for 124 kinases. Peptides are scored before and after a
mutation and a Bayesian approach is used to identify variants impacting the kinase site [146].
ReKINect utilises the NetPhorest [125] and NetworKIN [154] algorithms, which model
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kinase specificity using neural networks. The magnitude of loss or gain of phosphorylation
is then assessed through the predicted probabilities of kinase-binding to the wildtype and
mutant peptides [155]. PhosphoPICK-SNP is another tool that allows for prediction of
phosphosite-altering variants [156] by employing PhosphoPICK, a method which utilises
HMMs to model kinase-specificity. Unlike MIMP and ReKINect, PhosphoPICK incorporates
additional contextual information such as protein-protein interaction (PPI) networks and
protein abundance allowing to allow for more accurate kinase-substrate and variant impact
prediction. The described approaches have associated web servers and/or software libraries
that further facilitate the interpretation of protein-coding variants.
1.3.3 Short linear motifs
Short linear motifs (SLiMs) are short, conserved, stretches of sequences (typically 3-11
amino acids long) following a particular pattern that is able to mediate transient protein
interactions [157]. SLiMs are linear meaning that they are bound without the need of three-
dimensional structure to bring residues in close proximity to one another. The linear pattern
is often represented as a regular expression to reflect the positions and of residues critical
for binding. SLiMs typically occur in intrinsically disordered regions, which lack structure
and allow for the plasticity often required for binding [157]. It is characteristic that within a
SLiM, only a limited number of residues are responsible for mediating the interaction. SLiMs
are typically bound at low affinities meaning interactions are transient in nature, allowing
for the formation of highly rapid and dynamic interaction networks [157]. By recognising
and binding SLiMs, protein domains are able to carry out a variety of cellular functions
including, but not limited to, proteasomal degradation, apoptosis, ligand binding and PTMs
[157]. Since sequence specificity underlying PTMs, which was previously discussed, can
be thought of as a SLiM, I generally refer to SLiMs as those not involving PTM functions
throughout this thesis.
Both experimental and predicted SLiMs identified in the literature have been manually
curated and compiled into publicly accessible resources. These include the eukaryotic
linear motif (ELM) database, the LMPID database [158], Minimotif Miner (MnM) [159],
and Scansite [160]. The ELM resource is, by far, one of the largest and most commonly
used. It contains a total of 2,972 experimentally validated instances of SLiMs of 264
classes that mediate 1,429 interactions across 188 organisms [161]. Such resources provide
comprehensive and systematic datasets on identified SLiMs.
Variants altering critical residues in a SLiM can interfere with the underlying interaction
and thus function. There have been numerous examples linking mutations in SLiMs to
diseases. For instance, the 14-3-3ζ protein (YWHAZ) is responsible for regulating the
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Fig. 1.4 An example of a SLiM affected by a disease variant. (a) 14-3-3ζ protein (grey)
in complex with the RAF1 proto-oncogene peptide containing the SLiM (PDB:4IHL),
represented as a regular expression in (b). (c) A variant (red) affecting a key residue in the
SLiM (green) results in loss of binding by 14-3-3ζ .
activity of proto-oncogene RAF1 through binding at its motif RSXSpXP [162], where Sp is
a phosphorylated residue. The P261S substitution has been implicated in Noonan syndrome
and abolishes the SLiM mediating the interaction, thereby deregulating its activity [163]
(Figure 1.4). There have been cases where substitutions of non-critical residues in SLiMs are
associated with disease. Although such positions are not directly involved in binding, they
can contribute to the stability of the interaction, for example by forming hydrogen bonds
with the interactors [164].
1.3.4 Protein Stability
The three-dimensional configuration of a protein is key to its function. Upon protein folding,
a linear string of amino acids is converted into a functional three-dimensional structure that
is maintained and stabilised by forces and interactions formed between atoms of the residues.
The folds and interactions formed by a protein are driven primarily by its amino acid sequence
[165]. Throughout this process, the protein traverses an energy landscape whereby unstable
secondary, tertiary and quaternary folds and interactions are formed until a stable and minimal
energy structure is achieved (Figure 1.5). How proteins traverse this landscape and reach a
stable folded state ever so rapidly while avoiding misfolding and aggregation is very much
an open question in science. An improved understanding of mechanisms underlying the
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stability of protein intermediates during this process will allow us to better grasp how protein
misfolding drives proteopathic diseases and how disease variation can alter this landscape.
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Fig. 1.5 A schematic of the energy landscape traversed by a protein during folding. Figure
adapted from [166].
Forces driving protein stability
There are several forces that govern the stability of the native conformational state of
the protein. Commonly, these include ionic bonds, disulphide bridges, hydrogen bonds,
hydrophobic interactions and VdW forces [167, 168] (Figure 1.6). Ionic bonding or salt
bridges are forces that rely on the charge of the amino acid side chain. Naturally, the side
chain of some amino acids are either fully protonated or fully deprotonated making them
acidic (e.g. aspartic acid, glutamic acid) or basic (arginine, lysine). When oppositely charged
side chains of residues are in close proximity (typically within 5Å) the bond formed is often
highly favourable thereby contributing to the stability of a protein [169]. Hydrogen bonds
are another force that largely contributes to protein stability. They form when a hydrogen
atom covalently bonded to a highly electronegative atom (donor e.g. nitrogen or oxygen)
interacts with another electronegative atom (acceptor) through electrostatic interactions. This
will often occur when the hydrogen atom is less than 2.5Å away from the acceptor and
the donor-hydrogen-acceptor angle is between 90-180°[170]. Hydrophobic interactions
are thought to be one of the largest contributing forces to protein stability [168]. They
help reduce the surface area of the protein to avoid unnecessary interactions with polar
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solvents and occur when hydrophobic nonpolar residues in the protein (alanine, valine,
leucine, isoleucine, phenylalanine, tryptophan and methionine) interact with one another in
the presence of a polar solvent (typically water). VdW forces occur through electrostatic
interactions between any two or more atoms in close proximity to one another (typically less
than 4.5Å). They form between a temporary dipole (a molecule with uneven distribution of
electrons, causing slightly positive and negative poles) and another atom that, upon contact,
becomes dipolar (an induced dipole). Although VdW forces are much weaker in nature than
that of chemical covalent bonds, an accumulation of VdW forces can result in significant
stability contributions.
Overall, such forces and others, help provide the stability and allow conformational
flexibility required to carry out protein function.
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Fig. 1.6 Schematic representing common forces and interactions driving protein stability.
The thermodynamic stability of a protein
The thermodynamic stability of a protein that is constantly between folded and unfolded
states can be used to represent the overall stability of a protein (Figure 1.5). The stability of a
protein can then be calculated as the difference in Gibbs free energy, ∆G, between folded
(G f ) and unfolded (G f ) states of the protein:
∆G = G f −Gu (1.1)
G = H−T S (1.2)
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where G is the Gibbs free energy defined in terms of the enthalpy (H), temperature (T)
and entropy (S) of the system. Typically, ∆G is measured in kcal/mol and a negative value
indicates the protein is stable.
Experimental approaches to identify the stability of a protein typically involve first
denaturing a native-state protein using heat or denaturing agents (e.g. urea, guanidinium
chloride). The choice of denaturing agent often depends on the protein as some proteins
are resistant to denaturing by certain agents. A readout for how denatured the protein is
measured at different temperatures or denaturing agent concentrations. Examples of these
readouts include ultraviolet (UV) light absorbency, fluorescence, or the catalytic activity of
the protein. UV light absorbency and fluorescence utilise the presence of aromatic residues
like tryptophan, tyrosine and phenylalanine, which are often partially buried in the core of
the protein. As such, these residues absorb and fluoresce light differently when the protein is
folded or unfolded [171], serving as an ideal indicator of the denatured level. Similarly, the
catalytic activity of a protein often directly corresponds to the folding state, i.e. denatured
proteins lose their catalytic activity [172]. A curve is then drawn where the readout measured
is plotted as a function of the varying temperature or denaturant concentration (Figure 1.7a).
This can then be used to calculate the rate at which the protein folds and unfolds, defined as
k f and ku, respectively. The ratio between these values is defined as the equilibrium constant
Keq and is used to calculate the stability of the underlying protein, ∆G. Given the gas constant
(R) and the absolute temperature in kelvins (T ), the stability is calculated as follows:
Keq =
ku
k f
(1.3)
∆G =−RT lnKeq. (1.4)
Genetic variants altering protein folding and stability
Given the role of the forces formed between residues in the stability of a protein, mutations
substituting these critical residues can lead to a decrease in stability, and therefore function.
The impact a mutation has on protein stability is calculated by computing the difference
between the free energy of the wildtype (∆Gwt) the mutant (∆Gmut), which is referred to as
∆∆G:
∆∆G = ∆Gwt −∆Gmut . (1.5)
This value quantifies the magnitude of effect a mutation has on stability. A high value
here (>1.8) indicates that the mutation is highly destabilising, whereas a low value (<-1.8)
indicates the mutation introduces further stability [173]. Over the past several decades,
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Fig. 1.7 The impact of mutations on protein stability. (a) To experimentally identify ∆G
values, temperature or a denaturant are used to denature a protein while a readout, such as
catalytic activity, measures the denatured level. The generated curve aids the calculation of
∆G. (b) Energy landscapes of proteins before and after a destabilising mutation. The mutated
protein has a low ∆G value compared to the wildtype and therefore, the computed ∆∆G is
highly positive.
studies have carried out thousands of mutagenesis experiments to investigate the role of
mutations in protein stability. The majority of identified destabilising mutations occur in the
core of the protein compared to the surface. However, many surface mutations can still alter
function by, for instance, affecting the active site of a protein or a PPI interface [174] (see
section 1.3.5). The results of these experiments have been manually curated and collated in
numerous online resources such as the ProTherm database [175], protein mutant database
(PMD) [176], and the human genome mutation database (HGMD) [177]. ProTherm is one
of the largest database and most comprehensive resource listing experimental ∆∆G values
for 15,437 documented mutants in 311 protein structures [175].
It is no surprise that disease mutations have also been shown to alter protein stability.
There has been a wide range of diseases associated with either the stabilization or destabiliza-
tion of proteins such as prion [178, 179], muscular [180], retinal [181] and neurodegenerative
[182, 183] diseases, to name a few. For instance, the M114T substitution in profilin 1 (PFN1)
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is associated with amyotrophic lateral sclerosis through creating a cavity in the core of the
protein, thereby destabilising it [180]. Conversely, the H101Q substitution in the CLIC2
protein, which is associated with X-linked intellectual disability, further stabilises the protein.
Due to the added stability, the likelihood of conformational changes in CLIC2 is dramatically
reduced, which impedes its transport to the cell membrane [184, 185]. These examples
highlight the significance of disease-causing variants on protein stability.
Computational methods for predicting the impact of genetic variants on protein stabil-
ity
To facilitate identification of both stabilising and destabilising variants, computational ap-
proaches have been developed that predict the impact of a variant on protein stability (∆∆G).
Stability predictors can be classified into two primary classes: sequence-based predictors and
structure-based predictors. The performance of these methods is typically measured with
respect to experimentally identified ∆∆G values obtained from the ProTherm database [175].
A quantitative value describing the performance the stability of the underlying protein as the
correlation coefficient between experimental ∆∆G values and those predicted by the method.
Sequence-based predictors such as MuStab [186], EASE-MM [187], and iPTREE-STAB
[188] utilise machine learning methods such as decision trees [188] or SVMs [186, 187] to
predict ∆∆G values. Sequence features include biochemical features of amino acids, such
as the hydrophobicity, polarity, molecular weight, and acidity (pKa), as well as sequence-
based structural features such as the tenancies for an amino acid to form different secondary
structures and proportions of a residue estimated to be buried within the core [186]. Other
biological features have also been used such as the number of codons per amino acid, average
residue flexibility, refractivity and the relative mutability of an amino acid [186].
Alternatively, structure-based approaches such as FoldX [189], MAESTRO [190], Eris
[191], SDM [192] and PoPMuSiC [193] exploit three-dimensional features available in
protein structures to predict ∆∆G values. These approaches often utilise a set of physics-
based energy functions to estimate the overall free energy of folding, ∆G, of the wildtype
and mutant. The contribution of stabilizing forces, such as electrostatic interactions, covalent
bonding, and VdW forces, to the total energy, is identified and combined in a manner that
accurately reflects the free energy of folding [194].
Sequence-based predictors benefit from higher coverage since they do not depend on
the availability of protein structures yet often suffer from lower prediction accuracy. The
bottleneck of structural data availability in structure-based approaches is often mitigated by
hybrid approaches that incorporate sequence-based information [195]. Furthermore, recent
studies have shown that even predictions made with medium to low-quality homology models
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based on structures from closely related organisms show virtually no loss in prediction power
[196].
In summary, protein stability is a mechanism that plays a major role in maintaining
regular protein function. Mutations altering the biochemical properties of amino acids can
disrupt or create stabilising interactions, and potentially alter protein function. Stability is
also commonly altered in a wide variety of diseases. Understanding how mutations alter
protein stability is, thus, of considerable interest for genetically engineering proteins for
industrial, environmental and pharmaceutical applications, as well as better understanding
the role of mutations in disease. The developed methods for predicting the impact of variants
on protein stability is key for variant interpretation. However, much work is to be done to
improve the accuracy of these algorithms, which will partly be aided by increased availability
of structural data.
1.3.5 Protein-protein interaction interfaces
Rather than acting individually, proteins typically form macromolecular structures that carry
out biological function through cooperative interactions with one another. With the majority
of human proteins involved in at least one complex [197], PPIs are at the centre of a large
variety of biological processes. Much like protein stability, these interactions are stabilised
by forces within the interaction interfaces of both proteins such as hydrogen bonds, salt
bridges, hydrophobic effects and VdW forces [198]. Residues within an interface that are
crucial for binding are often referred to as ’hot-spots’ and contribute to the Gibbs free energy
of binding (∆Gbind). Understanding of the molecular determinants underpinning the stability
of PPIs will help us better understand how these interactions form and how genetic variation
can alter them.
Properties of protein interaction interfaces
PPIs are often mediated by structured globular domains that interface with the partner. The
complex formed as a result of the interaction between two different proteins is referred
to as heterodimers, whereas a self-interacting complex is a homodimer. The duration of
the interaction can also vary, ranging from short-lived interactions (e.g. those mediated by
SLiMs, see section 1.3.3) to more permanent ones (e.g. the ribosomal machinery).
Interaction interfaces often exhibit characteristic features that distinguish them from the
rest of the protein. For instance, the amino acid composition at interaction interfaces tends to
be more hydrophobic relative to other surface residues and less hydrophobic relative to the
core of the protein [199–201]. The geometric shape of interfaces also plays an important role
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in ensuring a complementarity between both proteins [202]. Computational predictors often
leverage this information to predict interface residues [203, 204], however, the increasing
availability of protein structures is simplifying the identification of bona fide interfaces. The
protein data bank (PDB) currently holds 123,388 protein structures, 6,363 (5%) of which
represent protein complexes of one or more PPIs. Resources such as Interactome3D [205]
and eppic [206] have readily made available the structures of binary PPIs from multimeric
protein complexes in PDB. Identifying interface residues in these structures is typically
carried out by computing the relative surface accessibility (RSA) of residues [199, 200, 207],
a measure that reflects how exposed or buried a residue is relative to its maximum solvent
accessible surface area. The RSA is computed for residues in both monomeric structures
and the interaction complex then subtracted to identify residues that are exposed in the
monomeric structure but buried in the complex (Figure 1.8a). Although this is effective at
identifying interface residues, not all residues will contribute equally to binding stability
[208], and additional measures must be taken to identify those that do.
Experimental and computational approaches to identify the contribution of interface
residues to binding
Many experimental techniques aim to identify the precise contribution of interface residues
to binding. For instance, alanine-scanning is a process by which surface residues are
systemically mutated to alanines. The binding affinity can then be assayed for each mutant to
assess the impact of the variant [209]. However, such approaches are often low-throughput
and time-consuming. Instead, techniques such as deep mutational scanning provide a more
high-throughput approach at assaying the contribution of interface residues to binding [210–
212]. While this is approach is exhaustive and highly effective at identifying residues
implicated in binding, routine application remains challenging and time-consuming.
Alternatively, computational approaches, similar in nature to those used for protein
stability, have been developed that predict the impact of mutations on the free energy of
binding, ∆∆Gbind (Figure 1.8b). The commonly used algorithms include FoldX [189],
BindProfX [213, 214] and MutaBind [215]. MutaBind and FoldX use empirical energy
functions to estimate ∆∆Gbind . BindProfX uses information on conserved residues within
homologous binding domains combined with ∆∆Gbind predictions from FoldX to improve
accuracy. These predictors are often benchmarked against experimentally derived ∆∆Gbind
values, which are deposited in resources like the SKEMPI database, which holds ∆∆Gbind
values for over 3,000 mutations across 85 PPIs [216] and more recently the PROXiMATE
database, with over 6,200 mutations across 175 complexes [217].
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Fig. 1.8 (a) To identify interface residues the RSA of residues in monomeric structures is
subtracted from that of the interaction complex. This identifies residues that are exposed
in the monomeric protein but buried within the complex. (b) Predicting the impact of a
mutation on a PPI involves predicting the binding energy, ∆Gbind , of both wildtype and
mutated interaction complex. The difference ∆∆Gbind between those two values typically
indicates whether the mutation destabilises, stabilises or has no impact on binding.
There still exists much room for improvement, with respect to the performance of
predictors, partially due to the relatively limited number of experimentally derived ∆∆Gbind
values and PPI structural data. These predictors do, however, provide a quick and inexpensive
alternative to experimental approaches and have been used to uncover valuable insights
into developing drug PPI inhibitors [218], PPI-mediated viral infections [219, 220], and
engineering of novel PPIs [221].
Disease variants in interaction interfaces
PPIs are commonly modified in disease. Disease variants have been known to occur in
interface residues, resulting in altered binding and leading to disease phenotypes. For
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instance, the substitutions K228E and N374H in T-box, brain, 1 (TBR1) are associated
with sporadic autism and have been shown to abolish both homodimerization of TBR1
and interaction with the TF FOXP2, which has been previously implicated in speech and
language disorders [222]. Another example is that of the proliferating cell nuclear antigen
(PCNA), which has been associated with multiple diseases including DNA repair diseases
such as xeroderma pigmentosum, Cockayne syndrome, and ataxia telangiectasia [223]. The
substitution S228I was shown to cause a large deformation of a binding pocket, abolishing
binding with multiple partners [224].
More systematic studies have been carried out that demonstrate, on a large-scale, the
role of disease variation in PPIs. For instance, a recent study analysed mutation data from
5,989 tumour samples across 23 different cancer types in the context of interfaces in over
10,000 proteins [225]. They identified over 100 PPI interfaces significantly enriched in
somatic cancer mutations, one-third of which were interfaces in known cancer driver genes,
which were also shown to serve as central hubs in PPI networks. The remaining proteins
showed literature implicating them in cancer. These findings were additionally coupled with
clinical data such as survival curves to highlight the implication of PPI interface mutations.
More structure-based studies have utilised predictions of ∆∆G of binding to assess the role
of disease variants in PPIs. For example, using FoldX, Billur Engin et al. analysed over
1.2 million somatic cancer mutations in the context of over 4,800 experimentally derived
interaction interfaces and found that over 20% of mutations on the surface of a protein were
predicted to affect binding affinity [226]. These mutations commonly fall within interaction
interfaces of known tumour suppressors and oncogenes to alter binding.
Understanding the molecular underpinnings of PPI specificity is key to understanding the
impact of mutations on protein interfaces. Advances in both physics and statistical-based
algorithms have allowed for computational tools, such as FoldX, to estimate the impact upon
which a mutation will have on the binding. While such approaches provide a convenient way
by which mutational impact can be assessed, their performance hampered by the scarcity of
experiential ∆∆Gbind values and structural data. Increasing availability of such data, along
with advances in NGS and proteomics, will propel a complete understanding of the molecular
basis upon which mutations alter PPIs.
1.3.6 Initiation and termination of translation
Translation is an intricate system by which ribosomes convert transcribed mRNA into a
folded, functional protein (Figure 1.9a). Initiation and termination of translation are guided
by start and stop codons, respectively. Start codons indicate the start of translation and in
eukaryotes it is almost always the AUG codon, which encodes for a methionine. Unlike
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eukaryotes, prokaryotes have a selection of primarily three start codons: AUG (73%), GUG
(14%) and UUG (3%) [227]. Stop codons, encoded by UAG, UAA, and UGA, indicate
a signal for the termination of translation (Figure 1.9b). This occurs because transfer
RNAs (tRNAs) do not harbour any anticodons that are complementary to stop codons, thus
forcing the release from the polypeptide. Mutations disrupting start or stop codons can have
drastic effects that hamper translation and result in mRNA degradation, protein truncation
or misfolding. Accounting for start and stop codons is therefore insightful to understanding
altered mechanisms and their role in disease.
1.3.7 Mechanisms for quality control of variants altering start and stop
codons
Mutations can have one of three effects on start and stop codons: disrupt a stop codon,
introduce a premature stop codon or disrupt a start codon.
A point mutation disrupting a stop codon, also known as a nonstop mutation, and results
in the stalling of the ribosome upon reaching the 3’ end of the mRNA. This triggers a
process termed nonstop-mediated decay (NSD). In S. cerevisiae, this process involves the
recruitment of the Ski complex, containing cofactors SKI2, SKI3, SKI8, and SKI7, as well
as the exosome complex. Together, the SKI and exosome complexes are responsible for
degrading the mRNA in a 3’ to 5’ fashion, while also repressing further translation of the
transcript [228] (Figure 1.9b). S. cerevisiae E3 ubiquitin ligases LNT1 and NOT4 then
promote polyubiquitination-mediated degradation of the produced polypeptide [229, 230].
Genes involved in the SKI and exosome complexes are highly conserved across eukaryotes
[231] and their homologs also play key roles in NSD [232].
Nonsense mutations introduce premature stop codons resulting in aberrant mRNA, which,
if translated, will produce shortened polypeptides that will likely lead to deleterious effects
on protein function [233, 234] (Figure 1.9c). The severity of nonsense mutations primarily
depends on their location in the protein, where variants closer to the N-terminal are more
likely to have a deleterious impact. Processes in place such as nonsense-mediated decay
(NMD) aim at reducing this likelihood by purging mRNA transcripts carrying nonsense
mutations (Figure 1.9c). In S. cerevisiae, when the ribosome reaches the termination codon it
is often unable to release an incomplete polypeptide [235]. Termination factors SUP34 and
SUP45 are recruited, which in turn recruit three additional factors UPF1, UPF2, and UPF3.
This promotes the disassociation of the ribosome, GTP hydrolysis of the generated peptide
and recruitment of the DCP1-DCP2 decapping enzyme complex to the 5’ of the mRNA
[235]. DCP1-DCP2 triggers hydrolysis of the 5’ cap, which quickly results in degradation
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Fig. 1.9 (a) Translation involves the ribosome machinery (blue) sliding across generated
mRNA transcribed from DNA and producing a polypeptide which folds into a fully functional
protein structure (b-d) mRNA surveillance pathways to deal with aberrant transcription or
translation. These include (b) the loss of a stop codon (c) premature gain of a stop codon
and (d) loss of a start codon. Such effects either result in a non-functional misfolded or
truncated protein or the triggering of respective pathways to degrade generated polypeptides
and mRNAs.
of mRNA in a 5’ to 3’ fashion by the exonuclease XRN1 [236]. Such fail-safe mechanisms
reduce misfolding of protein and aberrant functions.
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Finally, mutations disrupting the AUG start codon in eukaryotes significantly hamper
translation efficiency of mRNA. In many cases, either the mRNA or generated protein is
degraded (Figure 1.9d). A recent study in S. cerevisiae shows that the degree of efficiency
of non-AUG start codons depends on the sequence context. Specifically, if there is another
AUG codon upstream of the mutated start codon, translation initiation can be rescued.
Disease mutations in start and stop codons
Disease-causing mutations that alter start and stop codons have been well documented in the
literature. For instance, the nonsense mutation G542X in the CTFR gene results in significant
loss-of-function and has been implicated in cystic fibrosis [237]. Another example is the
nonstop mutation X420Y in the microphthalmia-associated TF (MITF), which is associated
with Waardenburg syndrome, a genetic disorder characterised by deafness and pigmentation
changes [238]. The mutation causes a 33 residue extension of the protein product, resulting
in the reduced transcriptional activity of MTIF [238]. A final example is the M1I substitution
identified in encephalomyelitis (inflammation of the brain and spinal cord) patients, causing
the loss of the start codon in CMT1X. This results in abolished gene expression, even though
the mutation had no effect on mRNA levels [239]. These examples highlight how disease
mutation can alter initiation and termination of translation. Disease mutations altering start
and stop codons have also been the subject of a number of therapies that aim to suppress
their effects [240, 241], further elucidating their importance.
1.4 Sequence conservation of proteins
Although not a biological mechanism per se, sequence conservation plays a crucial role in
identifying key functional regions in proteins. Regions of a protein that remain unchanged
over time despite mutational pressure are often due to natural selection and suggest that any
variation would be deleterious to the organism’s fitness [242]. Indeed, conserved elements
include protein domains, which often mediate key proteins function. Some of the most
conserved proteins include essential cellular machinery such as the 16S and 23S ribosomal
proteins, as well as binding domains of ATP-binding cassette transporters and yet these
sequences, remain virtually indistinguishable across organisms that separated by billions of
years of evolution [243]. Therefore, assessing similarities between protein sequences across
organisms offers significant insight into functionally relevant protein regions.
Computational methods have leveraged sequence conservation to predict whether an SNV
would impact protein function [244–246]. These commonly include SIFT [244], GERP++
[245], and PolyPhen2 [246], to name a few. These algorithms in one form or another utilise
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sequence conservation similarly. In brief, for a protein of interest a set of related homologous
protein sequences are identified, typically using programs like PSI-BLAST [247] and used to
construct a multiple sequence alignment (MSA). Given a nonsynonymous SNV, the algorithm
then uses a scoring metric to determine how frequently the mutated residue is observed at
that position within the MSA. Algorithms also often account for the chemistry of amino acids
when identifying how conserved a position is, rather than rely on sequence identity alone.
For instance, a position that exhibits an abundance of glycines, alanines, valines and leucines
does not necessarily lack conservation and could instead indicate the position is tolerant to
amino acids with similar chemical properties, in this case, a hydrophobic side chain.
Algorithms utilising sequence conservation have become a fundamental component of
variant analysis and prioritization pipelines. They have helped identify many causal variants
across human disease [248, 249] and other organisms [250, 251]. Although they do not
directly provide insight into affected mechanisms, they can often instead be combined with
mechanistic predictors to allow for an increased confidence of variant impact prediction.
1.5 Aims of the thesis
Not all genetic variation will influence the phenotype of an organism. I have described here
the approaches taken to identify causal genetic variants, such as GWAS and QTL-based
association methods. Furthermore, I discuss some of the biological mechanisms which
these variants can impact, how they can be computationally modelled and used to provide
mechanistic insight into variant effects. This thesis is primarily focused on the latter.
Having described the importance of kinase-substrate sequence specificity in the context
of disease variants, Chapter 2 describes a computational approach I have developed a method
which utilizes functional interaction data and phosphorylation data to predict specificities
of kinases. This method was applied to human kinases and was able to predict substrate
sequence preferences for over half of all known kinases, capturing known well-characterised
kinase specificities, as well as novel ones. Several specificities were additionally validated
experimentally and were shown to closely resemble predicted ones.
In Chapter 3, I compile a comprehensive set of ASB variants from numerous studies and
use them as a gold-standard to assess how TFBS predictors perform at assessing the impact
of variants on TF binding. Results suggest that TF specificity models exhibit variable levels
performance at predicting the impact of variants, that is independent of the performance of
the TF specificity model at predicting TFBSs. This suggests the mechanism underlying TF
binding for poorly performing TFs is one that is far more complex and robust than expected.
I further compare the performance of different scoring schemes across different methods
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(both PWMs and more sophisticated machine learning approaches) used to assess the impact
of TF binding. For TFs that are unable to accurately predict the impact of variants, I explore
alternative mechanisms such as methylation, DNA shape and binding co-factors that may
explain the poor performance.
Chapter 4 describes a comprehensive effort to compile and benchmark state-of-the-art
sequence and structure-based predictors of mutational consequences and predict the effect of
all possible amino acid and nucleotide variants in the reference genomes of H. sapiens, S.
cerevisiae and E. coli. Predicted mechanisms include protein stability, interaction interfaces,
PTMs and TFBSs. These variant effects are provided through mutfunc, a fast and intuitive
web tool by which users can query pre-computed predictions by providing amino acid or
nucleotide-level variants. I apply computed predictions to analyse known causal disease
variants as well as provide mechanistic hypotheses for causal variants of unknown function.
Chapter 5 involves the analysis of natural variants harboured by wild S. cerevisiae isolates
in the context of predictions generated in Chapter 4. The mechanistic impact predictions
are used to generate gene-level functionality scores, which are then used to perform gene-
phenotype associations. This provides a number of advantages over traditional GWASs,
namely, by identifying dysfunctional genes through analysis of rare genetic variants, it
alleviates the requirement of a large number of samples required to identify associations in
GWASs and uncovers many novel associations.
Chapter 2
Uncovering phosphorylation-based
specificities through functional
interaction networks
In this chapter, we describe a novel computational method, which utilizes functional
interaction data and phosphorylation data to predict sequence specificities of kinases. I
conceived the method and carried out all computational analysis under the supervision of
Pedro Beltrao. I was not involved in the generation of experimental data. Mass-spectrometry
experiments were carried out by collaborators Naoyuki Sugiyama and Yasushi Ishihama
at the University of Kyoto. The work in this chapter includes published material from the
following article:
Omar Wagih, Naoyuki Sugiyama, Yasushi Ishihama and Pedro Beltrao (2016). Uncover-
ing phosphorylation-based specificities through functional interaction networks. Molecular
& Cellular Proteomics, 15(1), 236-245
2.1 Introduction
Over the past decade, there has been an ever-increasing quantity of phosphorylation site
(phosphosite) data, typically identified using mass spectrometry (MS), with over 100,000
phosphosites identified in human [252–254]. Despite this, a large number of these phospho-
sites are without a known upstream regulatory kinase. Compendiums of kinase-substrate rela-
tionships curated from the literature [252–254] currently associate only 6% (6,320/107,444)
of known phosphosites to one or more kinases. While the experimental characterization of
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kinase target phosphosites allows for the discovery of many kinase specificities, they are
typically expensive, time-consuming, and are not feasible for kinases that are difficult to
work with. The ability to uncover specificities driving kinase-substrate phosphorylation will
allow us to better model cellular signalling networks and understand how genetic variation
can rewire such networks.
The only available computational method aimed at predicting kinase-substrate specificity
without any prior knowledge of its substrates is Predikin [255], which does so by employing
substrate-determining residues (SDRs) in the catalytic domain of the kinase. These are
residues that have been identified as driving the kinase’s specificity towards particular posi-
tions in the substrate phosphosite. In Predikin, SDRs are identified by aligning sequences of
kinase catalytic domains using HMMER [256] to identify semi-conserved elements. Residues
surrounding these elements are then mapped to three-dimensional structures of kinases in
complex with their substrate peptide and manually curated for interactions with positions
on the peptide (Figure 2.1a). To predict specificity of a kinase given its sequence, Predikin
first analyses the sequence for a kinase catalytic domain. If identified, the domain sequence
is scanned for previously reported SDRs (Figure 2.1a). Substrate phosphosites of kinases
with similar SDRs are then combined and used to construct a predicted specificity model
(Figure 2.1b). In this way, Predikin makes use of known kinase target sites. While effec-
tive, Predikin exhibits several shortcomings. First, it depends on the availability of protein
structures and therefore cannot be easily scaled to kinase families without three-dimensional
structures nor to other post-translational modification (PTM) recognition domains. Second,
it depends on the availability of kinase-substrate data to construct final specificity models,
further limiting scalability. Lastly, SDRs for tyrosine kinases have not been identified, and
therefore predictions can only be made for serine/threonine kinases.
We decided to take an alternative approach to predicting kinase specificity. Previous
studies have shown that it is possible to use information regarding the interaction partners of
a peptide-binding protein to identify potential motifs mediating these interactions [257]. As
such, putative interaction partners of a kinase should be more likely than random proteins to
be phosphorylated by that kinase. Phosphosites occurring on interaction partners of kinases
should, therefore, confer a bias in amino acid composition toward the kinase’s specificity,
which could be revealed by motif enrichment (Figure 2.1c). We applied our method using
the STRING functional interaction network [258] and publicly available phosphoproteomic
data to predict specificities for 57% (282) of all human kinases. These included kinases
with previously known specificities, as well as other understudied kinases. To validate the
proposed method, we experimentally determined kinase-substrate phosphosites for four
understudied kinases. Predicted models were shown to closely resemble the specificity of
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experimentally identified phosphosites. The analysis was extended to show that specificities
can be predicted, not only for kinases but also for other phospho-residue binding domains,
such as 14-3-3 proteins and the acetyl-lysine binding bromodomain. Finally, this method
was applied to mouse kinases to explore conservation of sequence specificity.
We demonstrate that it is possible to combine large-scale PTM data with protein network
information to derive the specificity of PTM regulators and believe that this approach can be
widely applicable to different PTM types.
2.2 Results
2.2.1 Network-based prediction of kinase-substrate specificity
We hypothesized that the interaction network of a protein kinase should be enriched in its
target proteins. This hypothesis was confirmed by the observation of a significant enrichment
of known kinase targets in the functional interaction or physical interaction partners of
kinases. Of phosphosites with an annotated kinase, 5.5% show a functional interaction with
the kinase as revealed by STRING, which was significantly larger than that of random pairs
of proteins (Figure 2.2, p<2.22×10−16). Similarly, 7.61% show a physical interaction in
BioGRID [261], which was also significantly higher than that of random kinase-substrate
pairs (Figure 2.2, p<2.22×10−16). In order to predict kinase specificities, information
on human protein interaction data and phosphorylation data derived from large-scale MS
studies were combined. Functional interactions derived from STRING [262] were used as
a source for potential kinase interactors. STRING reports a score ranging from 0 to 1000
reflecting the confidence of the interaction, which is a combination of scores from across
multiple evidence sources [263]. A total of 2,425,314 interactions in 22,523 proteins were
collected along with experimentally determined phosphosites from three public databases
(PhosphoSitePlus [117], PhosphoELM [253] and HPRD [264]). Phosphosites were mapped
back to proteins with STRING interactions resulting in 107,444 sites across 12,207 proteins
(Methods, section 2.3.1). A total of 493 kinases were identified within this reference proteome
(81% serine/threonine and 19% tyrosine kinases) using the Kinomer prediction tool [265]
(Methods, section 2.3.2). For a given kinase, enrichment was carried out on all phosphosites
occurring on the STRING partners using the motif-x algorithm [266] (Methods, section 2.3.3,
Figure 2.1c). A random sample of 10,000 unphosphorylated S/T/Y residues were used as
the background for enrichment. Phosphosites matching the most significant extracted motifs
were then used to build a position weight matrix (PWM) highlighting the predicted specificity
of the kinase, which could then be used to predict phosphosites (Figure 2.1c).
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Fig. 2.1 (a) Identification of SDRs in Predikin is carried out by (1) aligning sequences of
kinase catalytic domains to (2) identify semi-conserved elements. (3) Residues proximal
to these elements are manually curated to identify if they interact with specific positions
the peptide. The structure shows literature defined SDRs (magenta) interacting with proline
at position +1 of the substrate (yellow) [259, 260]. (b) Predicting kinase specificity with
SDRs using Predikin. (1) A kinase query sequence is first analyzed for a kinase catalytic
domain. (2) If identified, this domain is annotated with previously identified SDRs. (3)
Kinases with similar SDRs are then identified. (4) Their known target phosphosites are
collected and (5) used to construct a predicted specificity model (c) Overview of the proposed
method. (1) Experimentally identified phosphosites on functional interaction partners of a
kinase are collected. (2) The phosphosites are then subject to motif enrichment to identify
over-represented motifs in the flanking sequence, likely reflecting the kinase’s specificity. (3)
Phosphosites matching the top five significant motifs are then retained and used to construct
a specificity model.
A survey of all known phosphosites revealed a strong bias of prolines at position +1
(P+1) (Figure 2.3a-b). This results in consistent enrichment of P+1 motifs (Figure 2.3c). The
abundance of P+1 sites results in proline-directed motifs masking the true underlying motif
of non-proline-directed kinases. To circumvent this, we require prior knowledge on whether
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Fig. 2.2 Enrichment of kinase-substrate pairs in protein interaction networks. (a) In the
STRING interaction network for the human kinases, 5.5% of the interactions correspond
to known kinase-substrate interactions (p<2.22×10−16). (b) Similarly, BioGRID contains
7.61% known kinase-substrate interactions (p<2.22×10−16). The histograms show the
proportion of 1,000 random kinase-substrate pairs in STRING and BioGRID.
a kinase is proline-directed (i.e. prefers P+1) is required. We found that in almost all cases,
kinases belonging to the CMGC family, including CDKs, MAPKs, GSKs and CDK-like
kinases harbour P+1 motifs, as shown in their experimental binding sites (Figure 2.3d). Thus,
if a kinase was not predicted as belonging to the CMGC family, it was assumed not to be
proline-directed and P+1 phosphosites were removed from the foreground and background
sets prior to motif enrichment.
There are two variable parameters in the method (1) the threshold for the functional
interaction prediction score from STRING and (2) the top k number of significant motifs
extracted during the enrichment. To determine the optimal thresholds, we assessed the
performance of predicted kinase specificity models against a set of 9,595 gold standard kinase-
substrate relationships. We carried out benchmarking using a set of nine well-studied kinases
from a diverse set of kinase families (ABL1, AKT1, ATR, AURKB, CDK2, CSNK2A1,
GSK3B, MAPK1, and PRKACA) with well-recognized specificities in the literature. The
STRING score threshold and the top k motifs extracted were varied and the performance of
the resulting PWM in each case was evaluated using the Receiver Operating Characteristic
(ROC) and area under the ROC curve (AUROC or AUC) (Methods, section 2.3.4). Increasing
the STRING score threshold, on average, resulted in higher AUCs up to a value of 400, after
which no significant increase in performance was observed (Figure 2.4). Furthermore, more
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Fig. 2.3 Proline bias across all phosphosites. (a) Information content for each position
flanking the central residue for all known phosphosites. The highest information content
position is shown in red. (b) Amino acid frequencies for each position of all phosphosites.
Proline is highlighted in red. (c) Two examples of non-proline-directed kinases showing the
effect of removing P+1 phosphosites. Each example shows the predicted specificity before
(left) and after (right) removal of P+1 phosphosites. Consistent enrichment of proline is
observed for these cases if P+1 phosphosites are not removed, masking the true specificity of
the kinase. (d) Bar plot showing CMGC vs. non-CMGC kinases with at least 20 substrates
and the proportions of each class, which are proline-directed. Kinases were considered
proline-directed if a predominance of Proline was observed at position +1.
stringent STRING thresholds result in an insufficient number of sites for motif enrichment
thereby reducing the coverage of kinases for which we can predict specificity. Thus, a
STRING score threshold of 400 is used throughout. Additionally, the top five motifs resulting
from motif enrichment were selected for model construction for two reasons. First, varying
the top k motifs beyond a value of five did not show considerable improvement in performance.
Second, over selecting motifs was shown to mask the true predicted specificity of the kinase
(Figure 2.5).
The STRING score used here is based on a combination of multiple evidence sources
(e.g. text mining, co-expression, interaction data). STRING also provides source-specific
scores. To ensure certain evidences were not affecting performance, functional interactions
were defined using the inclusion or exclusion of individual evidences. However, on average,
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using alternate evidences did not provide a significant increase in performance, and resulted
in fewer numbers of kinases with predicted specificity (Figure 2.6).
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Fig. 2.4 Benchmarking of the method on nine kinases with well-defined specificities. Optimal
parameters of the method were computed by varying the STRING score threshold and the top
k significant motifs used in constructing the model. The performance of kinases is measured
in each case. The arrow corresponds to selected thresholds.
The collection of all phosphosites contain over-represented motifs. To ensure predicted
models were not due to random motif enrichment, we compared the performance of predicted
models against random models constructed without the STRING network information. If a
given kinase has n STRING interactions, and among those interactors, there are m phospho-
sites (s1,s2, ...,sm), then m random phosphosites are selected from all known phosphosites
(r1,r2, ...,rm). Specificity is then predicted, as previously described using these sites. Ran-
dom models were compared against the predicted models in their ability to discriminate
the gold standard sequences, as measured by the AUC. Predicted models for most of the
nine kinases, with the exception of AKT1 and MAPK1, performed significantly better than
random (Figure 2.7a). This does not imply that the predicted AKT1 model is incorrect since
it performs well at predicting known AKT1 target sites (AUC = 0.90, Figure 2.7a). However,
some kinases such as AKT1 have specificities that are well modelled by the common motifs
across all phosphosites. In such cases, the network information appears to provide almost no
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Fig. 2.6 Performance using inclusion or exclusion of different STRING evidences. (a)
Distribution of AUCs for predicted models of all kinases with≥20 known substrates by either
excluding a particular string evidence or using only that evidence to generate the prediction.
(b) The proportion of kinases with no prediction resulting from lack of interactions when
restricting evidences.
gain compared to random sampling. In contrast, ATR has an atypical specificity with a Q+1
preference that is well recovered by this approach (Figure 2.7a,f) but highly unlikely to be
observed in a random pool of phosphosites.
These results demonstrate the ability to integrate protein interaction information with
large-scale data on protein phosphorylation to derive kinase specificity models.
2.2.2 Prediction of kinase-substrate specificity across all human ki-
nases
Our method was applied to all human kinases, resulting in predictions for 282/493 (57%)
of kinases. Kinases that did not yield a prediction either had a low number of partners or
a scarcity of phosphosites on partners. Performance of predicted models for 85 kinases
with at least 20 literature-defined phosphosites was measured by how well they performed
at discriminating the literature-defined phosphosites from that of other kinases (Methods,
section 2.3.4, Figure 2.8). The average AUC across all kinases was 0.64 with 32% (27/85)
of kinases having an AUC greater than 0.7 (Figure 2.7b). On average, CMGC, PIKK, and
AGC families performed best, whereas TKL, STE and TK kinases had a larger fraction of
poorly performing models. When excluding the TKL, STE, and TK kinases, the average
AUC increases to 0.68 with 44% of kinases (27/61) scoring higher than 0.7 (Figure 2.7b).
Differences in performance across kinase families could reflect different degrees of sequence
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Fig. 2.7 Benchmarking of the method. (a) The performance of each predicted model compared
with models predicted using random phosphosites. Seven of nine cases perform better
than random (. p<.01, * p<0.05, ** p<0.01, *** p<0.001, one-sided Z-test). Error bars
represent the median absolute deviation for 1,000 random models. 85 kinases with ≥ 20
known substrates were used as the gold standard. (b) Performance of predicted models
by kinase family. The grey line denotes near-random performance. (c) Performance of
models constructed using experimental phosphosites is compared with that of the predicted
models. A strong correlation suggests a relationship between the specificity of the kinase and
predictability of a specificity model. (d-g) Examples of predicted specificity models. The top
and middle panel of each example shows the specificity of the kinase as constructed from
known phosphosites and as predicted by the described approach, respectively. The bottom
panel shows the top five extracted motifs and the number of phosphosites matching them.
specificity in the kinase-substrate recognition. For example, many tyrosine kinases have
additional targeting domains (i.e. PTB and SH2 domains) and several STE kinases are known
to have an additional interaction surface known as “docking motifs” [267, 268]. For these
kinases, targeting is achieved by multiple interfaces or often aided by other mechanisms and,
therefore, may be less specific in the recognition of sequences flanking the phosphosite. In
line with this reasoning, kinases that harboured additional protein domains also had poorer
performing models (p=1.88×10−3, Figure 2.9). This notion was tested more explicitly by
comparing predicted models with a proxy for kinase promiscuity. For the same set of kinases,
experimental specificity models were constructed using the literature-defined phosphosites
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and performance was measured using 10-fold cross validation (Methods, section 2.3.4).
Interestingly, a strong correlation was observed between the performance of predicted and
experimental models (r=0.757, p=2×10−16, Figure 2.7c), suggesting that kinases with higher
sequence specificity are more likely to have high predictability.
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Fig. 2.9 Impact of the number of domains
on predictions. Distribution of AUCs for
kinases, separated by the number of Pfam
domains they harbour. Kinases with multi-
ple domains, overall, demonstrate signif-
icantly lower performance. Significance
is measured using a one-sided Wilcoxon
signed-rank test.
In attempt to identify features comprised by better performing models, the performance
of the predicted models were correlated with several features including (1) the number
of functional interacting partners, (2) the number of phosphosites on interacting partners,
(3) the distribution of information content, and (4) the number of extracted motifs. Weak
correlations (r=0.361, Figure 2.10) were observed for each of the individual features. A
higher correlation was achieved by combining a number of features using a linear regression
model (r=0.542, p=8.37×10−8, Figure 2.10). This model could thus be used to assign a
quantitative measure of confidence related to the truth of predicted specificity, which is used
here to rank predictions.
Several additional adaptations to the method were explored. For example, using different
background sets for motif enrichment or restricting to high confidence phosphosites for motif
enrichment.
In the current implementation, we exclude all P+1 phosphosites when predicting the
specificity for kinases that are not proline-directed. This requires prior knowledge regarding
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the different kinase families, which might not always be available for different PTM types
or species. Rather than having to specify P+1 kinases, one can use all phosphosites as a
background for motif enrichment to decrease the importance of P+1 motifs. However, this
approach results in a moderate decrease in the mean AUC to 0.61 (Figure 2.11a) and fewer
predictions (32 vs. 85). Furthermore, the importance of prolines and arginines at certain
positions is decreased and in most cases are not enriched for, likely resulting in incorrect
enrichments and ultimately models (Figure 2.11b).
To test if phosphosite quality impacted performance, we restricted phosphorylation data
using two criteria. First, only phosphosites that were annotated to at least two PubMed
articles were retained. Second, since MS methods are biased towards highly abundant
proteins, phosphosites that occurred in the top 10% abundant proteins as defined in PaxDB
[269] were removed. Models were predicted using both sets of filtered phosphosites and the
performance was assessed. Overall, restricting phosphosites did not appear to improve the
performance of the models (Figure 2.11a).
2.2.3 Mass spectrometry-based validation of kinase specificity
To validate predictions, four kinases with few literature-defined phosphosites spanning
different kinase families were selected for experimental validation. These included CMGC
kinases SRPK2 and HIPK2, AGC kinase AKT2, and PEK kinase EIF2AK4. For each
of these kinases, in vivo target phosphosites were identified using the phosphoproteomic
approach described by Imamura et al. [270] (Figure 2.12a). Briefly, HeLa cell extracts were
treated with phosphatase to remove any existing phosphosites, and kinases were added in
separate experiments. The phosphorylated extract was then subjected to trypsin digestion,
phosphopeptide enrichment, and nanoLC-MS/MS (Methods, section 2.3.5, Figure 2.12a).
This resulted in a total of 483 novel phosphosites being identified for these kinases (AKT2,
n=248; EIF2AK4, n=91; HIPK2, n=106; SRPK2, n=38). The performance of predicted
models for these kinases was then assessed against these sites (Figure 2.12b-e). All predicted
models performed significantly better than random, and three of the four displayed an AUC
≥ 0.7 at classifying the experimentally identified sites (Figure 2.12f). These results are in line
with the benchmarks performed and further support the validity of the approach described
here. We note that the SRPK2 kinase was predicted to have a strong preference for serines
and arginines at several positions. This motif was unusual given previously described models,
though several elements of this motif are confirmed by the experimental sites (Figure 2.12d).
Furthermore, the kinase specificity of SRPK2 was recently determined using a chemical
genetic approach [271] that identifies the conserved RXXSP motif for SRPK2. This provides
further validation of the predicted specificity model of this kinase.
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Fig. 2.10 Feature correlations. Performance of predicted models correlated with (a) number of
phosphosite sequences on functional partners, (b) number of phosphosite sequences matching
the top five enriched motifs, (c) number of functional partners, (d) sum of information content
across positions of models (e) maximum information content amongst different positions, (f)
total number of enriched motifs and (g) number of annotated Pfam domains. (h) A linear
regression model built using a combination of features (a,d,e,f) is used to predict the AUC of
predicted specificity models, which are correlated against the true AUC. The line of best fit
is shown in red.
2.2.4 Prediction of post-translational modification binding specificities
To demonstrate the extensibility and application of the proposed method, it was applied to
other types of linear motif specificities, such as that of 14-3-3 proteins. 14-3-3 proteins are
conserved single domain proteins capable of binding a phospho-serine or threonine and are
responsible for tight regulation of several important pathways including cell death, cell cycle
control, and signal transduction [272]. Previous studies have shown that 14-3-3 proteins
demonstrate distinct specificities towards their target phosphosites [273] (Figure 2.13a). We
applied the method to human 14-3-3 proteins and similarly show that the recovered models
are good predictors of known binding sites (AUC > 0.80) while performing significantly
better than random (Figure 2.13b). Well-known determinants such as arginine at position -3
and some preference for proline at position +2 are recovered. Furthermore, little to no overlap
was found between sites used to construct individual models of the 14-3-3 proteins, despite
showing similar predicted specificity (Figure 2.13c-d). This suggests that the same motif is
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Fig. 2.11 Alternate motif enrichment background sets. (a) Performance of predictions using
different background sets: (1) using unphosphorylated STY sites as background for motif
enrichment, while filtering P+1 phosphosites versus, (2) restricting to phosphosites having
two or more associated PubMed IDs, (3) removing phosphosites occurring in highly abundant
proteins, (4) refining function partner phosphosites using the method described in Reimand et
al. [148], and (5) using all phosphosites as a background while retaining P+1 phosphosites in
non-proline-directed kinases. (b) Using phosphorylated sequences as background for motif
enrichment, while retaining P+1 sequences for non-proline-directed kinases. Examples of
predicted models for non-proline-directed kinases, using top five significant motifs. The left
predicted model is using unphosphorylated sequences as the background for motif enrichment
while filtering out P+1 sequences. The right predicted model is using all phosphosites as
background for motif enrichment while retaining P+1 sequences.
recovered in each case, from a different source of partner sites, adding to the confidence of
the recovered models.
The described method was also applied to the bromodomain-containing histone acetyl-
transferase p300. p300 has crucial roles in chromatin remodelling [274] and binds acetylated
lysines with a well-characterized specificity [275]. A collection of 12,149 human lysine
acetylation sites were obtained from dbPTM [116] and used along with the same network-
based motif enrichment to predict the specificity of p300’s bromodomain. The predicted
specificity (Figure 2.13e) is very similar to the known preference for KXXK or KXXXK
(where X is any amino acid and both lysines are acetylated).
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Fig. 2.12 Experimental validation. (a) Workflow for identifying phosphosites. (b-e) Predicted
specificity models of four kinases that were selected for experimental validation of their
target phosphosites. The top and middle panel of each example shows the specificity of the
kinase as constructed from the experimental target phosphosites and as predicted models,
respectively. The bottom panel shows the top five extracted motifs and the number of
phosphosites matching them. (f) The performance of each predicted model compared with
models predicted using random phosphosites.
These results recapitulate the benefit that PTM recognition specificity can be predicted
by combining network information with PTM data.
2.2.5 Conservation of kinase-substrate specificity
Catalytic domains of many kinases, particularly those within the same families, are highly
conserved across species [276], suggesting that their sequence specificity is likely conserved
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Fig. 2.13 Prediction of 14-3-3 domain
specificities. (a) The specificity of 14-3-3
domains as constructed by experimentally
verified substrates as reported by John-
son et al [273]. (b) The performance
of each predicted model compared with
models predicted using random phospho-
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ties for two 14-3-3 proteins. Each ex-
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dicted specificity (left) and the top five
extracted motifs and the number of phos-
phosites matching them (right). (e) Pre-
diction of acetylation-based specificities
for the bromodomain-containing protein
p300.
too. To test this hypothesis, the proposed model was applied to mouse (Mus musculus), which
contained 29,732 phosphosites and 2,425,424 STRING interactions. Using human kinases
with an AUC above 0.6, a total of 56 one-to-one ortholog kinases in mouse were identified,
using the InParanoid resource [277]. Results displayed a close resemblance between the
specificity determinants of human kinases and their corresponding mouse orthologs (Fig-
ure 2.14). Over 34% (19/56) of predicted mouse kinases demonstrated similar or better
performance at predicting known human kinase sites than the orthologous human model.
This suggests that at least these 19 kinase pairs have very conserved kinase preferences. For
the remaining cases, one cannot confidently say that there is a divergence in specificity since
we cannot rule an incorrect prediction.
2.2.6 The kpred resource for predicted kinase-substrate specificities
To facilitate visualization of results, predictions for all kinases are provided through a web
resource (Figure 2.15a), kpred, which is available at https://evocellnet.github.io/kpred. Users
can explore predicted specificity models through the sequence logo, investigate enriched
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Fig. 2.14 Conservation of kinase specificity. (a-f) Six examples showing the comparison of
predicted human versus mouse models. Each example shows logos for human gold standard
specificity (top) and the predicted specificity model in human (middle) and mouse (bottom).
motifs and phosphosites and bulk-download prediction models. This result page is split into
three main panels (Figure 2.15b-d), described in detail below.
The first panel highlights information on the kinase (Figure 2.15b). This includes the
kinase family and group it belongs to and the kinase class (serine/threonine or tyrosine).
Further information resulting from the method is also displayed such as whether P+1 se-
quences were removed prior to enrichment, the number of STRING partners and the number
of phosphosites found on partners. The predicted model is interactively visualized as a
sequence logo.
The second panel shows a table containing the top five enriched motifs used to iden-
tify phosphosites for construction of the predicted model (Figure 2.15c). The table also
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includes additional motif information resulting from the motif-x [266] enrichment such as
the enrichment score, the number of sequences matching phosphosites in the foreground and
background datasets, and the fold increase of foreground over the background.
The final panel contains a table of phosphosites matching the enriched motifs and used
to construct the predicted specificity model (Figure 2.15d). The table reports details of the
phosphosites such as the sequence context of the site, its position, kinases known from the
literature to phosphorylate this site (if any) and the source database of the phosphosite. The
table also includes the STRING score between the kinase and the protein containing the
phosphosite.
Fig. 2.15 The kpred resource. (a) Overview of a result page for the CK2 kinase CSNK2A1.
The result page is split into three panels highlighting (b) the kinase and prediction model (c)
the enriched motifs and (d) phosphosites used to construct the model.
Users can choose to download the logo in multiple formats or results as a flat file from
the top of the result page (Figure 2.15b). The flat file is provided in a tab-delimited format
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and similarly structured to the result page, where each panel is separated by //. Alternatively,
logos and flat files for all kinases can be downloaded in batch from the download page.
2.3 Methods
2.3.1 Phosphorylation and functional interactions data collection
Functional interaction data were collected from STRING (v9.1). Phosphosites were collected
from public databases, including PhosphoSitePlus [252], PhosphoELM [253], HPRD [254]
and from a study of mouse tissues [278]. Phosphosites were then mapped to protein sequences
provided by STRING. Kinase orthologs for 471/493 (95%) human kinases were obtained
from InParanoid v8.0 [277].
2.3.2 Kinase domain prediction
Given a protein sequence, we used Kinomer [265], which uses multilevel HMMs and
HMMER [256] to identify protein kinases and classify them into their appropriate kinase
family. E-value cutoffs for each family were used as defined in Martin et al. [265]. If a kinase
was predicted more than one family, the one with the highest E-value was retained. These
families were also used to determine if the kinase is serine/threonine-specific or tyrosine-
specific. A kinase is assumed to be either serine/threonine-specific or tyrosine-specific and
does not account for dual specificity kinases.
2.3.3 Phosphorylation-based motif enrichment
The motif-x algorithm [266] was used to identify motifs enriched within a set of phosphosites,
compared with a background (Figure 2.16). The background set used here was 10,000 11-
mers centred on non-phosphorylated serine, threonine or tyrosine residues, depending on if
the kinase is serine/threonine-specific or tyrosine-specific.
Given a foreground and background set of sites, motif-x first constructs a positional
frequency matrix from the foreground set. This matrix contains the observed count fi j of
each residue j at position i. Similarly, for the background, a positional probability matrix is
computed, containing the likelihood pi j of observing residue i at a certain position j. Given
the number of sites in foreground data n, the significance of residue/position pairs are then
identified using a binomially distributed model:
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P(n, fi j, pi j) =
n
∑
k= fi j
(
n
k
)
pi jk(1− pi j)n−k (2.1)
Significant residue/position pairs are then identified using a threshold of Pbinomial < 10−6.
These pairs are used to construct a motif, which is reported. Sequences in the foreground and
background data matching these motifs are then removed and the process repeats iteratively
until one of the following criteria is met (1) no significant residue/pairs exist below the
threshold or (2) fewer than 10 sites remain in the foreground or background data.
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Fig. 2.16 Overview of the motif-x algorithm. (1) Foreground and background sequences are
used to construct a frequency matrix and probability matrix, respectively which are used
to (2) compute binomial probabilities. (3) Significant residue/position pairs are identified
and used to construct the motif reported. (4) Sequences matching the reported motif are
then removed from the foreground and background sets and this process repeats until (5) the
algorithm converges (no significant pairs remaining) or too few input data remains.
A score s reflecting the significance of the extracted motifs are calculated using the
binomial probabilities of pairs used to generate the motifs:
s(moti f ) =
m
∑
i
−log(bi) (2.2)
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where m is the total number of significant residue/position pairs used to generate the motif
and bi is the binomial probability of the ith residue/position pair. This score is ultimately
used to define top significant motifs.
Since the motif-x tool was only available via an online web server, the algorithm
was re-implemented for the R programming language and made publicly available at
https://github.com/omarwagih/rmotifx.
2.3.4 Kinase specificity models and performance assessment
Specificity models were constructed as PWMs, which are commonly used to model speci-
ficities of linear motifs [58]. PWMs can then be used to score peptides. A single PWM
is constructed using a set of phosphosites. If S is a set of n phosphosites, each of length
l, s1, · · · ,sn, where sk = sk1, · · · ,skl and sk j represents one of the 20 amino acids. A PWM
M20×l with weights pi j as the relative frequency of each amino acid i at a particular position
j is constructed as follows:
pi j =
1
n
n
∑
k=1
fi(sk j)+ ε fi(q) =
1, if i = q.0, otherwise. (2.3)
Where ε is a pseudo-count added to each frequency value to avoid infinite values upon log
transformations.
An adapted version of the matrix similarity score (MSS), originally developed in the
MATCH algorithm [279], as described in Wagih et al. [146] is then used to score a phos-
phosite q also of length l, q1, · · · ,ql . The MSS uses the positional information content to
assign position-specific weights of importance. Additionally, scores are normalized against
the highest and lowest relative frequencies per position in the PWM. This results in a score
pi j reflecting the likelihood of binding ranging from 0 to 1, where 0 represents no binding
and 1 represents a perfect match. The MSS defined as:
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MSS =
Current−Min
Max−Min
Current =
l
∑
j=1
I( j)pq j, j
Min =
l
∑
j=1
I( j)pminj
Max =
l
∑
j=1
I( j)pmaxj
I( j) =−∑
i
pi, jlog(
pi, j
pb
)
(2.4)
Here, q j denotes the residue at position j of the query sequence, pminj and p
max
j denote the
minimum and maximum relative frequency at position j of the PWM, respectively, and pb is
the background frequency of a particular amino acid in the proteome.
The performance of a given PWM was evaluated using the AUC, which is the curve
representing the relationship between the false positive rate and true positive rate as the MSS
score cutoff is varied:
FPR =
FP
FP+T N
T PR =
T P
T P+FN
(2.5)
Here, FP, TP, TN, FN represent the number of false positives, true positives, true negatives,
and false negatives, respectively. The PWM is used to score positive and negative sequences
in order to generate these values. For a kinase of interest, the positive sequences are
defined as the set of phosphosites annotated to the kinase, whereas the negative sequences
as phosphosites annotated to any kinase not belonging to the same kinase family, where the
kinase classification is defined by Manning et al. [122].
In the case where the performance of experimental models was evaluated (i.e. using the
gold standard sequences), 10-fold cross-validation was carried out. The kinase sequences are
split into 10 random bins and each bin is iteratively used as the test set, while the remaining
nine are used to construct the PWM. This results in 10 AUCs, which are then averaged to
provide an unbiased proxy of the PWM’s prediction power.
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2.3.5 Profiling in vitro kinase substrates
Identification of in vitro kinase substrates was carried out by collaborators Naoyuki Sugiyama
and Yasushi Ishihama at the University of Kyoto using the previously described approach by
Imamura et al. [270]. Briefly, lysate proteins were extracted from HeLa S3 cells at about
80% confluence in 15 cm dishes, and the total protein amount was measured by a BCA
protein assay kit. Dephosphorylation was then carried out with TSAP (Promega, Madison,
MI, USA) at 37°C for 1 h, and TSAP was inactivated by heating to 75°C for 30 min. For in
vitro kinase reactions, each 100 µgµl−1 of dephosphorylated proteins (1 µg/µl) was reacted
with 1 µl of each recombinant kinase (0.5 µg/µl) or distilled water as a control at 37°C in
kinase reaction buffer (40 mmol Tris-HCl at pH 7.5, 20 mmol MgCl2, 1 mM ATP) for 3 h.
AKT2, catalytic domain [120–481(end), accession NP_001617. 1], full-length EIF2AK4
[1–1649(end) accession Q9P2K8.2], full-length HIPK2 [1–1198(end) accession Q9H2X6]
and full-length SRPK2 [1–688(end) accession NP_872633.1] were obtained from Carna
Biosciences Inc. (Kobe, Japan). The kinases were expressed as N-terminal GST-fusion
protein using the baculovirus expression system with SF9 cells and were purified using
glutathione Sepharose chromatography. The reaction was stopped by heating to 95°C for 5
min. After protein reduction/alkylation, Lys-C/trypsin digestion (1/100 w/w) was performed
and phosphopeptides were enriched by TiO2-based hydroxyl-acid-modified metal oxide
chromatography [280].
Phosphopeptides were desalted by StageTips and analyzed by nanoLC-MS/MS using
a self-pulled analytical column (150 mm length × 100 µm) inner diameter) packed with
ReproSil-Pur C18-AQ materials (3 µm), Dr. Maisch, Ammerbuch, Germany). An Ultimate
3000 pump (Thermo Fisher Scientific, Germering, Germany) and an HTC-PAL autosampler
(CTC Analytics, Zwingen, Switzerland) were used coupled to an LTQ-Orbitrap XL (Thermo
Fisher Scientific). A spray voltage of 2,400 V was applied. The MS scan range was m/z
300–1,500. The top 10 precursor ions were selected in MS scan by the Orbitrap with r
= 60,000 for MS/MS scans and the ion trap in the automated gain control (AGC) mode,
where automated gain control values of 5.00 × 105 and 1.00 × 104 were set for full MS and
MS/MS, respectively. To minimize repetitive MS/MS scanning, a dynamic exclusion time
was set at 20 s with a repeat count of 1 and an exclusion list size of 500. The normalized CID
was set to be 35.0. Mass Navigator v1.2 (Mitsui Knowledge Industry, Tokyo, Japan) was
used to create peak lists on the basis of the recorded fragmentation spectra with the default
parameters for the LTQ-Orbitrap XL. Peptides and proteins were identified by automated
database searching using Mascot v2.3 (Matrix Science, London, UK) against SwissProt
release 2010_11 (02/11/2010, 522,019 entries). A precursor mass tolerance of 3 ppm, a
fragment ion mass tolerance of 0.8 Da, and strict trypsin specificity allowing for up to two
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missed cleavages. Carbamidomethylation of cysteine was set as a fixed modification and
oxidation of methionines; phosphorylation of serine, threonine, and tyrosine was allowed
as variable modifications. Peptides were considered identified if the Mascot score was
over the 95% confidence limit based on the “identity” score of each peptide and if at least
three successive y- or b-ions with a further two or more y-, b-, and/or precursor-origin
neutral loss ions were observed, based on the error-tolerant peptide sequence tag concept.
After identification, phosphopeptides identified from the control samples were rejected. A
randomized decoy database created by a Mascot Perl program gave a 1% false-discovery rate
for identified peptides with these criteria. Phosphosite localization was evaluated using a site-
determining ion combination method based on the presence of site-determining y- or b-ions
in the peak lists of the fragment ions, which supported the phosphosites unambiguously.
2.4 Discussion
The advances in MS have expanded tremendously our knowledge of exact protein modifica-
tions sites for a number of different PTM types. However, there is almost no information
regarding the regulatory interactions connecting regulators to target proteins. Determining
the recognition preferences for PTM enzymes and binding domains in large scale is still
an open problem and remains a limiting factor in achieving this goal. In this chapter, we
used phospho-regulation as a model system and showed that it is possible to combine PTM
information with interaction network data to derive accurate models of enzymes and binding
domains. A resource that contains all of the information used for the specificity predictions
of each kinase can be accessed from http://evocellnet.github.io/kpred. The code required to
apply this approach can be found in the help page along with a tutorial.
It should be noted that even though some models do not perform better than that of
randomly sampled sites, this does not necessarily reflect the reliability of the predicted model.
Some kinase specificities are well-modelled by the most common motifs that are recovered
from a random sample. For these cases, the added information from the network data does
not result in a model that is more accurate than random. The power of the proposed approach
is, therefore, more obvious for regulators that have specificities that are less common such as
the DNA damage kinase ATR. For this kinase, the recovered model is accurate (AUC = 0.94)
while performing much better than models produced by random sites.
In the current implementation of this approach, kinases that are not CMGC are assumed
to not be proline-directed and P+1 phosphosites are removed prior to enrichment. This may
result in mispredicting cases where a non-CMGC kinase is proline-directed and where CMGC
kinases are not proline-directed. An alternative approach that does not require the removal of
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P+1 phosphosites was tested but, overall, yielded a lower performance. However, in cases
where P+1 phosphosites are retained, motifs can be recovered that are proline-directed. For
example, the CSNK2A1 kinase is a casein kinase belonging to the CMGC group. It is one of
the few non-proline-directed kinases belonging to the CMGC family. CSNK2A1 is known to
have a strong preference for acidic residues, predominately C-terminal to the phosphosite
[281]. Despite that P+1 phosphosites were not removed prior to enrichment for this kinase,
a strong bias for an acidic residue at positions +1, +3 and +4 is recovered (Figure 2.14).
Additionally, the class of the kinase (i.e. serine/threonine or tyrosine) is required a priori to
filter only phosphosites matching the class of the kinase. This is primarily due to the fact
that phosphotyrosine is in many regards a different PTM from that of phosphoserine and
phosphothreonine. In particular, it occurs at a much lower frequency and thus, if one would
not discriminate between these two types, the predicted specificities would be dominated by
serine/threonine phosphosites.
It is important to take into account that most phosphosite information was retrieved from
phosphoproteomics experiments that have used trypsin for protein digestion. Given that
trypsin cleaves C-terminal to arginine and lysine residues, it is possible to expect a bias
for arginine or lysine residues in the phosphopeptides. One would otherwise expect any
bias to be equally possible at positions before or after the phospho-residue and also not
specifically biased for arginine or lysine. Instead, arginine determinants are more frequent
than lysine determinants and are not symmetrically distributed. Of the 202 Arg determined
positions (defined as having >0.25 relative frequency at the position), 96% (194/202) are
found N-terminal to the phosphosite, whereas 0.039% (8/202) are found C-terminal to the
phosphosite. Overall, there are only 19 positions where lysine is the major determinant,
and these tend to be more evenly distributed with 42.1% (8/19) occurring N-terminal to the
phosphosite and 57.89% (11/19) occurring C-terminal to the phosphosite. Thus, this bias is
unlikely to influence the recovered motifs.
Kinase families show different average performance in their predictions and the perfor-
mance of gold standard specificity models is correlated with that of the predicted models.
These observations highlight the inherent limitation of the approach proposed here. PTM-
interacting proteins that recognize their target sites mostly by residues flanking the target
phosphosite will be more amenable to this approach than those that use multiple recognition
mechanisms. These include docking motifs, colocalization, coexpression, and scaffolding
interactions [123]. In addition, this approach assumes that the recognition occurs in a linear
epitope at the PTM position. It has recently been shown that kinase targeting can also occur
in a three-dimensional epitope [282]. As such, this linear motif enrichment strategy would
not be appropriate if a PTM enzyme or binding domain often recognizes the target site
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through three-dimensional epitopes. These observations should be taken into account prior
to future use of this method on other PTM recognition domains.
The proposed method was also successfully applied to different modes of site-directed
motif-binding domains, such as 14-3-3 domains and bromodomains, suggesting that the
method could thus be extended further to analyze specificities of other PTM recognition
domains. Finally, this approach was applied to study the conservation of kinase specificity
between human and mouse kinases. For the kinases analyzed, at least 34% appear to have
conserved specificity. Thus, in combination with an analysis of potential mutations in
specificity-determining residues, this approach could be used to identify PTM recognition
domains with diverged specificities across species. Given that these regulators interact with
many different target PTMs, it is expected that their specificity diverges slowly. This is
in contrast to the fast changes in PTMs targeted by these proteins, that can diverge more
quickly [283, 284]. Conserved regulator specificity with diverged target phosphosites is a
scenario that is analogous to what is observed in transcriptional regulation [285]. However,
there have been cases described for the divergence of transcription-factor specificity [286],
suggesting that analogous cases of PTM divergence recognition are likely to exist. In addition
to studying the evolution of specificity, applying this method to different organisms could
lend further confidence to the true specificity of a PTM recognition domain, since models
trained in different species could contribute complementary specificity determinants and
ultimately be combined to provide better models.
In summary, we describe here a novel approach to predict PTM recognition motifs
and believe it can be applicable to a wide range of recognition domains and contribute
significantly to our understanding of these signalling systems.

Chapter 3
Assessing performance of methods for
predicting impact of variants on
transcription factor binding
In this chapter, I employ over 146,000 allele-specific binding (ASB) ChIP-seq variants across
43 TFs as a gold standard to assess how TF-binding models across five different methods
perform at predicting variant impact. I compare the performance of different methods and
explore alternative mechanisms beyond sequence specificity that may be altered by variants.
This work was carried out by myself in collaboration with the company Deep Genomics and
under the supervision of Daniele Merico, Andrew Delong and Brendan Frey.
3.1 Introduction
Gene expression is a tightly regulated process governed by a multitude of variables [42].
One of the primary mechanisms contributing to the regulation of gene expression is the
binding of TFs to regulatory genomic elements. Differential gene expression can drive and
contribute to almost every aspect of disease phenotypes. Understanding the intricate process
of TF-DNA binding can, therefore, provide mechanistic hypotheses for variants and propel
the discovery of novel therapies. Fortunately, through the aid of high throughput techniques
such as ChIP-seq, SELEX and PBMs, the binding specificities of many TFs have been
exhaustively catalogued over the past decade [287].
Genetic variation falling within specificity determinants of TFBSs can alter binding by
introducing novel binding sites or diminishing existing binding sites, often resulting in a
substantial impact on molecular phenotypes through changes in gene expression. Approaches
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such as pooled ChIP-Seq have been used to experimentally map variants to molecular-level
traits such as TF-binding [288, 289]. These approaches are, however, costly and cannot yet be
routinely applied to the sizeable quantity of genetic variation data available. As such, much
effort has gone into modelling TF-DNA binding in silico, which range from rudimentary
approaches such as the PWM to state-of-the-art deep-learning methods. These methods
have also been employed to predict variants likely to alter TFBSs and have thus become an
essential component of many variant prioritization pipelines.
The performance by which TF binding models are able to distinguish their binding
regions from random genomic regions has been well characterised [290, 291]. To assess how
well these predictors perform at identifying the impact of variants, known regulatory variants
are often employed, which include variants from the Human Genome Mutation Database
(HGMD), GWAS-derived variants, and QTLs [292, 293, 103]. However, little has been done
to explore the ability of these models to assess the impact of genetic variants on binding in a
TF-specific manner. ASB ChIP-seq provides a valuable dataset to carry out such performance
assessments. Here, ChIP-seq reads are mapped to either allele of heterozygous variants
within an individual or cell line, allowing for the explicit identification of variants that alter
TF occupancy. Several studies have utilised ASB data to explore TF-specific performance at
assessing variant impact. For instance, Zeng et al. used a small number of ASB variants for
six TFs to validate their GERV method at identifying TFBS-altering variants [294]. Shi et
al. compiled a dataset of over 10,000 ASB variants across 45 ENCODE ChIP-Seq datasets
and demonstrated that ASB variants lie within highly relevant PWM positions [105]. These
studies are, however, often based on a small number of TFs or are focused on individual
variant impact methods.
In this chapter, we aimed to carry out a systematic and unbiased analysis of the perfor-
mance of TF-binding models at assessing variant impact. Using a compiled compendium
of over 20,000 ASB variants across 100 TFs, we compare a total of five methods. We
devise several scoring metrics for each model and assess how they affect the identification of
impactful variants. We also explore the performance of TFs individually, identifying TFs
that are able to accurately predict variant impact as well as those that, although have distinct
binding specificities, are unable to do so. We explore mechanisms that may explain this poor
performance and suggest improvements for modelling impact of variants on TFBSs. This
study offers novel insight into non-coding variant impact prediction in TFBSs.
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3.2 Results
3.2.1 A compendium of allele-specific binding data
To assess the performance of TF-binding impact predictions, we require a set of variants
known to alter binding or have no effect on binding. This is conveniently provided by ASB
ChIP-seq data. ASB variants were collected from five studies [106, 104, 295, 105, 296],
with each study providing heterozygous variants, the sample or cell line from which it was
obtained, and reference and alternate allele read counts and the TF affected (Figure 3.1a).
If an ASB variant was reported across multiple studies, the one with the highest number of
total mapped reads was retained. Variants with at least 10 reads mapping to the reference or
alternate allele were retained, for a total of 146,947 TF-variant pairs (ASB events) reported
across 94 TFs. The largest fraction of TFs was reported in a single study, with a total of 50
TFs and as few as three TFs were reported across all five studies (Figure 3.1b). Different
studies also contained a disproportionate number of TFs and samples for which ASB data
was available. The largest number of TFs was contained within the Santiago et al. dataset
with a total of 80 TFs across from 14 samples [106] (Figure 3.1c-d).
The binomial test was used to define how the significance of the imbalance between the
reference and alternate read counts (Methods, section 3.3.1), which is commonly used in
ASB studies [104, 297]. ASB variants that exhibit significant differences between reference
and alternate read counts were defined by a significance threshold Pbinomial < 0.01, resulting
in 21,183 ASB events, of which 57.5% (12,715) were loss events where the alternate read
count is lower and 9,397 (42.5%) were gain events, where the reference read count was lower.
A total of 54,826 balanced reads, or non-ASB events, were defined as those with Pbinomial >
0.5 (Methods, section 3.3.1). In total, 46 TFs had at least 10 non-ASB and ASB variants,
while 43 TFs had at least 20 non-ASB and ASB variants. To our knowledge, this is the
largest available ASB dataset compiled.
ASB variants are implicated in altering TF-binding and should be less likely to exist with
high frequency. We confirmed this by analysing the proportion of ASB variants which are rare
at a MAF < 1% using data from the ExAC consortium [298], 1000 genomes project [299], and
the ESP6500 project [300] (Methods, section 3.3.4). ASB variants consistently demonstrated
a higher fraction of rare variants, compared to non-ASB variants (p<9.1×10−3, Figure 3.1f).
We also assessed whether commonly used non-coding variant impact predictors, such as
GWAVA [301], Eigen [302] and CADD [303], could accurately distinguish ASB variants
from non-ASB using the area under the receiver operating characteristic curve (AUROC)
measure (Methods, section 3.3.4). However, near-random performance was observed for all
three methods (CADD AUROC = 0.51, Eigen AUROC = 0.46, GWAVA AUROC = 0.48,
66
Assessing performance of methods for predicting impact of variants on transcription factor
binding
Figure 3.1g). This suggests that current approaches, which do not incorporate TF specificity
are unable to identify variants altering TF-binding.
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Fig. 3.1 Properties of ASB and non-ASB variants. (a) The use of ASB data for assessing the
performance of TFBS variant impact. (b) The total number of TFs covered by a different
number of studies. Only three TFs have ASB data in all five studies. (c-d) The number of TFs
and samples per ASB study. (e) The number of ASB variants per TF at a Pbinomial < 0.01 and
at least 10 reads mapped to either allele. Only TFs with at least 20 ASB variants are shown.
Loss and gain ASB variants are shown in magenta and green, respectively. (f) ASB variants
(green) are relatively rare compared to that of non-ASB variants (orange). Significance
p-values represent a one-sided Fisher’s exact test. (g) Non-coding variant impact predictors
are unable to distinguish ASB variants from non-ASB.
We utilised the collected ASB data to assess and compare the performance of several
computational predictors of TF-binding variant impact (Figure 3.1a). The approaches
included in the analysis were those based on PWMs [287, 68], k-mer-based approaches
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GERV [294] and gkmSVM [103], and deep learning-based approaches DeepBind [68] and
DeepSEA [69].
3.2.2 Scoring metrics for evaluation of transcription factor binding
variant impact
The different methods available offer a variety of scoring metrics that describe the quanti-
tative impact of a variant on TF-binding. These metrics are typically signed, where strong
negative and positive values indicate loss and gain, respectively. DeepSEA produces a single
probability of binding for both the wildtype and mutant sequences and uses two metrics to
quantify the impact of a variant: the difference (diff ) and log fold change (log FC) between
the probabilities (Methods, section 3.3.3). gkmSVM provides a single score deltaSVM
reflecting the change in the sum of k-mer weights for wildtype and variant sequences and
GERV provides a single unsigned score (GERV score) that reflects the change in predicted
ChIP-seq read counts (Methods, section 3.3.3).
In contrast, PWMs and DeepBind only provide a score reflecting the likelihood of binding
and not the impact of a variant. For these approaches, we devise a number of metrics to assess
the impact of a variant. Because the TF specificity models receive as input a fixed-length
sequence, we score multiple overlapping sequences (“k-mers”) along the region of interest
with the reference and alternate allele. The defined metrics serve as a good starting point for
assessing how different approaches perform at scoring the variant impact on TF-binding and
are described in more detail.
Raw score metrics of variant impact
The difference in raw model scores is typically used to assess the impact of a variant [304–
306] (Figure 3.2). We similarly define delta raw as the maximum difference between the
raw wildtype and mutant scores across the k-mers. Because TF-binding can be made robust
through homotypic clusters of redundant binding sites, they can often mitigate effects of
impactful variants [307]. In line with this reasoning, we devised delta track as the difference
between the maximum of all wildtype k-mer scores and the maximum of all mutant k-mer
scores. Both metrics are signed, such that losses are indicated by negative scores and gains
by positive (Table 3.1, Methods, section 3.3.3).
Probability-transformed metrics of variant impact
We sought to aid interpretability and strengthen baselines for variant effect prediction. To
do this, we convert raw scores (which are not on any particular scale and not comparable
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Fig. 3.2 Defining TFBS variant-impact scoring metrics. (1) Wildtype and mutant k-mers
flanking the variant position are scored. (2) The generated raw scores are used to derive both
the delta raw and delta track metrics. (3) Pbind values are then computed for each wildtype
and mutant k-mer. (4) Ploss and Pgain scores are defined using the generated Pbind .
across TFs) to likelihoods of binding (which are normalized to [-1, 1] and are comparable
across TFs). We define positive and negative sequences as those used to train the DeepBind
or PWM model and random genomic regions, respectively (Methods, section 3.3.3). We
found that, in some cases, distributions of raw scores from the background followed a normal
distribution and in some cases, distributions of foreground scores were bimodal with one
component of scores exhibiting similar properties to that of the negative distribution. Because
the ChIP-seq/SELEX data obtained was used to train deep learning models, this is likely due
to lenient threshold used to call the ChIP-seq peaks, which was done to maximise the number
of sequences available to train models. As such we use a Gaussian mixture model (GMM) to
learn the two components comprising the foreground distribution. One component is fixed to
the parameters of the negative distribution and the "true positive" component is learned. A
linear model is then trained and used to compute the probability of binding (Pbind) from raw
PWM or DeepBind scores (Methods, section 3.3.3).
Using the Pbind score, we define the delta Pbind score as the maximum difference between
the mutant and wildtype Pbind probabilities across all k-mers. This value ranges from -1 to 1,
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where low negative values indicate a loss of binding and high positive values indicate a gain
of binding.
We additionally define a probabilistic score Ploss and Pgain that range from 0-1 reflecting
the likelihood of a binding site being lost or gained, respectively. For Ploss, this is computed
by taking the joint probability of binding for the wildtype sequence and the probability of
the mutant not binding and vice versa for Pgain (Figure 3.2a, Methods, section 3.3.3). Ploss
and Pgain are combined into a single score by first signing Ploss negatively and computing
the probability with the higher absolute value as Pcomb. Since Ploss and Pgain can have low to
moderate magnitudes we also compute Psum as the sum of the signed probabilities, resulting
in a near-zero score for such cases (Table 3.1, Methods, section 3.3.3).
Score metric Method Description
diff DeepSEA Difference in the probability of binding
log FC DeepSEA Log fold changes of the binding probability
deltaSVM gkmSVM Difference in the sum of SVM-based k-mer
weights
GERV score GERV Difference in predicted ChIP-seq reads
delta raw PWMs/DeepBind Maximum difference across each scored win-
dow
delta track PWMs/DeepBind Difference between the maximum score for
all windows
delta Pbind PWMs/DeepBind Maximum difference between probability-
transformed scores across each scored win-
dow
Pcomb PWMs/DeepBind Maximum signed Ploss or Pgain score
Psum PWMs/DeepBind Sum of signed Ploss and Pgain scores
Table 3.1 Summary of existing and devised scoring metrics used across different methods.
3.2.3 The use of allele-specific binding data for benchmarking variant
impact prediction
Given the numerous available predictors and scoring metrics available for prioritising the
impact of variants on TFBSs, we investigated how well each method and scoring metric
performed at distinguishing TFBS-altering variants using the ASB data as a gold standard.
We collected and trained models for TFs with ASB data from the described methods.
DeepBind models for 94 TFs were utilised, which we had previously trained on ENCODE
ChIP-seq data and SELEX data [68]. For DeepSEA, pre-trained models for 67 TFs were
used that were trained on similar datasets to those used for DeepBind, matched by the cell
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line from which the training data was obtained. The same data used to train DeepBind
models was used to train 94 corresponding gkmSVM models and pre-trained GERV models
for 62 TFs were collected, based on ChIP-seq data (Methods, section 3.3.2). We further
utilised PWMs for 56 TFs from the JASPAR database along with 92 sets of PWMs based
on over-represented motifs derived using MEME-ChIP [308] from the data used to train
DeepBind models. For each TF, sequences matching a set of the top five over-enriched
motifs were used to construct at most five PWMs. Using the set of PWMs, predictions were
generated for the (1) "signif" most significant PWM and (2) "best" the PWM that resulted in
highest magnitude variant-impact score (Methods, section 3.3.2).
Each method, model, and scoring metric variants was used to score both ASB and non-
ASB data. The resulting scores were used to assess the performance of the predictor at
discriminating variants implicated in loss or gain ASB from that of non-ASB variants using
the receiver operator curve (ROC) and precision-recall (PR) curve. The AUROC and area
under PR curve (AUPRC) are used to provide a quantitative measure of performance, where
both metrics provide a different view on performance.
The performance was measured using the definition of an ASB and non-ASB variants as
those with a Pbinomial < 0.01 and Pbinomial > 0.5, respectively and exhibited at least 10 reads
mapped to the reference or alternate allele. We further only considered TFs with at least 20
ASB or non-ASB variants to improve robustness.
A comparison of variant-impact scoring metrics within methods
We first explore performance of PWM-based scoring metrics. We compared the performance
of five scoring metrics used for PWMs in JASPAR and MEME-based PWMs. The perfor-
mance of scoring metrics in most cases was equivalent to one another in each of the PWM
sets, with the exception of delta raw which consistently demonstrated poor performance
(p<8.5×10−4, Figure 3.3). For instance, in JASPAR PWMs, the average difference between
AUROCs between delta raw and delta track was, on average, 0.06 and 0.07 for gain and loss,
respectively and 68% (19/28) of TFs show a 10% increase in delta track performance for
either loss or gain ASB events (Figure 3.4a). The source of poor performance for delta raw
can be attributed to the inflation of scores caused by maximising differences over all k-mers.
High delta raw scores do not necessarily indicate a loss or gain of due to the positional inde-
pendence of PWMs. For instance, a low-scoring wildtype sequence harbouring a variant in a
position of importance for the PWM will result in a high delta raw score. This effect coupled
with taking the maximum over sliding k-mer windows results in an inflation of scores, which
affects the identification of true negatives (non-ASBs) and true positives (ASBs). These
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effects are partially mitigated by metrics such as the delta track and probabilistic metrics
(Figure 3.3).
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Fig. 3.3 Distribution of differences in AUROCs between PWM scoring metrics. The p-value
on the y-axis represents a two-sided Wilcoxon test between AUROCs of the compared
metrics.
The early B-Cell Factor 1 (EBF1) is one of the TFs with lower performance for delta
raw compared to the other metrics. For the MEME signif PWM, the delta track showed an
AUROC of 0.75 and 0.70 for loss and gain, respectively whereas delta raw showed AUROCs
of 0.66 and 0.61, respectively. Figure 3.4b shows the distributions of scores for loss and gain
ASB and non-ASB variants, highlighting the inflation of scores for non-ASB variants.
Detailed examples showing the calculation of delta raw and delta track for an EBF1 ASB
and non-ASB variants are shown in Figure 3.5a-c. Here, the scores for the wildtype and
mutant track are shown, along with the difference for each k-mer and the final computed
scores. The first example highlights a non-ASB variant, where a near-zero predicted score is
desired, yet despite no predicted binding occurring on either the wildtype or mutant tracks,
the delta raw metric still results in an inflated score through differences computed in non-
binding regions (Figure 3.5a). The second example highlights a loss ASB variant and the
loss event is correctly identified by both metrics. However, the maximum difference for delta
raw here is obtained not from the k-mer exhibiting the loss (k-mer window 19), but rather at
another k-mer (k-mer window 14) (Figure 3.5b). The third and final example highlights a
gain ASB event that shows how the drawbacks of the delta raw metric lead to an incorrect
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Fig. 3.4 Comparison of delta raw and delta track metrics for the PWM. (a) AUROCs for
delta track compared to that of delta raw for the three PWM sets. (b) Density plots showing
the inflation of scores in the delta raw metrics for the EGR1 TF.
prediction of the variant as loss, whereas delta track correctly predicts the directionality
(Figure 3.5c). The delta track and similar metrics offer numerous advantages over identifying
the largest possible difference. All metrics will, however, be bottlenecked by the high degree
of false positives produced by PWMs.
The performance of scoring metrics used in both DeepBind and DeepSEA were also
assessed. We compared the two DeepSEA metrics and found that, overall, neither metric
significantly outperformed the other (p < 0.42). The log FC metric did, however, show an
average increase of 0.032 and 0.019 in AUROC for loss and gain, respectively (Figure 3.6a).
For DeepBind, no significant difference was observed in performance between the five
used metrics. However, delta raw did show a modest increase in AUROC over other
approaches, with an overall average AUROC difference of as much as 0.021, compared to
Pcomb (Figure 3.6b). Unlike the PWM, the delta raw did not overall show difference to that
of delta track (AUROC difference = 0.0089).
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Fig. 3.5 EGR1 examples of scores for individual k-mers highlighting the differences between
delta track and delta raw. The left plot shows the wildtype (black) and mutant (red) scores
for each k-mer, the middle plot shows the score difference, and the right plot shows the final
delta raw and delta track scores. This is shown for (a) a non-ASB that are misclassified by
delta raw, and correctly classified by delta track (b) loss ASB correctly identified by both
metrics, and (c) gain ASB misclassified by delta raw and correctly identified by delta track.
The choice of the scoring metric used in variant impact can often be critical to both
interpretability and performance. For PWMs, the delta raw metric in PWMs has been long
used in studies to quantify effect of a variant of a TFBSs [304, 306, 305, 76]. The results
demonstrated here indicate that the choice of score metric when using PWMs, particularly
delta raw, can drastically impact the reliability of predictions made on regulatory variants.
Alternative metrics such as delta track and the probabilistic metrics Pcomb and Psum offer
good approaches to mitigating effects by delta raw but still are bottlenecked by the inherent
limitations of PWMs. For deep learning approaches, little overall difference was observed
between metrics and the choice of metric in this case remains purely for interpretation
purposes.
Performance of binding models vary depending on the definition of ASB variants
We then asked whether performance varied if thresholds used to define ASB and non-ASB
variants were changed. We measured the AUROC for a combination of thresholds for both
the Pbinomial (p < 0.1, 0.01, 10−3, 10−4 and 10−5) and the minimum number of reference or
74
Assessing performance of methods for predicting impact of variants on transcription factor
binding
l
l
DeepSEA
−0.10 −0.05 0.00 0.05
Diff. − Log FC
p<0.42
AUROC difference
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
DeepBind
−0.1 0.0 0.1
Pcomb − Psum
p<0.80
Delta Pbind − Delta track
p<0.98
Delta Pbind − Psum
p<1.00
Delta track − Psum
p<0.99
Delta raw − Delta track
p<0.91
Delta raw − Delta Pbind
p<0.93
Delta Pbind − Pcomb
p<0.71
Delta track − Pcomb
p<0.80
Delta raw − Psum
p<0.93
Delta raw − Pcomb
p<0.72
AUROC difference
Co
m
pa
re
d 
m
et
ric
s
l lLoss Gain
Fig. 3.6 Distribution of differences in AUROCs between (a) DeepSEA and (b) DeepBind
scoring metrics. The p-value on the y-axis represents a two-sided Wilcoxon test between
AUROCs of the compared metrics.
alternate reads (≥10, ≥20 and ≥30 reads). Performance was measured for seven TFs (BATF,
CEBPB, CTCF, EBF1, RUNX3, SMC3, TBP) which had ≥20 ASB variants at 10−5 and
≥30 reads.
Utilising performance measures for seven TFs with sufficient data at ≥10 reads and
Pbinomial < 10−5 we found that, on average, more stringent definitions of Pbinomial thresholds
exhibited higher AUROCs, which was consistent across both loss and gain ASBs (Figure 3.7a).
For instance, for gain ASBs in DeepBind, at a ≥10 reads the average AUROC at Pbinomial <
10−5 and Pbinomial < 0.10 is 0.70 and 0.59, respectively. Conversely, increasing the minimum
number of reads did not show any substantial shift in performance (Figure 3.7a). These
results suggest that models are better able to distinguish variants with a higher imbalance
in the number of reads and that higher read imbalance is more likely driven by changes in
sequence specificity.
To determine if more stringent thresholds used to define non-ASB variants affected the
AUROC, we fixed the ASB Pbinomial to 0.01 with ≥10 reads and assessed performance at
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Fig. 3.7 Performance based on different definitions of ASB and non-ASB variants. Perfor-
mance as measured by the median AUROC for (a) ASB variants across seven TFs where
both Pbinomial and minimum reads thresholds were varied. (b) Similar performance was
measured for 21 TFs at different Pbinomial thresholds for non-ASB variants. Magenta and
green represent loss and gain, respectively and error bars represent the standard error.
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different Pbinomial thresholds of 0.5, 0.7, and 0.9 for 21 TFs which had at least ≥20 non-ASB
variants at p > 0.9. However, higher thresholds of Pbinomial did not show any significant
variation in performance (Figure 3.7b).
At stringent thresholds of Pbinomial, the number of TFs for which ASB data is available is
minute. Thus, to assess performance with a sufficient number of TFs, we retain the thresholds
of Pbinomial < 0.01. Furthermore, since no significant increase was observed at higher reads
we retain the ≥10 reads for further analyses. Lastly, it is not expected that the performance
of gain and loss differ significantly and any changes observed are likely due to the small
number of TFs being assessed.
Machine learning-based methods outperform PWMs at predicting the impact of vari-
ants on transcription factor binding
PWMs have been the de facto approach to modelling TF specificity and assessing impact
of regulatory variants on TF-binding. Machine learning, and in particular deep learning
approaches are able to capture more complex relationships and reduce false positive predic-
tions. We, therefore, next asked how the performance of k-mer-based and machine-learning
approaches compared to that of PWMs at predicting variant impact. For methods with more
than one scoring metric, we selected the top performing metric, which included delta track
for PWMs, log FC for DeepSEA and delta raw for DeepBind, the deltaSVM score from
gkmSVM and the GERV score from GERV. We compared performance based on the AUROC
and AUPRC (Figure 3.8).
Because there exists a different number of trained models with ASB data for each method,
we compared performances for 11 TFs with models across all five methods. GERV showed
near random performance across both loss and gain, performing poorer than PWMs. The
other machine-learning approaches including gkmSVM, DeepBind and DeepSEA signif-
icantly outperformed PWMs with respect to AUROCs (Figure 3.8a, p=0.034 DeepBind,
p=5.91×10−04 DeepSEA, p=0.038 gkmSVM) and AUPRCs (p=4.57×10−3 DeepBind,
p=1.24×10−3 DeepSEA, p=0.024 gkmSVM). We further limited the predictors being com-
pared in order to retain a larger number of common models between the methods. We
compared MEME-based PWMs, with gkmSVM and DeepBind for a total of 39 common
TFs, where both DeepBind and gkmSVM similarly outperformed the PWM-based models
with respect to AUROCs (Figure 3.8b, p=4.07×10−3 DeepBind, p=4.85×10−3 gkmSVM)
and AUPRCs (p=2.32×10−3 DeepBind, p=7.31×10−3 gkmSVM).
Comparing the AUROC of deep-learning-based methods to that of PWM delta track,
we identify the TFs SRF, CHD2, IRF4, BATF and CEBPB amongst those where deep
learning models perform better at predicting variant impact (Figure 3.8c-d). A more in-depth
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Fig. 3.8 Comparing performance of machine learning approaches to PWMs. (a-b) Compari-
son of AUROCs (left) and AUPRCs (right). Performance is shown for (a) nine TF models
shared amongst five methods and for (b) 31 TF models shared amongst four methods. (c-d)
Scatter plots showing the AUROCs for individual TFs for deep learning models (c) DeepBind
delta raw and (d) DeepSEA log FC against PWM delta track.
examination of DeepBind and PWM scores reveals that even the best performing PWM
metric often results in high numbers of false positives and false negatives. These results
further illuminate the importance of machine learning models in variant impact.
Alternative binding mechanisms explain differences in variant impact prediction per-
formance
Having established that machine learning approaches outperform PWMs, we sought to focus
on DeepBind and DeepSEA models and investigate the performance of individual TFs.
Amongst TFs that performed well are RUNX3, BATF, MAFK, and CEBPB, which
had an AUROCs of > 0.7 in either DeepBind or DeepSEA models. Conversely, TFs like
SP1, BRCA1, TBP, and TAF1 consistently showed near-random performance (Figure 3.10a-
b). We asked whether poor ASB performance is dictated by the model’s performance at
identifying binding sites. A model that is unable to correctly identify binding sites should not
perform well at identifying the impact of ASB variants. Indeed, we found that models with
an AUC < 0.80 in DeepBind also demonstrated poor ASB performance (Figure 3.10c-d).
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Fig. 3.9 Examples of three TFs showing score differences between machine learning ap-
proaches and PWMs. (a) The relationship between DeepBind delta raw scores and PWM
delta track scores for ASB and non-ASB variants highlight the high degree of false positives.
(b) True positive rates (blue) and false positive rates (red) computed at different DeepBind
delta raw and PWM delta track thresholds.
However, high-performing models showed a high degree of variation with respect to ASB
performance. For instance, SP1 and BRCA1 both have model AUROCs of 0.99. Despite
having explicit sequence specificities, such models are unable to detect in vivo occupancy
differences introduced by variants. This suggests alternate mechanisms beyond simple
binding site specificities affecting binding. Since a number of mechanisms have been shown
to contribute to TF-binding specificities such as methylation, DNA shape, TF cofactors and
regulatory PTMs on the TF, we explored whether such mechanisms are able to explain the
poor performance observed.
TFs that are involved in binding complexes can obtain their specificity by the binding
of cofactors [74]. We collected known physical TF-TF interactions from the transcription
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Fig. 3.10 Exploring performance of individual TFs for deep learning methods. (a) AUROCs
and (b) AUPRCs for loss (magenta) and gain (green) ASBs. TFs are ordered by the maximum
performance metric across methods and effects (c-d) AUROCs of binding performance is
compared against performance of models to identify impact of variants, as defined by (c)
AUROCs and (d) AUPRCs for DeepBind delta raw (red) and DeepSEA log FC (blue) models.
cofactors (TcoFs) database [309] for 35 TFs with performance measures and asked whether
the degree of interactors predicted ASB performance. We found that TFs such as the TATA-
binding protein (TBP) and the specificity protein 1 (SP1) which showed upwards of 50
interactions with other TFs also correlated with poor performance (Figure 3.11a).
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Cytosine methylation is another major factor shown to dictate binding for many TFs
[72]. A recent study by Yin et al. used a methylation-sensitive derivative of SELEX to
identify TFs influenced by methylation for over 500 TFs [72]. Here, TFs were charac-
terised into three groups MethylPlus, where the TF preferred to bind methylated sequences,
MethylMinus, where little to no TF binding was found for methylated binding sites and
LittleEffect, where methylation had little to no effect on binding. We collected classes
for 14 TFs with performance measures across the different methods and compared perfor-
mance for each class. Interestingly, we found that TFs classified as MethylPlus consistently
showed significantly lower performance compared to that of MethylMinus in DeepBind
(Figure 3.11b, p=9.9×10−3), gkmSVM (p=6.1×10−3) and PWMs (p=2.8×10−4) (Fig-
ure 3.11b). MethylPlus TFs included included SP1, RFX5, POU2F2, and GATA3, which
demonstrated low average AUROCs across methods RFX3 (0.53), SP1 (0.49), POU2F2
(0.55), GATA3 (0.59). Indeed, TFs such as RFX3 and SP1 methylation has been shown
to positively regulate binding [310, 311]. This suggests that TFs relying on methylation
for binding are likely to perform worse when only sequence information is used for model
training.
TFs are known to be able to detect three-dimensional shape of DNA [312]. We utilised
data from Mathelier et al., where models were trained that incorporated DNA shape features
to show performance of binding can be improved [71]. We identify TFs that rely on DNA
shape for binding by computing the percent increase in AUROC (∆%) for models. The
percent increase is binned values into three bins, < 5, 6− 10, and > 10, which represent
minimal improvement, medium improvement and strong improvement. We found that TFs
that showed strong improvement had significantly lower performance when compared to
those that showed minimal improvement for PWMs (p=4.4×10−3) and gkmSVM (p=0.039).
Significance was borderline significant for DeepBind (p=0.061) and DeepSEA (p=0.035).
This can be explained by the fact that deep learning approaches should at least in part be
able to extract DNA shape features from the sequences they are trained on (Figure 3.11c).
TFs in which DNA shape aided binding prediction (>10%) included SRF (mean AUROC
= 0.62, ∆% = 23), BRCA1 (mean AUROC = 0.48, ∆% = 15), NFYB (mean AUROC =
0.50, ∆% = 12.6), MEF2A (mean AUROC = 0.62, ∆% = 12), MAFK (mean AUROC =
0.68, ∆% = 11.7), TBP (mean AUROC = 0.53, ∆% = 11), PAX5 (mean AUROC = 0.63,
∆% = 10.1), and SP1 (mean AUROC = 0.50, ∆% = 10.1). In contrast, TFs where DNA
shape played a minimal role in binding prediction included ELF1 (mean AUROC = 0.65,
∆% = 1.8), TFAP2C (mean AUROC = 0.62, ∆% = 2.6), BHLHE40 (mean AUROC = 0.69,
∆% = 3.5), and USF2 (mean AUROC = 0.65, ∆% = 3.8). This suggests DNA shape as a
valuable feature when assessing variant impact on TF-binding.
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Finally, we explore the impact of PTMs on TFs binding. PTMs are key regulators of
transcriptional activity and are known to govern binding specificity [313]. We asked if TFs
that are more likely regulated by PTMs also performed poorly. We collected 1,645 PTM sites
for seven modifications in 43 TFs from PhosphoSitePlus [117]. We binned the TFs by the
number of PTM sites they harboured by percentiles. In many cases, we found that heavily
modified TFs such as BCLAF1 (mean AUROC = 0.49, n = 192), POLR2A (mean AUROC =
0.52, n = 171), EP300 (mean AUROC = 0.59, n = 139) and SMC3 (mean AUROC = 0.57,
n = 90) showed significantly lower performance levels, compared to TFs that harboured
fewer than 10 PTM sites in DeepBind (p=6.6×10−5), DeepSEA (p=5.6×10−5), gkmSVM
(p=2.1×10−4) and PWMs (p=1.6×10−3, Figure 3.11d). We similarly utilised 42 PTM
sites across 17 TFs known to be regulatory and compared performance of TFs with a single
regulatory PTM to those with more than one. We observed a similar trend, where TFs such as
BRCA1 (mean AUROC = 0.48, n = 6), SP1 (mean AUROC = 0.50, n = 5), and NFKB1 (mean
AUROC = 0.51, n = 4) with a high number of known regulatory PTMs displayed significantly
lower performance across DeepBind (p=0.011) and gkmSVM (p=0.042) Figure 3.11d).
For certain TFs with distinct sequence specificities, elucidating impact of variants can be
more challenging due to the sequence specificity depending on a multitude of factors that
involve mechanisms beyond proximal sequence information alone. These results demonstrate
the importance of such factors, in silico, when assessing variant impact in TFBSs.
3.3 Methods
3.3.1 Collection of allele-specific binding data
ASB data were collected from five studies [106, 104, 295, 105, 296]. In each study, ChIP-seq
reads are mapped to both alleles of heterozygous variants in individuals or cell lines. A count
for the number of reads mapping to the maternal and paternal allele of each locus is provided
by the studies. Allelic read imbalance is computed across all studies using a binomial test:
Pbinomial(X = k) =
(
n
k
)
pk(1− p)n−k (3.1)
where n is the total number of reads mapped at a given loci, p is the probability of success,
which is fixed to 0.5. This assesses deviation from the expected 50/50 read count. Finally,
SNP positions for hg18-mapped variants are converted to hg19 using liftOver [314] and
loci that did not map were discarded.
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Fig. 3.11 Alternative mechanisms that contribute to poor variant-impact prediction. Perfor-
mance, as measured by AUROCs across DeepBind, DeepSEA, gkmSVM and PWMs for
(a) Number of TF-TF interactions, (b) MethylPlus versus MethylMinus TFs (c) TFs where
binding is influenced by DNA shape and (d) PTMs. Significance p-values are based on a
one-sided Wilcoxon test.
3.3.2 Transcription factor binding model training and scoring
DeepBind models for a total of 94 TFs based on SELEX and ChIP-seq datasets were obtained
from Alipanahi et al. [68]. Performance of each model was evaluated by applying models to
left out test sequences (sequences not used to train the model) and random genomic regions.
In the cases where there were multiple DeepBind models per TF, the model with the highest
performance was selected. Scoring was carried out using the deepbind executable v0.11
with default parameters. Scores for DeepSEA were obtained through the online web server
http://deepsea.princeton.edu/. Models for a total of 62 TFs were used that matched DeepBind
models by cell line.
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A total of 54 PFMs for 54 TFs with a DeepBind model were collected from JASPAR
[287]. If a TF has more than one model, the model with the latest accession version is
used. Motif enrichment data carried out using MEME-ChIP [308] on ChIP-seq data used to
train DeepBind models was used to construct a second set of PWMs. Each contained a set
of enriched motifs along with matching ChIP-seq sequences and an e-value reflecting the
enrichment significance. Motifs with an e-value > 0.05 or less than 10 associated sequences
were discarded and the sequences associated with the top five enriched motifs were used to
construct PWMs. The "signif" PWM set was defined as the PWM for each TF with the most
significant e-value, whereas in the "best" PWM set the top five most significant PWM was
used for scoring and the PWM that gave off the highest variant effect prediction was used. All
PWMs were constructed using the toPWM function of the TFBStools package [315] and the
PWMscoreStartingAt function of the Biostrings package was used to score sequences
using the generated PWMs [316].
The gkmtrain command from the LS-GKM library (https://github.com/Dongwon-
Lee/lsgkm) was used to train gkmSVM models [103] with default parameters, except for
word length option “-l” set to 10. ChIP-seq and SELEX sequences were used as positive
sequences, and random genomic sequences with the same length were used as negative
sequences. The deltaSVM scores were generated from using the gkmpredict command
along with the deltasvm.pl script (http://www.beerlab.org/deltasvm/). Finally, pre-trained
GERV models for a total of 60 TFs were obtained from http://gerv.csail.mit.edu/ ChIP-seq
experiments from ENCODE project and the preprocess and score options of the run.r
script with default options was used to score the impact of variants.
3.3.3 Variant impact scoring metrics
DeepBind and PWMs
Given a PWM or DeepBind model, we define a window of size k using the width of the
PWM or the detector length of the DeepBind model (see [68]), respectively. Given a variant
at position q, we score both the wildtype and mutant sequences starting q− k to q+ k at
increments of k for a set of raw wildtype scores w1,w2, . . . ,wk and mutant scores m1, . . . ,mk.
Given the set of indices S = 1, . . . ,k, the delta raw (∆R) and delta track (∆T ) metrics are
computed as follows:
i∗ = argmax
|mi−wi|∀i∈S
∆R = mi∗−wi∗
(3.2)
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∆T = max
∀i∈S
mi−max∀i∈S wi (3.3)
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Fig. 3.12 The conversion of raw scores into probabilities of binding using generalised linear
models.
To compute Pbind scores we score a given an individual raw score, we compute a fore-
ground and background distribution of raw scores using a set of positive and negative
sequence respectively. The negative sequences are defined as 10,000 randomly sampled
genomic sequences of size k. The positive sequences for JASPAR PWMs are defined as
generated sequences from the PWM, whereas for MEME-ChIP PWMs this is defined as
the corresponding matching ChIP-seq sequences used to construct the PWM. The positive
sequences as the ChIP-seq or SELEX sequences used to train the DeepBind models. We
assume the background distribution follows a Gaussian distribution N ∼N (µn, σn) and
learn the parameters of the true positive distributions by fitting a two-component Gaussian
model mixture model. Here, one component is fixed to µn, σn and the true positive parameters
are learned as µp, σp. A total of 10,000 random samples are generated using the given the
parameters of background and used to train a generalised linear model, which is used to
compute a posterior probability (Figure 3.12) of binding (Pbind) and not binding (Pnot binding).
The Pbind scores are computed for both the wildtype Pbw1 , . . . ,Pb
w
k and mutant Pb
m
1 , . . . ,Pb
m
k
k-mers. The Pnot binding scores are computed similarly as Pnw1 , . . . ,Pn
w
k and Pn
m
1 , . . . ,Pn
m
k .
The delta Pbind (∆P) score is then computed similarly to that of ∆R:
i∗ = argmax
|Pbmi −Pbwi |∀i∈S
∆P = Pbmi∗−Pbwi∗
(3.4)
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The probabilistic scores of a loss (Ploss) and gain (Pgain) events are computed by multi-
plying the likelihood of the wildtype allele binding and the mutant allele not binding for loss,
and vice versa for gain:
Ploss = argmax
Pbwi ·Pnmi ∀i∈S
Pbwi ·Pnmi (3.5)
Pgain = argmax
Pbmi ·Pnwi ∀i∈S
Pbmi ·Pnwi (3.6)
Both probabilities are then combined into individual scores Psum and Pcomb as follows:
Psum =−Ploss +Pgain (3.7)
Pcomb =
Pgain, if Pgain > Ploss−Ploss, otherwise (3.8)
DeepSEA
Given a probability of binding in the wildtype and mutant alleles, as ρw and ρm respectively,
DeepSEA utilises two scoring schemes: the difference (DSD) and log fold change (DSL)
computed as follows:
DSD = ρm−ρw (3.9)
DSL = log(
ρm
1−ρm )− log(
ρw
1−ρw ) (3.10)
gkmSVM
Given k-mer weights computed for wildtype and mutant sequences flanking the variant posi-
tion as ωw1 , . . . ,ω
w
10 and ω
m
1 , . . . ,ω
m
10, the deltaSVM (∆SV M) score is computed as follows:
∆SV M =
n=10
∑
i
ωmi −ωwi (3.11)
3.3.4 Allele frequencies and non-coding variant impact predictions
Allele frequencies for the 1000 genomes project, ExAC variants and ESP6500 project, along
with non-coding variant impact predictions for CADD, Eigen and GWAVA were obtained
from the ANNOVAR tool [317], using the table_annovar.pl script.
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3.3.5 Performance measures
ROC and PR curves were generated by assessing the TPR (or recall), FPR and precision.
The ROC curves compare the FPR against the TPR, whereas PR curves compare the TPR
against the PPV (or precision). Given the number of true positives (TP), false positives (FP),
true negatives (TN) and false negatives (FN), these are computed as follows:
T PR =
T P
T P+FN
FPR =
FP
FP+T N
PPV =
T P
T P+FP
(3.12)
All ROC and PR curves, along with area under the curve measures were computed using
the PRROC R package [318].
3.4 Discussion
Non-coding variation has the ability to greatly alter gene expression and influence disease
phenotypes. Understanding the impact of non-coding variation is an ongoing challenge in
genetics. One of the primary modes for this is through impacting TFBSs. Yet, despite the
wealth of TF specificity available through high throughput technologies, accurate in silico
prediction of TFBS-altering variants remains a non-trivial task.
This chapter describes efforts to compare TF-based variant impact predictors using ASB
variants as a gold standard. Since both alleles exist in the same cellular environment, ASB
variants serve as a valuable source to assess performance of TF-binding models at assessing
impact of variants. We have shown that the ability for machine learning models, in particular,
deep learning methods, to significantly reduce the number of false positives allows for more
accurate variant impact predictions. Deep learning approaches are able to utilise the full
extent of ChIP-seq and SELEX data to learn far more complex positional dependencies in
binding sites. Deep learning approaches are also not confined to the exact motif location and
therefore can model sequence context of the binding site, which has been shown to contribute
to binding [64, 319].
We finally show that TFs with poor performance at assessing variant impact often rely
on additional mechanisms such as binding partners, methylation, DNA shape and PTMs
(Figure 3.11).
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Assessing TF-DNA binding and how it is influenced by genetic variation in silico is a
much more complex process than once thought. Current methods available for interpreting
effects of TFBS variants rely primarily on binding specificity. Although this provides a useful
framework for prioritizing non-coding variants, as demonstrated by results, even the most
sophisticated methods are often unable to capture the full extent of altered binding in the
genome. This can be attributed to several reasons. First, there are several other mechanisms
that have been known to significantly contribute to binding specificity such as epigenetic
modifications, cooperative binding, geometric shapes of DNA, PTM modifications and more.
Epigenetics, in particular, methylation, can play a major role in enhancing or inhibiting
TF-binding [320, 72]. The recent study by Yin et al. carried out methylation-sensitive
SELEX in 542 TFs and identified many methylation-dependent TFs [72]. Epigenetics can
also greatly affect regions TFs can occupy. Nucleosome occupancy, for instance, results in
closed chromatin which is inaccessible to TFs. Indeed, DNAase hypersensitivity sequencing
(DHS-seq) has revealed regions of open chromatin in many cell lines, which have been shown
to improve binding prediction [321]. PTMs is another major regulator of TF activity through
altering its structural conformation, stability or sub-cellular localization thereby affecting
binding [313]. For instance, phosphorylation of p53 on S378 allows it be recognized by
14-3-3 proteins, which associate with p53 and significantly enhances DNA-binding [322].
Second, binding preferences of a TFs have been shown to be heterogeneous across different
cell lines. For instance, Arvey et al. comprehensively analysed ChIP-seq data for 67 TFs
across multiple different and found that many cell-type-specific sequence models were able
to capture binding variability, which was primarily due to differences in heteromeric complex
formations [323]. Since the samples and cell lines from which ASB variants were obtained
do not always match that of the experiments used to generate TF-specificity models, this is a
potential confounding factor of poor performing models.
Another factor greatly limiting the prediction of TFBS-altering variants is the availability
of TF motifs. It is estimated that the human genome contains approximately 1,400 TFs
containing DBDs [324]. Although the current catalogue of TF-binding specificity has
significantly expanded in the past decade with the aid of high throughput approaches such as
ChIP-seq, SELEX and PBMs, almost half of identified TFs are yet to have their specificity
determined [325]. This is perhaps due to technical limitations, such as transient binding or
expression of the TF. The lack of such data further hampers ability for us to systematically
understand variant impact in TFBSs.
Significant advances in interpreting non-coding variation have been greatly aided by the
emergence of deep learning methods to the field of genetics over the past few years. However,
accurate assessment of variant impact on TFBSs will require models to systematically
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integrate additional epigenetic, proteomic and genetic data in order to account for mechanisms
beyond sequence specificity in a cell-type-specific manner.
Chapter 4
Functional consequences of single
nucleotide variants across different
molecular features
In this chapter, I describe a comprehensive effort to compile and benchmark commonly-used
sequence and structure-based predictors of mutational consequences, which are used to
precompute the effects of coding and non-coding variants in the reference genomes of H.
sapiens, S. cerevisiae, and E. coli. I utilise this data to analyse known pathogenic disease
variants and provide mechanistic hypotheses for causal variants of unknown function.
Lab members Danish Memon and Marco Galardini have contributed multiple sequence
alignments used for SIFT and FoldX-generated data to the project for H. sapiens and E. coli.
All work was otherwise carried out by myself under the supervision of Pedro Beltao. Parts of
this work were published in the following article:
Marco Galardini, Alexandra Koumoutsi, Lucia Herrera-Dominguez, Juan Antonio
Cordero Varela, Anja Telzerow, Omar Wagih, Morgane Wartel, Olivier Clermont, Erick
Denamur, Athanasios Typas and Pedro Beltrao (2017). Phenotype prediction in an Es-
cherichia coli strain panel. Biorxiv, page 141879.
4.1 Introduction
GWASs have come a long way at identifying causal genetic variants. Over the past decade,
thousands of associations have been made between genetic variation and phenotypic traits
including disease risk [326]. However, GWASs are inherently limited in their ability to
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explain the underlying mechanism that is likely influenced by the variant in question. This
missing mechanistic layer poses several roadblocks in the comprehensive understanding of
how variants influence phenotypic variability.
In previous chapters, I have discussed the importance of modelling sequence specificity
mediating both kinase-substrate phosphorylation and TF-binding and their role in uncovering
mechanistic consequences of genetic variation. In addition to such mechanisms, variants
occurring in coding and noncoding regions can influence a diversity of molecular functions.
For instance, non-coding variants can affect chromatin accessibility [327], splice sites [328],
and epigenetic modifications [329]. Coding variants can affect PTM sites [121, 146], protein
folding and stability [330], protein interaction interfaces [226], sub-cellular localization
[331], as well as introduce premature stop codons. Understanding the disrupted biological
mechanisms underlying genetic variation is key to many applications in genetics such as
genetically engineering organisms, assessing drug efficacy and drug discovery [332–334].
The ability to predict the degree to which genetic variation would alter such mechanisms
offers a time and cost-effective alternative over classical experimental validations and can
greatly facilitate the understanding of mechanisms underlying causal variants. A multitude of
in silico predictors aimed at predicting such effects have been proposed [146, 189, 305], yet,
for the average user, they are often cumbersome to set up and use and/or require significant
computational power and time. For instance, structure-based protein stability predictors
can take on the order of minutes to hours to assess the impact of a single variant [189].
Furthermore, the currently available tools do not comprehensively combine effects across
different molecular mechanisms [335] or are limited to analysing coding or noncoding
variation [305].
In this chapter, I first investigated natural and disease-variation in both H. sapiens and
S. cerevisiae in the context of functional elements in the genome to show that such regions
display higher evolutionary constraint. Accordingly, I have compiled and benchmarked
commonly-used sequence and structure-based predictors of mutational consequences and
predicted the effect of all possible amino acid and nucleotide variants in the reference
genomes of H. sapiens, S. cerevisiae, and E. coli. The impact of variants was measured in the
context of conserved protein regions, protein stability, PPI interfaces, PTMs, kinase-substrate
interactions, SLiMs, start and stop codons, and TFBSs. This data is deposited in the mutfunc
platform, which allows for prioritization of variants while providing insight into the altered
mechanisms.
Because all data is precomputed, variants can be rapidly annotated and prioritised. The
data available in mutfunc was validated by analysing both natural and disease genetic variation
data in S. cerevisiae and H. sapiens data. For instance, we have shown that genes deemed
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essential for survival are less likely to harbour impactful variants and that common genetic
variants are less likely to be impactful. Variants curated to be relevant for function or deemed
pathogenic were also more likely to be predicted as impactful. We further demonstrate the
utility of mutfunc by analysing clinical variants that identified in disease patients but have an
uncertain significance of pathogenicity. Mutfunc is a valuable resource that will facilitate the
understanding of the mechanistic impacts of genetic variation.
4.2 Results
4.2.1 Functional genomic regions display evolutionary constraint
across S. cerevisiae and H. sapiens
We first aimed to investigate how both natural and disease variants manifest themselves
within functional regions of the genome. We asked if certain functional regions relevant
to protein structures, PTMs and TFBSs were under evolutionary constraint or negative
selection. If these regions are indeed critical for function, arising deleterious variants would
be purged over time in order to retain function. The evolutionary constraint, defined as c, can
be measured by taking the ratio between observed mutation counts in a region of interest
and random regions, where, values below 1 confer negative selection, and values above 1
confer positive selection. To do this, publicly available genetic variation data for both S.
cerevisiae and H. sapiens were used. For S. cerevisiae, 896,772 natural variants for over
400 S. cerevisiae strains were collated from four studies [336–339], of which 478,857 were
coding variants. For H. sapiens, over 3.2M coding variants from over 65,000 individuals
were obtained from the ExAC consortium [298] (Methods, section 4.3.1).
Buried protein regions and interaction interfaces exhibit negative selection
It is well established that buried residues contribute more to protein stability relative to
surface residues [340] and have been shown on a smaller scale to harbour fewer mutations
[341]. To assess this on a larger scale, variants from S. cerevisiae and H. sapiens were
mapped to a total of 9,837 resolved protein structures and homology models (n=6,737 H.
sapiens, n=3,100 S. cerevisiae) and residues were grouped based on the computed relative
surface accessibilities (RSAs) of residues (Methods, section 4.3.4). Residues were binned
into four RSA groups (0-25%, 26-50%, 51-75% and >76%). The number of mutations falling
within positions of each bin is then counted and compared to counts observed by the same
number of random positions in the protein, permuted 1,000 times. Buried residues were
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found to harbour fewer variants in both S. cerevisiae and H. sapiens, relative to those of
higher RSA (Figure 4.1a, p<1.28×10−34).
This was similarly measured in structures of PPI interfaces. A total of 9,883 structures
(n=7,693 H. sapiens, n=2,190 S. cerevisiae) for binary PPIs were collected from Interac-
tome3D [205]. The difference in RSA between, ∆RSA, between monomeric proteins and
proteins in the interaction complex, was used as a measure of how buried or exposed a residue
was within an interface (Methods, section 4.3.4). Residues were grouped into four ∆RSA
bins, similar to those defined for stability. Residues buried within interface residues were
found to harbour far fewer variants compared to those that are exposed, with a low ∆RSA
(Figure 4.1b, p<2.28×10−33).
The strong negative selection observed in buried residues with respect to both monomeric
proteins and interaction interfaces suggest that they are of higher functional relevance, which
is in agreement with what is reported regarding the importance of buried residues in the
stability of proteins [340] and interaction interfaces [342].
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Fig. 4.1 The evolutionary constraint in monomeric protein structures, interaction interfaces
and PTMs. (a) Regions buried within a protein structure with a low RSA typically exhibit
higher evolutionary constraint. Similarly, (b) regions buried within interaction interfaces
exhibit a high ∆RSA and demonstrate stronger evolutionary constraint. P-values represent a
one-sided Wilcoxon test. (c) Evolutionary constraint on PTMs, where numbers reflect the
number of PTM sites for each modification. (d) PTMs with a higher number of neighbouring
PTMs are much under stronger constraint, compared to those that exist individually.
Post-translational modification regions exhibit negative selection
To explore PTM-associated variation, a total of 296,147 and 26,560 H. sapiens and S.
cerevisiae PTM sites were gathered from publicly available databases and the common PTMs
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included ubiquitination, acetylation, phosphorylation, methylation and O-linked glycosilation
(Methods, section 4.3.5). The frequency of variant frequency within ±5 flanking residues
of modified sites was compared to that of randomly sampled residues. The random set
is defined as non-PTM matching residues sampled from the same proteins harbouring the
modifications. Different PTMs exhibited variable levels of constraint with modifications like
O-linked glycosilation displaying the strongest (Figure 4.1c, c=0.64 H. sapiens, c=0.58 S.
cerevisiae), followed by methylation (c=0.84 H. sapiens, c=0.62 S. cerevisiae). In contrast,
modifications such as ubiquitination demonstrated lower constraint (c=0.85 H. sapiens,
c=0.97 S. cerevisiae). This could be partly explained by the fact that ubiquitination is
far more robust to genetic variation. There have been numerous documented cases in the
literature suggesting that the disruption of one ubiquitination site has little impact on the
targeting and degradation of the protein since the ubiquitination of a proximal lysine will
often achieve a similar function [343, 344].
Clusters of PTM sites, where a high number of PTM modifications are observed, have
been shown to confer functionally relevant regions of the protein [283]. An example of
this is the multi-phosphorylation cascade in beta-catenin, where the phosphorylation of
several neighbouring phosphosites must be achieved in order for beta-catenin to be targeted
for degradation [345]. To test whether clusters of PTM sites confer stronger evolutionary
constraint, PTM sites were binned depending on the number of neighbouring PTMs within a
±10 window and the variants were analysed within each bin. A strong positive relationship
was observed between the number of neighbouring PTMs and negative selection. Sites with
5 or more other neighbouring PTMs demonstrated much stronger negative selection when
compared to those that occurred individually (Figure 4.1d, p<5.41×10−6). This suggests
that such clusters could indeed represent signalling hotspots, relevant for carrying out critical
biological functions.
Transcription factor binding sites exhibit negative selection
We next sought to measure the constraint of non-coding variation in TFBSs in the S. cerevisiae
genome. To do this, we predicted genes likely regulated by a TF by identifying differentially
expressed genes in TF-knock-out strains (Methods, section 4.3.7). This resulted in a network
of 1,711 TF-gene relationships across 93 TFs. Using a total of 176 PWMs from JASPAR
[346] the corresponding ChIP-seq or ChIP-chip regions in promoters of associated genes
were scanned. A total of 4,523 potential binding sites were identified across 93 TFs. The
constraint was measured by computing the ratio of variant frequency within the predicted
binding sites to that of random genomic sites of the same length and within the same gene
promoter and ChIP regions. Interestingly, TFs that were relevant for regulating genes in
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response to lack of nutrients (PHD1, SFP1) and oxidative/osmotic stresses (SKN7, MOT3)
were not found to be under negative selection. This is in contrast to TFs that regulate
more basic cellular function such as those involved in the expression of respiratory genes
(HAP4), termination of RNA polymerase I transcription (REB1), and general transcription
activation, repression and chromatin silencing (RAP1), which exhibited a much higher degree
of negative selection (Figure 4.2a).
Clusters of multiple TFs (heterotypic clusters) or single TFs (homotypic clusters) are
have been shown to have increased importance in the regulation of gene expression, likely
through promoting cooperative TF binding [347, 348, 348]. To assess evolutionary con-
straint within heterotypic and homotypic TFBS clusters, predicted binding sites were binned
based on the number of neighbouring TFBSs within a 50 bp window and constraint was
measured for each bin, similar to PTMs. Clusters of TFBSs displayed high negative selection
(Figure 4.2b), where binding sites with 6 or more adjacent neighbours showing signifi-
cantly stronger negative selection (c=0.37) compared to those that occurred individually
(Figure 4.2b, c=0.77, p=1.26×10−34), suggesting that regions harbouring a higher number
of TFBSs likely represent functional regulatory hotspots.
Given that TFBSs were overall constrained, we next asked if positions relevant for
binding were under stronger negative selection. Using the PWMs, the position-specific
information content (IC) was computed and used as a proxy for binding relevance. For
TFs with greater than 20 putative binding sites, the IC of positions was binned based on
whether it was low (<0.5), medium (0.5-1.5) and high (>1.5). Positions with high IC were
found to display significantly stronger negative selection compared to those with low IC
((Figure 4.2d), p=0.017). Examining position-specific constraint for individual TFs further
demonstrates the relevance of high IC positions (Figure 4.2e).
4.2.2 mutfunc: a one-stop resource for mechanistic effects of single
nucleotide variants
Given that functionally-relevant regions of the genome are under negative selection, we sought
to better understand the mechanistic impact of point mutations affecting these functional
elements. To do this, a set of commonly-used predictors were used to assess the impact of
every possible single amino acid or nucleotide substitution across H. sapiens, S. cerevisiae,
and E. coli, where applicable. We precomputed data of variants that impact conserved protein
regions, protein stability, protein interaction interfaces, kinase-substrate phosphorylation and
other PTMs, linear motifs, TFBSs and start and stop codons (Methods, section 4.3.8). These
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Fig. 4.2 Evolutionary constraint of TFBSs in S. cerevisiae. (a) Variability in constraint
amongst bindings sites for TFs with at least 40 sites. (b) TFBSs that co-exist with other
binding sites are under stronger constraint. P-value shown is computed using a one-sided
Wilcoxon test (c) Position-specific constraint shows that positions of higher relevance for
binding in TFs with at least 20 sites are under stronger constraint. P-value shown is computed
using a one-sided Kolmogorov-Smirnov test. The clear correlation between the positions
relevant for binding and constraint is visually represented through (d) four examples where
the bar plots reflect the position-specific constraint in (blue) and around (grey) the binding
site, along with sequence logos for the binding specificities.
results were deposited in a web tool, mutfunc, which offers a quick and interactive way by
which users can gain mechanistic insight into variants of interest.
A compiled resource of precomputed mechanistic variant impact
To measure the impact on conserved regions, we constructed 29,027 multiple sequence
alignments for proteins of the three organisms (n=19,497 H. sapiens, n=5,498 S. cerevisiae,
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n=4,032 E. coli), and used the SIFT algorithm [244] to assess the impact of all possible
291.7M variants (n=212.2M H. sapiens, n=53.4M yeast, n=26.1M E. coli). To measure
the impact on protein stability, the FoldX algorithm [189] was applied to 17,893 structures
(including homology models) across the three organisms, and precomputed effects of 66.3
million all substitutions (n=42.7M H. sapiens, n=10.3M S. cerevisiae, n=13.4M E. coli,
Methods, section 4.3.4). We identified interface residues in 10,675 structures of binary PPIs
from Interactome3D across the three organisms and similarly applied FoldX to compute the
effects of all 11.2M possible mutations on binding stability (n=7.2M H. sapiens, n=2.3M
S. cerevisiae, n=1.6M E. coli). To identify variants that could impact kinase-substrate sites,
we used MIMP [146] to predict the impact of all possible 541,161 variants (n=485,736 H.
sapiens, n=55,425 S. cerevisiae) falling within ±5 residues of a known kinase-substrate
phosphorylation site (phosphosite) on a kinase’s specificity. Specificities for 56 kinases in
H. sapiens and 46 kinases in S. cerevisiae were considered. For all other PTMs such as
methylation, ubiquitination, and acetylation that do not exhibit explicit flanking sequence
specificities, a variant was considered damaging if it directly altered the modified site. This
resulted in a total of 6.3M possible variants that could alter such PTM sites across the three
organisms (n=5.8M H. sapiens, n=537,434 S. cerevisiae, n=9,177 E.coli). For linear motifs,
we gathered 1,668 experimentally identified linear motifs (n=1,525 H. sapiens, n=143 S.
cerevisiae), along with their derived regular expression pattern from the ELM database [161]
and computed the impact of all possible variants 226,920 (n=205,120 H. sapiens, n=21,800
S. cerevisiae) on binding patterns. Finally, for TFBSs, for organisms without well-defined
functional TFBSs (H. sapiens and S. cerevisiae), we defined putative TF-gene regulatory
network using TF-knockdown expression data and/or ChIP-seq/ChIP-chip, as previously
described. We then used PWMs to identify putative binding sites, and predict the impact
of all possible 3.6M variant substitutions (n=3.3M H. sapiens, n=236,382 yeast, n=46,768
E. coli) on specificities of 217 TFs (n=72 H. sapiens, n=104 S. cerevisiae, n=41 E. coli). It
is noteworthy to mention that although in Chapter 3 (section 3.2.3) we show that machine
learning-based approaches outperform PWMs (used here) at predicting TFBS variant impact,
the work presented in this chapter was carried out prior to that of Chapter 3.
The precomputed mechanistic variant effects data are stored in a normalised MySQL
database in a mechanism-specific manner (Figure 4.3). All variants are stored within a
primary mutation table, which then relates to the individual mechanism-specific tables in a
one-to-many manner. The mutation table also references a position table containing positions
of all variants, which in turn references a gene/chromosome table in a many-to-one manner.
All these tables are indexed to allow for rapid lookup amongst millions of entries.
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Fig. 4.3 The MySQL mutfunc database schema showing the structure of the database, tables,
and relationships. The primary table MUT (yellow) stores all possible DNA and amino acid
variants, which relate to mechanism-specific tables (red). These then relate to additional
tables (blue) containing information on the affected mechanisms.
The mutfunc web server user interface
The mutfunc user interface provides an intuitive, user-friendly and interactive way by which
users can query the database using their own variants. Both DNA or protein substitutions
can be provided to mutfunc in one of two formats, plain text format or the variant call
format (VCF). The plain text format is a simplified format for variants, where variants are
line separated. Variants should be formatted as follows NAME_X123Y or NAME_123_X_Y,
where NAME is name of the gene (UniProt accessions, gene names or IDs are acceptable) or
chromosome (number or NCBI IDs), 123 is the position of the variant, and X and Y are the
wildtype and mutant amino acid or base, respectively (Listing 4.1). Alternatively, the VCF
format can be used, which is a format commonly used by variant calling pipelines. In its
simplest form, a VCF file is a five-column tab-delimited file containing the chromosome,
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position, id, wildtype and mutant alleles of a DNA variant (Listing 4.2). Both formats can be
provided either via the text box or by uploading a file.
Listing 4.1 Plain text format example
chr1_61177_G/A
YPL228W_N274C
MYO4_K1366N
YJL158C K63A
Listing 4.2 VCF format example
chr17 10987590 ID1 G T
chr10 23508363 ID2 A G
chr16 52599188 ID3 C T
chr16 20932709 ID4 T C
Variants are processed then queried against the database. If DNA variants fall within a
coding region and encode a nonsynonymous substitution the corresponding protein variant is
also queried against the database. Since all predictions are precomputed, mutfunc is able to
analyse an extremely large number of variants typically within seconds.
An interactive report of variant effects is returned to the user, which contains a table
of variants matching the database (Figure 4.4a). The predicted effect of each variant are
categorised into six classes: (1) PTMs and linear motifs (2) Stability (3) Interfaces (4)
Conservation (5) TFBS (6) Start-stop codons. Each row in the table contains a series of
coloured and labelled badges, where each badge is coloured and labelled distinctively based
on the mechanism class (Figure 4.4b). Expanding the row allows for mechanistic effects
to be further explored, providing additional information on the prediction made such as the
score as provided by the predictor, visual representations of the variant, and external links
to references. For instance, details of a variant affecting protein stability or interfaces will
show FoldX-predicted ∆∆G values, alongside an interactive visualization of the variant in
the context of the three-dimensional structure. Variants impacting conserved regions will
show SIFT scores and an MSA of the affected position in context. Variants impacting SLiMs,
PTMs or TFBSs will show the local sequence context before and after the mutation as well
as sequence logos if a motif is involved (Figure 4.4b).
Variants of a single protein can be visually inspected using the interactive protein viewer
(Figure 4.4c). Using an adapted version of the neXtProt [349] feature viewer, variants within
a protein are visualised in the context of different protein feature tracks including protein
domains from PFAM [350], regions of disorder from MobiDB [351], secondary structure
from UniProt [149] and PTMs. A separate track is separately displayed for each class of
variants. The viewer allows interactive zooming and interfaces with the results table i.e.
selecting a variant in the viewer will highlight the corresponding row.
Results can be filtered by gene or chromosome keywords and by different classes of
variants. All results can also be exported for analysis offline, in which an archive of tab-
delimited flat (one for each variant class) files are made available to download. All jobs are
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stored for 48 hours, after which all submitted data and generated results are removed from
the server.
The mutfunc resource serves as a useful platform for small and large-scale studies,
allowing variants to be mechanistically explained and prioritised.
4.2.3 Validation of predictions
To demonstrate the ability of predictions provided in mutfunc, we aimed to explore the
properties of a large number of predictions generated for yeast and H. sapiens. We explored
the deleteriousness of variants in the context of essential genes as well as allele frequency.
We further leveraged a number of data sets that have manually curated variants as either
being deleterious to function or having no effect in order to validate predictions.
Essential genes harbour fewer deleterious variants
Essential genes are those required for survival and are often identified by disrupting the gene
and assessing the viability of the organism or cell. In S. cerevisiae, roughly 20% (1,114)
genes have been identified as essential well over a decade ago by the Saccharomyces Genome
Deletion Project (SGDP) consortium. More recently, this has been made possible in H.
sapiens through CRISPR and gene trapping technology [352, 353]. For instance, Blomen et
al. identified roughly 8% (1,734) of H. sapiens genes as essential in two cell lines [352].
Utilising knowledge of essential genes in both S. cerevisiae and H. sapiens, we explored
how often essential genes exhibit variants impacting conserved regions (sift score < 0.05),
protein stability and interface residues (∆∆G > 2), altering start codons or stop codons (non-
sense and nonstop variants). We counted deleterious variants in essential and non-essential
genes, normalised by the length of the protein. We found that essential genes consistently
demonstrated significantly lower frequencies of variants predicted to affect conservation,
stability, interfaces and alter start and stop codons in across H. sapiens and S. cerevisiae (Fig-
ure 4.5). Specifically, conservation showed the most significant separation between essential
and non-essential genes (p=1.04×10−46 H. sapiens, p=1.52×10−22 S. cerevisiae), followed
by protein stability (p=1.82×10−12 human, p=7.07×10−10 S. cerevisiae). Although in S.
cerevisiae fewer deleterious interface variants impact essential genes (p=5.43×10−4), in
H. sapiens there was surprisingly no observed difference (p=0.70, Figure 4.5c). Finally,
of the variants affecting the start and stop codons, nonsense variants showed the highest
significance (p=8.49×10−23 H. sapiens, p=1.08×10−5 S. cerevisiae), followed by start loss
and nonstop variants (Figure 4.5d-f). However, similar to interfaces, start loss variants did
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not show a significant difference in H. sapiens (p=0.51), whereas S. cerevisiae exhibited mild
significance (Figure 4.5f, p=0.012).
These results demonstrate that essential genes, in most cases, harbour fewer variants
that would affect its function, confirming both the essentiality of the genes as well as the
reliability of predictions made.
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Fig. 4.5 Essential genes harbour fewer variants impacting mechanisms across H. sapiens
(top) and S. cerevisiae (bottom). (a-f) Box plots show the count of variants, normalised
by protein length for essential and non-essential genes in each mechanism. P-values are
calculated based on a one-sided Wilcoxon test.
Common variants are more tolerated
Variants that occur commonly in the population should by definition less likely to have
strong effects on molecular phenotypes. To confirm this, we analysed the predicted impact
of variants in the context of allele frequencies. Variant effect predictions for conservation,
stability, and interfaces were binned by their MAF into 5 groups (0-1%, 1-5%, 5-20%,
20-50% and >50%) and the distribution of variant impact scores in each bin was assessed.
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Both conservation and stability showed a clear linear relationship between the MAF and
predictor score across H. sapiens and S. cerevisiae. Variants with a MAF < 1% showed an
average SIFT score of 0.27 and 0.4 in H. sapiens and S. cerevisiae, respectively, compared
to variants with MAF > 50%, which showed significantly higher SIFT scores of 0.60 and
0.60 (p<2.2×10−16). Stability effects for variants followed similar trends with < 1% MAF
variants showing an average ∆∆G of 1.5 and 0.75 in H. sapiens and S. cerevisiae, respectively,
compared to 0.2 and 0.15 in high MAF variants (> 50%). Interfaces did not follow such
trends, likely due to the highly imbalanced number of variants across MAF bins.
Grouping MAFs by bins often relies on having a significant number of MAF values per
bin. To more directly compare distributions of MAFs, we compared the quantiles of MAF
distributions of impactful variants to that of all nonsynonymous variants. For conservation,
stability and interface predictions, deleterious variants were defined by cutoffs of s < 0.05
for conservation, and ∆∆G > 2 for stability and interface predictions. Results showed that
impactful variants typically exhibited significantly lower MAF values with the exception of
both nonstop and start lost variants (Figure 4.6b). Variants affecting PTMs in S. cerevisiae
also did not show a significant difference (Figure 4.6b).
The AF is a useful metric to consider when interpreting variant effects. These results
demonstrate that it is often the case predicted deleterious variants demonstrate lower AF.
Predicted deleterious variants are enriched in functionally important variants
We next tested the ability of predictors included in mutfunc to identify functionally significant
variants in S. cerevisiae and H. sapiens. For H. sapiens we used a total of 34,600 variants
annotated to be pathogenic (n=17,167) or benign (n=17,433) in ClinVar database[354]. For
S. cerevisiae we utilised 8,083 variants consolidate by Jelier et al. [355] as either tolerated
(n=5,271) or affecting function (n=2,812) (Methods, section 4.3.1).
Using the quantitative score of conservation, stability, and interface predictions, we
assessed the performance at which predicted scores are able to discriminate functional
variants. Predictors consistently demonstrated satisfactory performance across both H.
sapiens and S. cerevisiae. Predictions based on SIFT performed the best at discriminating
pathogenic variants from benign (AUC H. sapiens = 0.87, S. cerevisiae = 0.92), followed by
FoldX interfaces (AUC H. sapiens = 0.64, S. cerevisiae = 0.72) and FoldX stability (AUC
H. sapiens = 0.70, S. cerevisiae = 0.62, Figure 4.7a). A possible explanation for stability
and interface predictors having lower performance is that they explain only individual
mechanisms and, therefore, misclassified variants are likely involved in alternate mechanism
driving the pathogenicity.
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Fig. 4.6 Common variants are less impactful across H. sapiens and S. cerevisiae. (a-c) Bar
plot of mean SIFT scores and predicted ∆∆G values for variants within different MAF bins.
Error bars represent the standard error and p-values are calculated based on a one-sided
Wilcoxon test. (d) Quantile-quantile plots of MAFs between observed MAFs of variants
impacting a mechanism and expected MAFs of all coding variants.
Other heuristic-based predictors such as SLiMs and PTMs that provide a binary classifi-
cation of deleteriousness were also checked if variants predicted to be affecting a cellular
mechanism were enriched in pathogenic/deleterious variants. For each class of predictions,
the proportion of functional variants is computed and compared against a background set of
variants using a one-sided Fisher’s exact test to obtain a p-value describing the significance
of observing the proportion by random chance. This was carried out on variants that lie
within a SLiM and disrupt or retain the regular expression, variants that impact PTM and
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non-PTM residues, and variants altering start and stop codons. We found that, despite
low numbers, variants disrupting regular expression patterns of linear motifs were enriched
(p=5.23×10−3 H. sapiens, p=0.12 S. cerevisiae). The insignificant p-value observed in S.
cerevisiae is likely due to a scarcity of observed SLiM-disrupting variants. Similarly, in S.
cerevisiae, variants altering PTM sites were shown to be enriched in deleterious variants
(p=8.44×10−7). This observation did not extend to H. sapiens, likely due to the much higher
quantity of PTMs, many of which are non-functional [283]. Finally, variants that disrupt
start codons as well as nonsense and nonstop variants all displayed high proportions of
deleterious/pathogenic variants (>80%), which was significantly higher than the proportion
of all variants (p<2.14×10−4 H. sapiens, p=0.052 S. cerevisiae).
The results here demonstrate that predictors utilised in mutfunc are capable of identifying
variants of functional significance, further demonstrating the practicality of mutfunc.
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Fig. 4.7 Validation of predictors in mutfunc using functional and pathogenic variants in S.
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show the proportion of variants in each bin deemed functional. Numbers above each bar plot
denote the number of variants. All p-values are calculated using a one-tailed Fisher’s exact
test.
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4.2.4 Predicting mechanistic insight into variants of uncertain signifi-
cance
Variants that have been identified through genetic testing but are yet to be deemed benign
or pathogenic are termed variants of uncertain significance (VUS). The interpretation of
such variants is a common challenge in genetics, one that is often aided by computational
predictors. We sought to employ the mutfunc database to predict protein-coding VUSs. A
total of 64,692 variants labelled with “uncertain significance” were collected from ClinVar
[354], along with the disease phenotype in which they were tested for. VUSs were annotated
using mutfunc and 21,584 variants were predicted impactful by at least one of the mechanistic
predictors, not including SIFT (n=7,547 stability, n=751 interfaces, n=139 linear motifs,
2,372 PTMs, 57 kinase-binding). We focus on variants predicted to impact the structural
integrity of proteins (stability and interaction interfaces) since they hold the highest coverage.
Over 38% (751/1981) of VUSs are predicted to interfere with interface binding stability.
VUSs were retained if (1) the protein also harbours a pathogenic variant predicted by the same
predictor as impactful and (2) both the pathogenic variant and VUSs are identified in patients
carrying the same disease. This allows us to focus on higher confidence VUS predictions
for which we know a pathogenic variant alters the same mechanism. We demonstrate a few
examples of VUSs that are predicted to alter binding to highlight the utility of predictions
in mutfunc. For instance, primary hyperoxaluria is a disease caused primarily by mutations
in the GRHPR gene, a glyoxylate and hydroxypyruvate reductase [356, 357]. Enzymatic
activity of GRHPR requires homodimerization [358]. The VUS R171H is predicted to
impact a conserved region as well as the homodimerization stability (∆∆G = 2.19, s <
0.018), thereby impinging on the function of GRHPR. Interestingly there have been two
other pathogenic variants R302H and E113K that are implicated in primary hyperoxaluria
and are also predicted to impact conserved regions and binding stability (∆∆G > 2.15, s <
0.012), further supporting the evidence of an altered mechanism for the VUS. Similar to this
example, mutations in fumarate hydratase (FH) have been shown to play crucial roles in
fumarase deficiency and cancer [359] and regular function for FH is attained through the
formation of a homotetramer [359]. A number of VUSs throughout the FH homotetramer
interfaces identified in fumarase deficient patients have been predicted as disrupting binding
stability, such as the S334R mutation, which shows a ∆∆G of 6.31, which would result in
loss-of-function of FH. The pathogenic variants R233C and D341N have been predicted
as impacting binding stability (∆∆G > 2.81) and are implicated in cancer and fumarase
deficiency, respectively.
Similar to interface variants, we analysed variants that destabilise the protein structure. We
identified 1,182 VUSs predicted to alter stability in proteins containing pathogenic variants
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also predicted destabilizing. For example, in the ubiquitin ligase PARK2, implicated in
Parkinson’s disease, two rare VUSs (R42H, V148E) identified in Parkinson’s disease patients
are predicted to destabilise the protein (∆∆G > 4.7, Figure 4.8d). PARK2 also contains other
pathogenic variants implicated in Parkinson’s disease and predicted to be destabilizing. In the
tumour suppressor serine/threonine-protein kinase STK11, pathogenic and VUS identified in
Peutz-Jeghers syndrome patients show ∆∆G scores predicting destabilisation (Figure 4.8e).
In particular, the VUS G242W shows an exceptionally high destabilizing score (∆∆G >
38.96).
The analysis here demonstrates how mutfunc could be applied to systematically describe
altered mechanisms through candidate disease variants.
4.3 Methods
4.3.1 Genetic variant data collection
A total of 896,772 genetic variants occurring in for 405 haploid and diploid S. cerevisiae
strains were collected from four studies [336–339]. All but one study by Strope et al. [336]
provided processed variant calls in VCF format. Variants were called for the Strope et
al. study using the following pipeline. Raw reads were obtained from the ENA resource
[360]. Adapter sequences were removed using cutadapt v1.8.1 [361] and reads were mapped
to the S. cerevisiae genome version 64 using BWA-MEM v0.7.8 [362]. Duplicate reads
were discarded using picard v1.96 (https://github.com/broadinstitute/picard) and reads were
realigned using the GATK indel realigner v3.3 [363]. Base alignment qualities were computed
using samtools v1.2 [364] and variants were called using freebayes v0.9.21-15-g8a06a0b
[365] and the following parameters –no-complex, –genotype-qualities, –ploidy 1
and –theta 0.006. The VCF was filtered for calls with QUAL > 30, GQ > 30 and DP >
4. VCF for individual S. cerevisiae strains were combined and coding variants were called
using the predictCoding function of the VariantAnnotation R package [366].
A total of 3,198,692 coding variants in H. sapiens for over 65,000 individuals was
collected from the ExAC consortium [298] in the ANNOVAR [317] output format along
with corresponding adjusted allele frequencies. Ensembl transcript positions were mapped
to UniProt by performing Needleman-Wunsch global alignment of translated Ensembl
transcript sequences against the UniProt sequence using the pairwiseAlignment function
in the Biostrings R package. The mapping between Ensembl transcript IDs (v81) and UniProt
accessions was obtained from the biomaRt R package [367]. In the case that multiple alleles
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Fig. 4.8 In silico validation of VUSs using mutfunc predictions. (a-c) Three examples of
interaction interfaces containing variants predicted to impact binding stability. Subunits of
the interaction complex are coloured in dark grey and white, and respective interface residues
in dark green and green. (b) Two examples of variants predicted to impact protein stability.
Pathogenic variants are labelled "P" in red, and VUSs "U" in blue.
mapped to the sample single amino acid substitution, the one with the highest adjusted allele
frequency was retained.
A total of 139,167 variants were obtained from ClinVar [354]. Only variants that did
not match one of the following clinical significance terms were removed: ’Benign’, ’Be-
nign/Likely benign’,’Likely benign’, ’Likely pathogenic’, ’Pathogenic/Likely pathogenic’,
and ’Pathogenic’. Variants with a review status of ’no assertion criteria provided’ were
also removed, as those reflect variants that have been assigned clinical significance without
any particular criteria. The final filtered set contained 39,597 variants. Of these variants,
44% were classified as pathogenic or likely pathogenic. For S. cerevisiae, a total of 8,083
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manually curated variants were obtained from [355], 34.5% (2,812) of which were labelled
as deleterious. Variants were collected from a combination of the UniProt database [149],
Protein Mutant Database [368], Saccharomyces genome database [369] and mutations that
are identified in essential genes [370].
4.3.2 Evolutionary constraint
The evolutionary constraint, defined as c, is computed by taking the ratio between observed
mutation counts in a region of interest and that of random regions.
To assess the difference between c in buried vs. exposed protein structures and interfaces,
variants are counted in each of the four bins of RSA. An equal number of variants are then
sampled 100 times and the number of variants in each bin are counted. The observed and
expected counts for each bin are divided for 100 values of c.
For PTMs, the observed number of mutations in and around the modified site is counted.
The expected number of mutations is calculated by sampling an equal number of un-modified
sites in the same genes harbouring the observed PTMs. This is repeated 100 times, for each
of which c is calculated.
For TFBSs, the observed number of variants is computed by counting the number of
mutations in predicted TFBSs which also overlap with ChIP-seq or ChIP-chip regions. This
is compared to mutation counts in random regions of the same length in the ChIP-seq or
ChIP-chip regions. This is similarly repeated 100 times.
There are a number of limitations related to this approach of computing evolutionary con-
straint. Namely, it does not consider variable mutation rates between nucleotides. Mutation
rates have been shown to vary significantly in regions with base composition biases [371],
local recombination rates [372], chromatin structure [373] and many other factors. Including
these would allow for more accurate constraint measurements.
4.3.3 Essential genes
A total of 2,501 essential genes identified using gene trapping technology in two haploid H.
sapiens cell lines KBM7 and HAP1 were obtained from [352]. These were further filtered
for genes that were essential in both cell lines, for a total of 1,734 genes. A total of 1,156
essential genes in S. cerevisiae were obtained from the Saccharomyces Genome Deletion
Project [374].
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4.3.4 Predicting impact on protein stability and protein interaction in-
terfaces
Experimentally determined structures were obtained from the protein data bank (PDB). Large
structures that did not have a corresponding PDB file were downloaded in mmCIF format and
converted to PDBs using the PyMOL Python library v1.2r3pre [375]. Mapping of coordinates
from PDB to UniProt residues was derived from the SIFTS database [376]. Structures with
a resolution above 3 were discarded and a single representative structure maximising the
coverage of the protein was retained. Homology modelling was carried out for proteins with
no experimentally determined structures using ModPipe version 2.2.0 [377] and the following
parameters: –hits_mode 1110 and –score_by_tsvmod OFF. For each protein, the model
with the highest normalised DOPE score was retained. Experimental and homology modelled
structures for protein interactions were obtained from the Interactome3D database [205].
Relative solvent accessibility (RSA) for all residue atoms was computed using NACCESS
[378] for proteins individually, and in the interaction complex. Interface residues were
defined as those with any change in RSA. All other cases of RSA were computed using
freeSASA v1.1 [379].
The impact of variant on stability was computed using FoldX v4.0 [189]. All struc-
tures were first split by chain into individual PDB files and repaired using the RepairPDB
command, with default parameters. The Pssm command is then used to predict ∆G with
numberOfRuns=5. This performs the mutation multiple times with variable rotamer con-
figurations, to ensure the algorithm has achieved convergence. The average ∆G of all runs
is computed and the ∆∆G is computed as the difference between the wildtype and mutant.
The impact of variants on interaction interfaces is measured similarly, with the exception of
structures being provided in binary interaction, rather than individual chains.
4.3.5 Predicting the impact of variants on PTMs and linear motifs
For S. cerevisiae, a total of 20,056 phosphosites and 2,219 kinase-substrate associations
were obtained from the PhosphoGRID database [380]. A total of 1,070 of other PTM sites
was obtained from the dbPTM database [116]. For H. sapiens, all PTM data, including that
of phosphorylation and kinase-substrate associations were obtained from PhosphoSitePlus
[252], for a total of 296,147 sites. For E. coli, a total of 483 PTM sites were obtained from
dbPTM [116]. Linear motif data for S. cerevisiae and H. sapiens, including annotated linear
motif binding sites and regular expression patterns, were obtained from the ELM database
[381].
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Impact of variants on phosphosites and flanking regions was measured using the MIMP
algorithm [146], with default parameters. For other PTMs, a variant was predicted to be
impactful if it affected the modified residue. For linear motifs, a variant was predicted to be
impactful if it causes a loss of match for associated regular expression pattern.
4.3.6 Predicting the functional impact of variants using conservation
All protein alignments were built against UniRef50 [382], using the
seqs_chosen_via_median_info.csh script in SIFT 5.1.1 [244]. The siftr R pack-
age (https://github.com/omarwagih/siftr), an implementation of the SIFT algorithm that was
developed by myself, was used to generate SIFT scores with parameters ic_thresh=3.25
and residue_thresh=2.
4.3.7 Transcription factor binding sites
A total of 177 S. cerevisiae TFs binding models were collected in form of a position frequency
matrices (PFMs) from JASPAR [287] and converted to position weight matrices (PWMs)
using the TFBSTools R package [315]. PWMs were trimmed to eliminate consecutive
stretches of low information content (<0.2) on either terminus. To identify genes likely
regulated by a particular TF, a combination of TF-knockout expression and ChIP-chip
experiments were used, as similarly described in [383]. Genome-wide gene expression
profiles for 837 gene-knockout strains were obtained from three studies [384–386], 148 of
which were a known TF with a defined PWM. Studies provided either a Z-score or p-value
for each gene as a measure of over or under-expression, relative to the distribution of values
for all genes. Two-tailed p-values were computed from Z-scores when a p-value was not
provided [384]. In cases where TF knockout was repeated between studies, the lowest p-value
for each gene was used. ChIP-chip tracks for 355 TFs were collected from four studies
[387–390], via the Saccharomyces genome database [369]. Of the 355 of the TFs, 144
(56%) had a defined PWM. Potential binding sites were then only searched for in TF-gene
pairs with a p-value below 0.01 and the corresponding ChIP-chip region upstream of the
regulated gene. A normalised log score of 0.80 was used as the cutoff for defining putative
binding sites. Similarly, for H. sapiens, 454 TF PWMs were generated from JASPAR PFMs.
ENCODE clustered ChIP-seq data were obtained for 161 TFs, of which 72 had a PWM.
Only those regions were scored against the corresponding PWM. For E.coli, a total of 1,905
TF-matching sequences across 84 TFs were obtained from RegulonDB [391] and used to
construct PWMs. A total of 2,416 experimentally identified TFBS were obtained for 79/84
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TFs from RegulonDB. These sites were used as putative binding sites for downstream variant
predictions.
Potential target sequences could then scored against the PWM using the log-scoring
scheme defined in [60] and normalised to the best and worst matching sequence to the PWM.
The resulting score lies between 0 and 1, where 1 signifies strong predicted binding by
the factor, whereas 0 signifies predicted lack of binding. Potential binding sites are scored
in the presence (swt) and absence (smt) of a variant. Three separate metrics are used to
quantify the change in binding between the reference and alternate allele. The first one is
simply the difference in the normalised log score, Swt − Smt , where a large positive value
indicates loss of binding. The second is the difference in binding percentile. Here, random
oligonucleotides are used to generate a negative distribution of log normalised scores for
each TF. The percentile of each wildtype pwt and mutant scores pmt is computed from this
distribution, and the difference, pwt − pmt , is used to quantify the magnitude of impact.
The last is the difference in the relative information content. This can be thought of as the
difference of letter height in a sequence logo. Given that the wildtype and mutant bases have
relative frequencies of fwt and fmt , respectively and a position has an IC value of γ , then this
is computed as ( fwt · γ)− ( fmt · γ). This value ranges from 0 to 2, where 0 indicates little to
no impact on a critical base, and 2 indicates a strong one.
4.3.8 Implementation of mutfunc
Described predictors were used to precompute effects for all amino acid and nucleotide
substitutions. The resulting data serves as the basis for mutfunc, allowing users to rapidly
query thousands of variants on predictions that would otherwise take on the order of days or
weeks to compute, particularly those involving 3D structures.
The mutfunc web server at http://mutfunc.com is free and open to all users and requires
no login. The web application uses the Java and Scala-based Play Framework v1.3.7 backend
(http://www.playframework.org) along with a MySQL database. The front-end utilises a
modified version of the the Twitter Bootstrap UI library (http://twitter.github.com/bootstrap).
Visualization tools used include a modified version of the neXtProt feature viewer v0.1.52
(https://github.com/calipho-sib/feature-viewer) for interactive visualisation of protein se-
quence features, WebGL protein viewer v1.1 for interactive visualisation of protein structures
v1.8.1 (https://github.com/biasmv/pv), and a modified version of the JSAV v.1.10 library
(https://github.com/AndrewCRMartin/JSAV) for visualization of multiple sequence align-
ments.
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4.4 Discussion
A complete understanding of how genetic variation drives phenotypic variability relies
majorly on understanding the mechanisms they impinge on and how this propagates through
to phenotype. Computational predictors that utilise both sequence and structure features have
been developed to aid this process. In this chapter, I have described the mutfunc resource,
in which numerous predictors were used to precompute millions of variant effects across H.
sapiens, S. cerevisiae, and E. coli. I have further explored predictions made in the context
of natural and disease variation in both H. sapiens and S. cerevisiae genomes and validated
the performance of predictors. Such predictors have shown a promising capacity at not only
identifying causality of a variant but also which mechanisms they likely impact.
The increasing availability of individual genomes is allowing for the detection of many
common and rare variants in both coding and non-coding regions. Such variants can easily
be queried in mutfunc, allowing for rapid hypothesis-driven annotation and prioritisation.
Currently, conservation effects hold the highest coverage, (H. sapiens 98.6%, S. cerevisiae
87.9%, and 96.1% E. coli) followed by stability (H. sapiens 18.9%, S. cerevisiae 16.9%, and
49.2% E. coli) and interfaces (H. sapiens 2.20%, S. cerevisiae 2.84%, and 4.45% E. coli).
Other mechanisms like kinase-substrate phosphorylation, SLiMs, and TFBSs have much
lower coverage and depend on the availability of external, often manually curated, data. As
additional data become available, mutfunc will be updated to improve coverage.
Hypotheses derived from in silico predictions, such as those provided in mutfunc, should
be exploited with caution. Despite the accuracy of many predictors, the inherent effect
of a genetic variation in vivo can be far more complex and depend on both genetic and
environmental factors [392]. Several studies have shown that many variants annotated as
disease-causing or predicted as deleterious have been identified in healthy humans [393],
emphasizing the discretion required when deeming a variant deleterious. One of the major
factors confounding variant effect predictions is epistatic effects, where the impact of a
variant can be mitigated or aggravated by the occurrence of alternative genetic variants
[394]. The genetic background in which a variant exists is therefore critical to understanding
genomic regions that have undergone co-evolution to suppress deleterious effects. Ultimately,
in silico predictions should not be used as actionable clinical evidence, but rather to guide
follow-up validation experiments, which could then either confirm or deny the role of the
variant in the underlying mechanism [395].
The utility of mutfunc lies within the precomputed effects of individual point mutations
allowing a large number of variants to be rapidly queried without the need for on-the-fly
computations, which can often be time-consuming. Within such a framework, epistatic
effects cannot be precomputed due to a large number of possible combinations. Similarly,
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many other types of genetic variation that largely contribute to phenotypes such as CNVs
and indels [396, 397] cannot be consistently precomputed in mutfunc due to their atypical
structure. Other aspects mutfunc that could be improved in future versions. For instance,
despite there being several well-studied mechanisms available in mutfunc, there are many
mechanisms that are yet to be integrated, such as splicing, protein localization, and epigenetic
modifications. Some of these mechanisms are not currently included in mutfunc since they
remain difficult to predict with existing poor accuracy options. The development of accurate
predictors of molecular phenotypes relies upon both the biological understanding of molecular
determinants underpinning the mechanism as well as the availability of experimentally-
verified training data. Lastly, many organisms in which genetic variation is commonly
studied are not included in mutfunc. These include as M. musculus, D. melanogaster and
A. thaliana, which contain an abundance of data on PTMs, SLiMs, structural data and
TFBSs. Predictors employed here could thus be applied to provide mechanistic variant
impact predictions for these organisms, expanding the utility of mutfunc.
Understanding how disrupted cellular mechanisms propagate to changes in phenotypes is
critical for variant interpretation. For instance, predicting the disruption of a phosphorylation
event alone is less constructive if the functional role of the phosphorylation event is not
known. Much effort has gone into identifying molecular phenotypes associated with a
particular cellular event. For instance, prioritizing functional PTMs and understanding their
function [283], investigating the role of particular PPIs in disease [398], and identifying
TFBSs that are likely to influence expression [399, 400]. Such studies are critical to aiding
the interpretation of mechanisms predicted to be disrupted by genetic variation.
All in all, mutfunc is a unique resource that will greatly facilitate the identification of the
molecular mechanisms altered by point mutations that lead to phenotypic differences and
can be broadly applied to different model organisms.

Chapter 5
Gene-level aggregation of mechanistic
variant impact for gene-phenotype
associations
In this chapter, I describe the use of mechanistic variant impact predictors to construct gene
burden scores in a panel of 93 S. cerevisiae strains. Phenotypic screening of S. cerevisiae
strains under 43 different conditions was carried out, further allowing for the testing of
gene-phenotype associations. All analysis was carried out by my self, under the supervision
of Pedro Beltrao. I was not involved in the generation of experimental data. Phenotypic
screens were carried out by lab member Bede Busby and the processing and scoring of
phenotyped data was carried out by lab member Marco Galardini.
5.1 Introduction
Rare genetic variants extensively contribute to disease biology [401]. Yet, traditional GWASs
is often unable to implicate rare variants in phenotypic differences primarily due to their low
prevalence. Such associations would often require the genotyping of sufficiently large cohorts,
which is in many cases is impractical or infeasible. For cases where sufficient data is available,
the high number of statistical tests combined with stringent multiple testing correction often
result in the dissipation of any signal. In addition, the design of GWASs revolves around
genotyping chips for a set of tag variants, which rely on linkage-disequilibrium for imputation
of rare variants from a reference panel like the HapMap project [402]. However, the marker
variant must be observed in the reference panel in order for successful imputation, which
may not always be the case. Much effort has gone into designing rare variant association
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studies that involve whole genome and exome sequencing as well as rare variant genotyping,
yet, these approaches focus on achieving a higher number of samples, which will not always
guarantee sufficient improvement statistical power [403].
One way to tackle the lack of statistical power for association studies is to combine
the effects of rare variants by predicting their impact on gene function or "gene burden".
This, in turn, can be used to carry out gene-phenotype associations. Studies utilising gene
burden for associations have employed different approaches to quantify the effect of rare
variants. For instance, DeBoever et al. used 18,228 protein truncating variants (PTVs),
including nonstop, nonsense and frameshift variants to generate gene burden scores which
were associated with 135 phenotypes from the UK Biobank and uncovered 27 high confidence
associations [404]. Iorio et al. utilised prior information on known cancer driver variants
and copy number variants to define whether a gene is affected across 1,001 cancer cell
lines and computed associations across drug response profiles for 265 drugs uncovering
many known and novel associations [405]. Olde Loohuis et al. quantified gene burden by
assessing deleteriousness of rare coding variants by assessing PTVs, splice-site variants and
deleteriousness predictions by predictors like SIFT and PolyPhen. Through the analysis of
rare variants in 1,042 schizophrenia patients against 961 controls, they were able to uncover
many schizophrenia-associated genes under high burden [406]. While such approaches are
effective at improving our understanding of rare variant impact, they commonly focus a
single predictor or rely on previously identified pathogenic variants. Little has been done
to comprehensively assess effects across multiple predictors. In addition, predictors of
deleteriousness such as SIFT are unable to explain the altered biological mechanism.
The use of mechanistic variant impact predictors can significantly contribute to improving
statistical power while shedding light on the altered mechanisms caused by rare variants
beyond single variant-based testing. In this chapter, we aimed to test this using S. cere-
visiae as a case study. We utilised coding variants from whole genome sequences for 93 S.
cerevisiae strains and collect pre-computed mechanistic variant effects for protein stability
(FoldX), conservation (SIFT) and PTVs to define gene burden scores (see section 4.2.2).
We phenotyped corresponding growth profiles of 166 strains across 43 conditions including
common drugs, nutrient stressors and environmental stressors. The resulting data was used
to test gene-phenotype associations and uncover several known and novel associations. We
further show that gene burden can be expanded to compute complex-level burden, which
provides additional power to statistical tests.
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5.2 Results
5.2.1 Phenotypic variation across S. cerevisiae strains
We first phenotyped growth for a panel of 166 S. cerevisiae strain in 43 conditions including
common drugs (e.g. ketoconazole, benomyl, caspofungin, cisplatin, rapamycin), nutrient
stressors (e.g. glucose, glycerol, sorbitol, amino acid deprivation, nitrogen starvation), and
other environmental stressors (e.g. high heat, anaerobic conditions, UV light, sodium chlo-
ride). Colony sizes for strains were quantified using the IRIS software [407] then normalised
and scored relative to all strains in a condition to produce a phenotypic measure defined
as the S-score, where a positive value indicates higher growth and negative values indicate
poorer growth (Methods, section 5.3.1). S-scores for biological replicates demonstrated a
high degree of concordance (r = 0.91, p<2.22×10−16, Figure 5.1a), demonstrating a high
degree of confidence in phenotypic measurements.
Hierarchical clustering of growth phenotypes revealed known clusters of related stressors
(Figure 5.1a). Clusters of similar phenotypic profiles included, (1) UV light, cisplatin and
MMS, which are all DNA damaging agents (mean pairwise r = 0.51) (2) nystatin and
caspofungin, which act by interfering with the fungal cell membrane (r = 0.49) (3) rotenone,
DMSO and pH levels of 7.5-8.5 all inflict oxidative stress (mean pairwise r = 0.46) (4)
caffeine and rapamycin, both involved in multiple signalling pathways, namely that of TOR
(r = 0.41), and (5) 5-fluorouracil and 6-azauracil, which both act by altering nucleotide
pool levels ultimately influencing transcriptional elongation (r = 0.42). Furthermore, strains
belonging to the same population structure [336] or environmental origin often showed
similar phenotypic profiles (Figure 5.1b).
Since strains belonging to the same population structure typically arise from a common
ancestor, we asked if strains with similar SNP profiles also show similar phenotypic trends.
We collected variants for 56% (93/166) of phenotyped strains from Strope et al. [336]
(Methods, section 5.3.2) and computed SNP profile distances and phenotypic distances for all
4,278 pairs of strains using the Euclidean distance measure. We found that strains extremely
similar in their SNP profiles were also phenotypically similar (Figure 5.1c). However,
at increased genotype distance, pairs of strains exhibit a much higher variability in the
phenotypic distance. This suggests that predicting phenotypic distance amongst strains
displaying heterogeneous genotypes is a non-trivial task.
The screened phenotypes presented here, along with collected variants for 93 strains
serve as a useful starting point for performing subsequent gene-phenotype associations.
118 Gene-level aggregation of mechanistic variant impact for gene-phenotype associations
Fig. 5.1 Phenotypic screening of 166 S. cerevisiae strains. (a) Concordance between S-
score measurements between two biological replicates. (b) Heatmap of S-scores showing
hierarchical clustering of both strains and conditions reveals clusters of phenotypically
similar strains and conditions. (c) Comparison of pairwise genotype and phenotype distances
between strains shows little observable correlation.
5.2.2 Mechanistic gene burden scores identify novel gene-phenotype
associations
We next sought to define gene-level burden scores to aid the interpretation of phenotypic
variability amongst strains. To compute gene-level burden scores for a given protein, we
utilised mechanistic predictions for conservation (SIFT), protein stability (FoldX) and protein
truncating variants (PTVs, including start loss, nonstop and nonsense variants) (Figure 5.2a).
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Fig. 5.2 Gene-level aggregation of variant effects. (a) Diagram demonstrating the aggregation
of variant impact. Each variant is first assigned a probability of deleteriousness, which is
aggregated at the gene level using the maximum impact. (b) The probability of deleteriousness
for FoldX and SIFT is computed by assessing the proportion of deleterious variants in gold-
standard data for FoldX and SIFT. A logistic regression model (red line) is fit to compute
subsequent probabilities. (c) Once gene burden is computed for each gene and strain, gene-
phenotype associations can be carried out by comparing growth of strains containing high
and low PAF scores for a particular gene.
We first standardise the variant impact predictions for each of the mechanistic predictors.
Scores produced by predictors are recalibrated to reflect the likelihood they are deleterious
(Pdel). For SIFT, a curated gold standard set of 8,083 variants in 1,346 S. cerevisiae genes with
known tolerated or deleterious effects were obtained from Jelier et al. [355]. The negative
natural logarithm of the SIFT score was binned by 0.5 and for each bin, the proportion of
deleterious variants was computed. A binomial logistic regression was fit to the proportion
values and used to compute subsequent Pdel values for subsequent SIFT scores. For FoldX,
964 gold-standard mutations across 34 experimentally identified proteins structures with
both experimentally quantified ∆∆G values and FoldX-predicted ∆∆G values were obtained
from Guerois et al. [408]. A variant was labelled destabilising if ∆∆G was greater than
1. Mutations were binned by predicted ∆∆G at intervals of 0.4 and for each bin, the
proportion of destabilising variants was computed. A binomial logistic regression model
was similarly fit to the data and used to compute subsequent Pdel for FoldX-predicted ∆∆G
values (Figure 5.2b). For PTVs, we resorted to using heuristics to define Pdel values. Variants
disrupting start or stop codons were assigned a value of 1. Since nonsense variants occurring
closer to the C-terminal of a protein are less likely to impact function, we only assign Pdel
value of 1 for nonsense variants occurring in the first 50% of the protein, otherwise a value
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of 0 is assigned. Gene burden scores are then computed as the variant with the maximum
Pdel score and describes the predicted likelihood that a protein has an affected function (PAF ).
This allows for effects of rare variants to be combined across different protein positions
and predictors, which can then be used to identify gene-level phenotype associations by
comparing phenotypic readout for strains with high gene burden compared to those with low
gene burden (Figure 5.2c).
Using natural variation data for the 93 strains, we computed PAF scores for all genes.
If a gene did not contain any coding variants, a PAF score of 0 is assigned. Scores were
binned based on high (PAF> 0.90) or low (PAF< 0.90) gene burden. Using a linear model,
associations were carried out for 1,446 genes (with at least three strains containing a PAF>
0.90) against growth phenotypes across 43 conditions (Methods, section 5.3.1). All reported
p-values were corrected using the false discovery rate (FDR) method. In addition to statistical
significance, to ensure sufficient magnitude in growth phenotypes, we compute the effect size
using the Glass’ ∆ approach. Here, change in mean values relative to the standard deviation
of one group is measured. We compute two Glass ∆ values, relative to both groups and report
the minimal absolute ∆, signed by the direction of the association (Methods, section 5.3.4).
We identified a total of 626 statistically significant gene-phenotype associations at
(p<1×10−3 and FDR < 10%, Figure 5.3a). A total of 83% (520/626) of are negative
associations i.e. decreased growth, and 17% (106/626) were positive. To validate associa-
tions we utilised chemical genetic data where genes are knocked out in the reference strain
and allowed to grow under various conditions. The growth defect for a knock out can then
be used to associate a gene with a particular condition. Although these experiments are
carried out in the reference strain and conditions rarely match in concentration, this data
provides a useful starting point to systematically validate associations. We collected genes
associated with 35/43 of the assayed conditions using data from high-throughput chemical
genetic screens [409] as well as literature-curated cases from the Saccharomyces Genome
Database (Methods, section 5.3.3). Of all significant negative associations, a total of 9%
(48/520) are validated by the chemical genetic data. It is also important to note that not
all gene-phenotype association have been tested in the chemical genetic data, and thus this
number could, in theory, be higher. Increasing the effect size threshold shows an increasing
trend in the proportion of validated associations (Figure 5.3b). At ∆> 1, 13% (38/282) are
validated and at ∆> 1.7, 24% (15/64) are validated, suggesting that associations of higher
effect sizes are more reliable. To assess whether these values are obtained by chance, we
sampled the same number of genes from the pool of 1,446 tested genes at each of the effect
thresholds and similarly measured the proportion of these gene-condition pairs observed in
the chemical genetic data. This was repeated 1,000 times for each threshold. We found that
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Fig. 5.3 Significant identified associations. (a) A volcano plot showing significant associa-
tions. The size of each point is proportional to the number of strains containing a high PAF
score. Associations validated by chemical genetics are coloured in purple. (b) The proportion
of associations validated by chemical genetics at different effect size thresholds for observed
(black) and randomly permutated (red) associations. Grey ribbon represents the one standard
deviation. (c) The number of associations across different conditions where positive and
negative associations are shown in green and dark grey, respectively. (d) Phenotypic variance
across strains compared against the number of significant associations.
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at lower effect sizes expectation was near random. However, at larger effect sizes (∆> 1.7),
observed proportions were significantly higher (p=0.03, Figure 5.3b).
We next checked if larger phenotypic variability for a condition results in a higher number
of identified associations. However, no strong correlation was observed between growth
variability and the number of identified associations at ∆ > 1 (r = 0.27, p=7.19×10−2,
Figure 5.3c-d). Specifically, conditions such as high heat, sodium chloride and amino acid
deprivation showed high phenotypic variability and a high number of identified associations.
However, many conditions that showed high phenotypic variability showed very few asso-
ciations, such as low pH (n=2) and high glucose (n=1). Interestingly, several conditions
including paraquat, ketoconazole and nystatin seemed to explain the majority of identified
positive associations suggesting that coding variation are advantageous in such conditions.
Why this is the case remains unclear.
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Fig. 5.4 Examples of high confidence associations. Each example shows the S-score of the
negative (red) and positive (blue) group in a given condition. Horizontal black lines represent
the median S-score.
To explore resulting associations we focus on a subset of 366 associations with a high
effect size (|∆| > 1, Figure 5.4). For instance, high heat associated with mutations in
the heat shock protein HSP31 (∆=-1.13, p=4.65×10−4), outer mitochondrial membrane
GTPase GEM1 (∆=-2.09, p=5.12×10−4) and acetyl-CoA carboxylase ACC1 (∆=-1.51,
p=5.49×10−4), all of which when knocked out in the reference strain result in growth
5.2 Results 123
defects under high heat [410–412]. Nutrient stressors like sodium chloride showed signif-
icant associations to the ABC transporter VMR1 (∆=-1.46, p=2.99×10−4). Amino acid
deprivation showed significant associations with numerous genes involved in the uptake,
catabolism, and biosynthesis of amino acids including BAP2 (∆=-1.58, p=7.40×10−6),
PDC6 (∆=-1.53, p=6.02×10−6), ARO9 (∆=-1.49, p=8.46×10−6) and SER33 (∆=-2.15,
p=1.83×10−6). Common drugs like Caffeine, which is involved in cell cycle arrest and
DNA damage [413, 414] showed associations to genes like the cell cycle checkpoint pro-
tein RAD24 (∆=-1.71, p=3.23×10−4) and the SUMO-ligase WSS1 (∆=1.17, p=1.65×10−5)
which is involved in DNA repair. The anti-fungal drug ketoconazole interferes with ergos-
terol synthesis, thereby disrupting the cell membrane. The phosphatidylinositol synthase
PIS1 is key for biosynthesis of cell membrane polyphosphoinositides, and strains carrying
impactful mutations show stronger growth in ketoconazole (∆=2.13, p=4.08×10−4). The
ATP-binding multi-drug resistance transporter PDR5 is another gene negatively associated
with ketoconazole (∆=-1.26, p=2.40×10−5) as well as other drugs including 6-azauracil
(∆=-1.08, p=3.78×10−4) and cycloheximide (∆=-1.02, p=8.91×10−5). Given its general
role in drug resistance [415], it is appropriate that mutations disrupting gene function would
result in such growth defects. Hydroxyurea is a drug that arrests DNA replication and is
involved with DNA damage and is associated with the DNA damage inducible protein DDI3
(∆=-1.57, p=8.76×10−4), which is over-expressed 100-fold by DNA damaging agents [416].
Paraquat is a drug that induces oxidative stress by interfering with the electron transport
chain. We find the heat shock protein HSP31 strongly positively associated with paraquat
(∆=1.06 p=4.57×10−4). Heat shock proteins have been previously identified to suppress
paraquat-induced effects in rat and H. sapiens [417, 418] suggesting the existence of a
similar mechanism in S. cerevisiae. Other genes positively associated with paraquat include
reductases YJR096W (∆=1.43, p=1.32×10−4) and LYS2 (∆=1.75, p=2.01×10−4) as well as
the hydrolase YSA1 (∆=1.42, p=9.26×10−4, Figure 5.4).
Investigation of variants responsible for associations reveals the collective impact rare
variants have on a gene. For instance, the GLN4-heat association is driven by destabilising
rare mutations in glutaminyl-tRNA synthetase domain (Figure 5.5a) whereas the ACC1-
heat association is driven by both destabilising and conservation-affecting variants in the
biotin carboxylase domain (Figure 5.5b). The VMR1-sodium chloride association is driven
by two nonsense variants in the ABC transmembrane domain and conservation-affecting
variants in and around the ABC transporter domain (Figure 5.5c). The RAD24-caffeine
association is driven by three conservation-affecting mutations within the Rad17-like domain
(Figure 5.5d). The DDI3-hydroxyurea association driven by a start loss variant and two
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Fig. 5.5 (a-f) Variant impact plots for six genes from figure 5.4. Coloured boxes represent
annotated Pfam [350] domains. The height of mutations reflect the Pdel score and the value
indicated in white denotes the number of strains harbouring the variant. Variants predicted as
deleterious (Pdel> 0.90) show different coloured outlines depending on the predictor: PTV
(red), SIFT (green), FoldX (purple) and both SIFT and FoldX (blue).
conservation-affecting variants. Finally, the PIS1-ketoconazole association is driven by two
nonstop variants.
The suggested gene burden approach has proven valuable at revealing many known and
novel gene-phenotype associations through combining effects of rare variants to increase
statistical power.
5.2.3 Complex burden scores further improve association power
Genes often form complexes that carry out the majority of cellular processes. Altering
any constituent parts of a complex could, therefore, result in a similar phenotypic outcome.
Assessing burden on a complex level could thus provide additional power when conducting
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associations. To test this, we collected gene sets for 408 S. cerevisiae complexes from the
CYC2008 resource [419]. The complex-level burden was computed by taking the maximum
PAF score across all genes in a complex (Methods, section 5.3.4). For 258 complexes that that
contained at least two high PAF genes across strains, associations were carried out against the
43 conditions similarly to that of gene-level associations.
We identified 75 significant complex-phenotype associations (p<1×10−3, FDR < 10%),
25 (33%) of which had a high effect size (∆> 1). The 25 associations involved 15 conditions
and were constituted of 17 (68%) negative associations and 8 (32%) positive associations.
Complex-level burden scores were able to uncover associations not possible on the gene-level.
For instance, high heat was shown to be associated with the FBP complex responsible for
protein degradation (∆=1.01 p=5.7×10−4, Figure 5.6a). Members of the FBP complex
with affected function (PAF> 0.90) VID24, GID7, FYV10 and RMD5 are not detected by
gene-level burden associations, yet 3/4 show heat sensitivity within chemical genetic data
[411]. The drug 5-fluorouracil suppresses DNA replication by blocking synthesis of the
pyrimidine nucleotide thymidine and significantly associates with the guanyl-nucleotide
exchange factor complex (∆=1.25 p=7.4×10−4, Figure 5.6b). Benomyl interferes with
microtubule stability and associates with the AP-2 adapter complex, which is responsible
for clathrin-mediated endocytosis (Figure 5.6c). Clatherin is also involved in stabilising
microtubules that attach to kinetochores during meiosis [420]. Similarly, the AP-1 adaptor
complex associates with ketoconazole (∆=1.61 p=2.2×10−4, Figure 5.6d). Since ketocona-
zole alters cell membrane by interfering with ergosterol biosynthesis and ergosterol play key
roles in endocytosis, this potentially explains the link between mutations in members of the
AP-1 adaptor complex and ketoconazole. The transcription factor TFIIH complex positively
associates with ketoconazole (∆=2.03 p=1.1×10−4, Figure 5.6e), which can possibly be ex-
plained by the transcriptional repression and activating functions of ketoconazole. Lastly, the
DNA replication factor C positively associates with ultraviolet light (∆=1.26 p=8.2×10−4,
Figure 5.6f), which could be explained by the DNA-damaging properties of UV light.
Complex-level burden provides additional power when testing gene-phenotype associa-
tions, particularly when the sample size is limited. Associations performed on the pathway
or domain level may also provide additional insight into novel associations.
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Fig. 5.6 Aggregating effects on a complex level. (a-f) Examples of complex level associations.
For each example, the growth of strains predicted to have at least one complex member
altered (blue) is compared against those that do not (red). Complex members are shown
connected by an edge if they are known in the BioGRID database [261] to physically interact.
The values indicated on node labels denote the number of strains with a high PAF score for
that gene.
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5.3 Methods
5.3.1 Phenotyping of S. cerevisiae strains
Phenotyping for 166 S. cerevisiae strains across 43 conditions was performed by lab member
Bede Busby. The screening was carried out in 1536 format on synthetic complete media
with the addition of the appropriate chemical at a specific concentration. The Singer RoToR
(Singer instruments, UK) was used to replicate screening plates in 1536 format. Agar plates
were pinned onto the conditioned media in quadruples and allowed to grow for 48 or 72 hours
at 30 degrees centigrade (unless specified otherwise). A total of four technical replicates
were carried out. For each technical replicate, up to 12 biological replicates were carried out.
After incubation, plates were imaged and the processing of plate images was carried out
by lab member Marco Galardini. Colony sizes were extracted using IRIS version v0.9.7
[407] with the "Colony growth" profile, which extracts colony size, circularity and opacity
from each colony in each plate. Individual strains were scored using the E-MAP software,
which transforms colony sizes into S-scores [421]. In brief, a surface correction algorithm is
applied to each plate, the outer frame effect is corrected by bringing the two outermost rows
and columns to the plate middle median. All the plates are then normalized to the overall
median, followed by a variance correction (Figure 5.7a). Finally, the S-score is calculated
based on a modified t-test, as defined by Collins et al. [421]:
t =
µˆ− µˆ0√
var(µˆ)+ var(µˆ0)
. (5.1)
Here, µˆ and µˆ0 are the median observed and expected colony sizes across technical
replicates, respectively. Expected colony sizes are computed as growth for a strain across all
conditions. The resulting S-scores are quantile normalized in each condition separately (Fig-
ure 5.7b). Final S-scores are then computed by averaging S-scores of biological replicates.
5.3.2 Genetic variants for S. cerevisiae strains
Genetic variants for the 93 strains analysed here were called from whole genome reads
obtained from Strope et al. [336]. Variants with a MAF > 20% were discarded. Additional
information on data collection and variant calling can be found in section 4.3.1.
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Fig. 5.7 S-score calculation and normalisation. (a) Normalisation of raw quantified colony
sizes and calculation of the S-score. (b) Quantile normalization of S-scores.
5.3.3 Chemical genetic data
Chemical genetic data for heterozygous and homozygous knockout reference strains
were obtained from Hillenmeyer et al [409] for 5,900 genes across 568 conditions.
The files hom.z_tdist_pval_nm.pub and het.z_tdist_pval_nm.goodbatch.pub were
used. Conditions were manually matched to assayed conditions in section 5.3.1 and genes
were considered associated with the condition if their p-value was below 1×10−5, as rec-
ommended by the authors. For cases where data for multiple generations or replicates are
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reported or the phenotype is observed for both heterozygous and homozygous knockdowns,
the association with the most significant p-value is retained. The final set contained 7,944
gene-phenotype associations across 5,883 genes and 28 conditions.
Chemical genetic data for null strain mutants from various other high-throughput and
low-throughout studies was obtained from the Saccharomyces Genome Database [422]
through the phenotype_data_sgd.tab file. The "phenotype" and "chemical" columns
were manually matched to assayed conditions section 5.3.1 resulting in a total of 15,194
gene-phenotype associations across 3,508 genes and 30 conditions.
5.3.4 Computing gene and complex-burden scores and associations
For a gene g, given a list of n variants v1, · · · ,vn with Pdel scores of Pv1del, · · · ,Pvndel the gene-
level burden scores are computed as:
PAF = max
1≤i≤n
Pidel (5.2)
Similarly, given a set of k genes g1, ...,gk in a complex with PAF scores of P
g1
AF , · · · ,PgkAF ,
complex-burden scores are computed as:
PCAF = max
1≤i≤k
PgiAF (5.3)
All associations were carried out using the MatrixEQTL R package [423] with the
modelLINEAR mode. The package was developed for rapidly conducting hundreds of thou-
sands of associations between variants and gene expression, although the methods are
generally applicable. The significance of the association is then measured using a t-statistic.
Here, binarised PAF scores are used as genotypes where a PAF score above or below 0.9 is
given a value 1 and 0, respectively and growth phenotypes are used in lieu of gene expression.
A p-value threshold of 0.001 is used for all associations and multiple testing correction is
carried out using the false discovery rate method.
The effect size was computed using Glass’ ∆. For the case (p) and control (n) group,
differences in the mean is computed relative to the standard deviation of one of the groups.
Given the mean (µi) and standard deviation (σi) for a given group i this is computed as:
∆i =
µp−µn
σi
(5.4)
To ensure sufficient effect size in either direction, this is computed in either direction
and the final effect size, ∆, is reported as the minimum absolute value of effect sizes in both
directions, signed by the direction of the association:
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∆= ε ·min{∆p,∆n}
ε =
−1, if µp < µn1, otherwise (5.5)
5.4 Discussion
In this chapter, we describe an approach to combine effects of PTVs, SIFT-predicted deleteri-
ousness and FoldX-predicted stability impact to collectively define a gene burden score.
While the maximum predicted variant impact is used here, there exist several other
approaches at computing gene burden. For instance, Jelier et al. additively modelled gene
burden by taking the product of probabilities that a variant is neutral [355]. Although it
is true that the impact of variants accumulate additively, the measure of deleteriousness
(Pdel) as defined here does not directly reflect the intrinsic probability of deleteriousness.
For instance, a Pdel score of 0.3 that is based on a protein stability predictor will not always
indicate there is 30% chance of this variant impacting function. This would result in the
inflation of gene PAF scores should the gene harbour numerous mutations with mild Pdel
scores. Benchmarking which gene burden scoring metric is appropriate remains a challenging
task due to the lack of gold-standard gene-phenotype associations. Chemical genetic screens
available for S. cerevisiae is a potentially useful resource, yet, there are several inherent
limitations. First, the chemical genetic data is often carried out in a reference strain which
may not always reflect individual-specific growth behaviour. Second, the conditions in which
these screens are carried out do not necessarily match growth phenotypes used to conduct
the associations. These limitations would not allow us to accurately detect false positive
associations. Approaches such as individual-specific gene knock-in experiments, where the
endogenous gene is replaced with a wildtype copy of the reference strain gene, would provide
a valuable way by which the accuracy gene burden scores could be measured.
There are several notable drawbacks to the use of in silico variant impact predictors for
gene burden. First and foremost, there is the issue of false positives. Predictors used here
measure variant impact independently relative to the reference individual. However, the
genetic context of an individual has been shown to play significant roles in dictating variant
impact. For instance, phenomena like epistatic interactions between variants commonly
occur, where the occurrence of a variant can suppress or aggravate effects another variant
[424]. Commonly used variant impact predictors such as SIFT and FoldX were not designed
to account for such context-specific effects, resulting in the misclassification of many variants.
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Second, predictors provide no information on whether an impactful variant confers gain or
loss-of-function. Such information would improve both statistical power and interpretation
of gene burden association tests. Future improvement of variant impact predictors will,
therefore, be paramount to gene burden association tests.
In addition to predictors, there are several limitations with respect to the associations
carried out. First, although the 93 strains utilised here are geographically and environmentally
heterogeneous [336], it is possible that sub-populations of strains exist. This population
structure could thus be a potential confounding factor. Strains that belong to the same sub-
population are likely to exhibit similar phenotypes and therefore many identified associations
may be due to strains belonging to the same sub-population. Second, the number of strains
utilised here limits the number of genes that can be tested: for the 93 strains, we were able
to perform associations for about 25% of the S. cerevisiae genome (1,446) that had at least
three high PAF scores. Relative to H. sapiens, the number sequenced S. cerevisiae strains still
remains low at 500 strains, and even fewer with sufficient phenotypic growth data [336–339].
A larger number of strains would provide additional variation and allow for associations
to be carried out for a larger number of genes and allow for testing associations within
sub-populations. Lastly, genes that do not harbour any genetic variation are assigned a PAF
score of 0, which may not always be accurate since there are other types of mutations beyond
SNVs, including indels, frameshift mutations, and copy number variations (CNVs) that were
not accounted for here. The inclusion of such variation in the future could further improve
the calculation of gene burden scores. Lastly, strains that are more distant from the reference
strain are more likely to have suppressed effects of deleterious variants. Thus, approaches
that are able to generate strain-specific variant impact scores or normalise against distance
from the reference strain would allow for more accurate individual PAF scores.
Although there are several aspects of the described approach that could be improved, this
study offers initial insight into the use of mechanistic variant impact, particularly protein
stability, in the calculation of gene burden scores. Incorporation of additional mechanisms in
the future will allow for us to comprehensively and accurately carry out hypothesis-driven
gene burden associations that can be traced back to individual variants for which we could
then mechanistically explain. Future expansion to human would offer unprecedented insight
into disease risk and potential therapeutics.

Chapter 6
Summary and future directions
The arrival of next-generation sequencing technologies has brought about an abundance of
individual genome data and a new era of genetics. The analysis of genomic data is, however,
bottlenecked by variant interpretation, where an individual’s genetic variants can be classified
as pathogenic or benign. This has prompted an out pour of bioinformatic tools aimed at
aiding variant interpretation. The abundance of corresponding molecular and organism-level
phenotype data corresponding to an individual genome has also driven many association-
based studies as a means of identifying causal variants. These approaches have been routinely
applied to large-scale datasets in both human and model organisms to both guide clinical
validation of variants and aid drug development [425, 426]. Uncovering the biology behind
genetic variants will, therefore, have many implications in personalised therapies and drug
development
The purpose of this thesis was to explore cellular mechanisms that are regularly influ-
enced by genetic variation. A significant portion of this thesis discusses the role of sequence
specificity-mediated interactions, specifically TF binding and kinase-substrate phosphoryla-
tion. Because these interactions are mediated by short motifs, they play a key role in variant
interpretation. In Chapter 2, we discussed a computational approach that was developed to
predict kinase-substrate specificity without any prior information on kinase-specific target
sites. By leveraging functional interaction data and the abundance of available phosphoryla-
tion data, we were able to uncover predicted specificities for over half the human kinases.
We have also shown that this approach can also easily be expanded to other PTM-binding
domains. Since kinase target sites are frequently mutated in disease, and specifically cancer
[148], the ability to uncover additional specificities allows for a better understanding of
how phosphorylation is altered in disease. Much like kinase-substrate phosphorylation, TF
binding also depends on DNA sequence specificity. In Chapter 3, we explored five compu-
tational methods used for the modelling of TF-binding and assessing the variant impact on
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TFBSs. Using variants known to alter TF-binding from allele-specific ChIP-seq data, we
systematically assessed the performance of specificity models in the five methods at predict-
ing variant impact across over 40 TFs. We defined and compare the performance several
variant impact scoring metrics across the methods and show that machine learning-based
significantly outperform the PWM, which is commonly used to assess variant impact [427–
429]. We highlight differences in performance across different TFs and explore alternative
mechanisms that may contribute to the inability to assess variant impact using sequence
specificity information alone.
These methods, including others, have the ability to shed light on altered mechanisms
caused by genetic variants. In Chapter 4, we compile predictors for mechanistic variant
impact, including protein stability, PPIs interfaces, PTMs, kinase-substrate phosphorylation,
TF-binding, short linear motifs, and start and stop codons. We use these tools to pre-
compute variant impact predictions that we provide through the mutfunc web server. This
interactive tool allows for rapid annotation and prioritisation of variants in a mechanistic
light, without requiring the cumbersome set up of any of the individual predictors. We
validate the predictions generated by analysing natural and disease variants in human and
yeast genomes. We show that variants altering mechanisms are more likely rare than common
and that they are depleted in essential genes. We also analysed known pathogenic variants
to show that altered mechanisms are enriched in pathogenic variants and show that these
mechanistic variant impact predictions can be used to shed light on clinical variants of
uncertain significance.
Identifying variants associated with phenotypic trait differences using traditional GWAS
requires the variant to be, to a certain degree, prevalent in the population. Since many disease
phenotypes are driven by rare genetic variants, identifying such associations with traditional
variant-based association methods is not always feasible [430]. In Chapter 5 we utilised the
predictions in mutfunc to predict mechanistic consequences of rare variants in a panel of 93
yeast strains and define gene burden scores. We carried out phenotypic screening for the
corresponding strains in over 40 different conditions and employed this data in combination
with gene burden scores to perform gene-phenotype associations, uncovering many known
and novel associations. We demonstrate the added benefit of generating gene burden scores
using mechanistic variant impact predictions over variant-level associations and show that
this can be taken a step further by assessing complex-level burden.
Understanding the mechanistic basis for variants is very much an open question in the
field of genetics and has fundamental roles variant interpretation. As such, there are numerous
future avenues that can be taken. Specifically, with the advent of deep learning methods
and increasing abundance of molecular-level phenotypic data, there exist many possibilities
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to employ deep learning in modelling cellular mechanisms for which current approaches
do not perform well at such as protein localisation [431], splicing [432], PTMs [433], and
more. These models could, in turn, be used for variant impact prediction. Furthermore,
high throughput experimental assaying of variant impact on protein function, such deep
mutational scanning, are increasingly generating data that could be utilised for the training
of variant impact predictors.
A primary drawback of many existing variant impact predictors is their inability to
account for differences in genetic background. More specifically, they revolve around
the assumption that genetic variants act individually when many diseases can be driven
by the additive effect of numerous variants [434, 435]. The increased development of
methods that can quantitatively model the cooperative impact of variants will allow for more
accurate individual-specific variant impact predictions. Furthermore, additional factors such
as epigenetics can greatly affect the deleteriousness of a variant [436]. Thus, the incorporation
of additional context-specific omics data such as epigenomics, proteomics and metabolomics
is fundamental to better understanding the role of such factors in cellular processes and
accurately modelling tissue and cell type-specific variant impact.
Interpretation of variant impact predictors output is another key area of future research.
As genetic testing becomes more prevalent in the clinical setting, the ability for healthcare
professionals to be able to interpret and act on variant impact predictions is becoming more
of a concern. The standardisation of predictor output is one way to aid variant interpretation
and simplify the comparison of variant impact across multiple methods. Such standardisation
would further streamline the incorporation of data from multiple predictors and improve the
utility of variant impact predictions in phenotype association methods. Developed methods
must also be user-friendly and intuitive to facilitate the construction of variant interpretation
pipelines and allow use by a wide range of expert and non-expert users.
Ultimately, a paradigm shift in variant interpretation and GWAS is required whereby
more light is shed on the affected biological mechanisms. To do this, our understanding
of biology must be incorporated into assessing variant impact through the development of
mechanistic variant impact predictors, which can be employed to assess higher order impact
on gene, complex and pathway levels. Such a layering approach will be able to capture the
propagation of variant impact through cellular processes and improve our ability to associate
genetic variation as a whole to phenotypic differences.
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